
<html lang="en"     class="pb-page"  data-request-id="a7564be6-ea6c-4500-9e38-01114b6e9e78"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2016.59.issue-1;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01582;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis" /></meta><meta name="dc.Creator" content="Guido  Bold" /></meta><meta name="dc.Creator" content="Christian  Schnell" /></meta><meta name="dc.Creator" content="Pascal  Furet" /></meta><meta name="dc.Creator" content="Paul  McSheehy" /></meta><meta name="dc.Creator" content="Josef  Brüggen" /></meta><meta name="dc.Creator" content="Jürgen  Mestan" /></meta><meta name="dc.Creator" content="Paul W.  Manley" /></meta><meta name="dc.Creator" content="Peter  Drückes" /></meta><meta name="dc.Creator" content="Marion  Burglin" /></meta><meta name="dc.Creator" content="Ursula  Dürler" /></meta><meta name="dc.Creator" content="Jacqueline  Loretan" /></meta><meta name="dc.Creator" content="Robert  Reuter" /></meta><meta name="dc.Creator" content="Markus  Wartmann" /></meta><meta name="dc.Creator" content="Andreas  Theuer" /></meta><meta name="dc.Creator" content="Beatrice  Bauer-Probst" /></meta><meta name="dc.Creator" content="Georg  Martiny-Baron" /></meta><meta name="dc.Creator" content="Peter  Allegrini" /></meta><meta name="dc.Creator" content="Arnaud  Goepfert" /></meta><meta name="dc.Creator" content="Jeanette  Wood" /></meta><meta name="dc.Creator" content="Amanda  Littlewood-Evans" /></meta><meta name="dc.Description" content="This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyros..." /></meta><meta name="Description" content="This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyros..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 21, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01582" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01582" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01582" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01582" /></link>
        
    
    

<title>A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01582" /></meta><meta property="og:title" content="A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0015.jpeg" /></meta><meta property="og:description" content="This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular assays, the compounds exhibit single-digit nanomolar potency toward VEGFR2. Compounds of this series show good exposure in rodents when dosed orally. They potently inhibit VEGF-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by ELISA for TIE-2 in lysates or by immunohistochemical analysis. This novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01582"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01582">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01582&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01582&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01582&amp;href=/doi/10.1021/acs.jmedchem.5b01582" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 132-146</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01119" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01165" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guido++Bold">Guido Bold</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Schnell">Christian Schnell</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pascal++Furet">Pascal Furet</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++McSheehy">Paul McSheehy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Josef++Br%C3%BCggen">Josef Brüggen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%BCrgen++Mestan">Jürgen Mestan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+W.++Manley">Paul W. Manley</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Dr%C3%BCckes">Peter Drückes</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marion++Burglin">Marion Burglin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ursula++D%C3%BCrler">Ursula Dürler</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacqueline++Loretan">Jacqueline Loretan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Reuter">Robert Reuter</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Markus++Wartmann">Markus Wartmann</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Theuer">Andreas Theuer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beatrice++Bauer-Probst">Beatrice Bauer-Probst</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Georg++Martiny-Baron">Georg Martiny-Baron</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Allegrini">Peter Allegrini</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arnaud++Goepfert">Arnaud Goepfert</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeanette++Wood">Jeanette Wood</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amanda++Littlewood-Evans">Amanda Littlewood-Evans</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div><div class="corresp-info"><strong>*</strong>For G.B.: phone, +41 61 696 24 97; fax, +41 61 696 62 46; E-mail, <a href="/cdn-cgi/l/email-protection#1473617d707b3a767b7870547a7b627566607d673a777b79"><span class="__cf_email__" data-cfemail="8deaf8e4e9e2a3efe2e1e9cde3e2fbecfff9e4fea3eee2e0">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For A.L.-E.: phone, +41 61 3249909; fax, +41 61 3248001; E-mail, <a href="/cdn-cgi/l/email-protection#caaba7aba4aeabe4a6a3bebea6afbda5a5aee7afbcaba4b98aa4a5bcabb8bea3b9e4a9a5a7"><span class="__cf_email__" data-cfemail="06676b67686267286a6f72726a63716969622b6370676875466869706774726f752865696b">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01582&amp;href=/doi/10.1021%2Facs.jmedchem.5b01582" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 132–146</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 2, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 July 2015</li><li><span class="item_label"><b>Published</b> online</span>21 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01582" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01582</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D132%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGuido%2BBold%252C%2BChristian%2BSchnell%252C%2BPascal%2BFuret%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D1%26contentID%3Dacs.jmedchem.5b01582%26title%3DA%2BNovel%2BPotent%2BOral%2BSeries%2Bof%2BVEGFR2%2BInhibitors%2BAbrogate%2BTumor%2BGrowth%2Bby%2BInhibiting%2BAngiogenesis%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D146%26publicationDate%3DJanuary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01582"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2448</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01582" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Guido&quot;,&quot;last_name&quot;:&quot;Bold&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Schnell&quot;},{&quot;first_name&quot;:&quot;Pascal&quot;,&quot;last_name&quot;:&quot;Furet&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;McSheehy&quot;},{&quot;first_name&quot;:&quot;Josef&quot;,&quot;last_name&quot;:&quot;Brüggen&quot;},{&quot;first_name&quot;:&quot;Jürgen&quot;,&quot;last_name&quot;:&quot;Mestan&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;W. Manley&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Drückes&quot;},{&quot;first_name&quot;:&quot;Marion&quot;,&quot;last_name&quot;:&quot;Burglin&quot;},{&quot;first_name&quot;:&quot;Ursula&quot;,&quot;last_name&quot;:&quot;Dürler&quot;},{&quot;first_name&quot;:&quot;Jacqueline&quot;,&quot;last_name&quot;:&quot;Loretan&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Reuter&quot;},{&quot;first_name&quot;:&quot;Markus&quot;,&quot;last_name&quot;:&quot;Wartmann&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Theuer&quot;},{&quot;first_name&quot;:&quot;Beatrice&quot;,&quot;last_name&quot;:&quot;Bauer-Probst&quot;},{&quot;first_name&quot;:&quot;Georg&quot;,&quot;last_name&quot;:&quot;Martiny-Baron&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Allegrini&quot;},{&quot;first_name&quot;:&quot;Arnaud&quot;,&quot;last_name&quot;:&quot;Goepfert&quot;},{&quot;first_name&quot;:&quot;Jeanette&quot;,&quot;last_name&quot;:&quot;Wood&quot;},{&quot;first_name&quot;:&quot;Amanda&quot;,&quot;last_name&quot;:&quot;Littlewood-Evans&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;132-146&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01582&quot;},&quot;abstract&quot;:&quot;This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular assays, the compounds exhibit single-digit nanomolar potency toward VEGFR2. Compounds of this series show good exposure in rodents when dosed orally. They potently inhibit VEGF-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by ELISA for TIE-2 in lysates or by immunohistochemical analysis. This novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01582&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01582" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01582&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01582" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01582&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01582" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01582&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01582&amp;href=/doi/10.1021/acs.jmedchem.5b01582" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01582" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01582" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01582%26sid%3Dliteratum%253Aachs%26pmid%3D26629594%26genre%3Darticle%26aulast%3DBold%26date%3D2016%26atitle%3DA%2BNovel%2BPotent%2BOral%2BSeries%2Bof%2BVEGFR2%2BInhibitors%2BAbrogate%2BTumor%2BGrowth%2Bby%2BInhibiting%2BAngiogenesis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D1%26spage%3D132%26epage%3D146%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/jmcmar.2016.59.issue-1/20160114/jmcmar.2016.59.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular assays, the compounds exhibit single-digit nanomolar potency toward VEGFR2. Compounds of this series show good exposure in rodents when dosed orally. They potently inhibit VEGF-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by ELISA for TIE-2 in lysates or by immunohistochemical analysis. This novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38587" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38587" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Angiogenesis is the formation of new vessels from existing ones, whereas vasculogenesis is the formation of new vessels from hematopoietic precursors. Both processes are reliant upon vascular endothelial growth factor (VEGF) and its family of receptors (VEGFR).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The VEGF family, which includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF), signals via VEGFR2, VEGFR1, and VEGFR3 cell surface tyrosine kinase receptors located on the host vascular endothelium, lymphatic, and hematopoietic systems.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These receptors become autophosphorylated at the tyrosine kinase domain upon engagement of VEGF which subsequently leads to downstream events, resulting in proliferation and migration of the vasculature.</div><div class="NLM_p">Although these are normal processes in wound healing, and during the female reproductive cycle, aberrant angiogenesis and vasculogenesis are observed in a number of pathological conditions such as rheumatoid arthritis, psoriasis, retinal complications, and tumor growth.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Growth of most solid tumors is highly dependent on the presence of newly formed vessels which provide nutrients and oxygen to the tumor microenvironment.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> VEGF has been shown to be secreted by tumor cells, thereby encouraging new growth and maintenance of a vascular network and culminating in promotion of metastatic spread.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Because the main pro-angiogenic signal for vasculature stems from VEGFR2 (also known as KDR), specific inhibition of signal transduction via the VEGF/VEGFR system is a promising approach to starve the tumor cells of nutrients and thus impede tumor growth<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and metastasis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">The respective biology and progress in modulating this system have been summarized in recent review articles.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In a collaborative effort between CIBA/Novartis and Schering AG, the phthalazine Vatalanib (PTK787/ZK222584)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and the anthranilamide AAL993<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> have been discovered as potent and selective VEGFR2 inhibitors (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). In a new screen for follow up compounds, the observation that the FLT3 inhibitor AST487 also inhibits VEGFR2 autophosphorylation (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) resulted in the discovery of the 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective VEGFR inhibitors. The activity but not the structure of two of the compounds within this series, BFH772 and BAW2881, have been described previously.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Herein we describe their structure, synthesis, and in vitro potency, which translates to excellent in vivo activities. We compare their profile to our forerunner compounds PTK787 and AAL993 as well as evaluating them against established kinase inhibitors, in particular, Sorafenib (Bayer/Onyx pharmaceuticals) and Sunitinib (Pfizer).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Forerunner compounds PTK787 and AAL993 are shown in comparison to AST487 and later generation BAW2881. Comparative inhibitory activity toward VEGFR2 versus FLT3 in cellular assays shown for the latter two compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The kinase inhibitor AST487 was originally designed as an FLT3 inhibitor. It was synthesized as described by Shieh et al.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In the FLT3-ITD-Ba/F3 cell system, AST487 blocked FLT3 dependent cell proliferation with an IC<sub>50</sub> value <5 nM.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, it exhibited only moderate selectivity for FLT3.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Besides its effects on RET kinase, AST487 also inhibited VEGFR2, VEGFR3, KIT, and ABL. Of special interest was its inhibitory activity against VEGFR2, with the compound demonstrating an IC<sub>50</sub> value of 0.23 μM in a VEGF-driven cellular receptor autophosphorylation assay in CHO cells transfected with the VEGFR2 receptor<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). To understand its binding interactions with VEGFR2, we used the crystal structure of AAL993 in complex with the kinase domain of VEGFR2.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> AAL993 binds to the inactive “DFG out” conformation of the VEGFR2 kinase as represented in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. In addition to hydrogen bonds formed with residues C919, E885, and D1046, the inhibitor makes a key hydrophobic interaction with residue V916, the “gate keeper” residue. Analogous docking of AST487 into the binding pocket of AAL993 placed the aminopyrimidine residue as the hinge binding motif of the inhibitor. Molecular modeling experiments indicated that replacing the anthranilic acid core of AAL993 by a naphthyl moiety maintains all the favorable interactions of the inhibitor with the binding pocket. This design concept illustrated in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> led to the synthesis of BAW2881,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> in which the pyridine hinge binding moiety of AAL993 was changed to an aminopyrimidine, as is the case for AST487. In contrast to AST487, BAW2881 showed higher potency and selectivity for VEGFR2 versus FLT3. The VEGF-driven cellular receptor autophosphorylation in CHO cells of BAW2881 was inhibited with an IC<sub>50</sub> of 4 nM, in the same range as for AAL993 and significantly more potent than for PKT787 (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. AAL993 (green) bound in the ATP pocket of the VEGFR2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW3">5EW3</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Only the residues proximal to the inhibitor are represented. Hydrogen bonds appear as dashed lines. BAW2881 docked in the pocket according to the design concept (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Docking of BAW2881 in a homology model of the kinase domain of FLT3 in the “DFG out” conformation<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> provided a hypothesis to explain the lack of FLT3 inhibitory activity of this compound. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, BAW2881 can form interactions with FLT3 similar to those formed with VEGFR2. However, the “gate keeper” residue in FLT3 is a phenylalanine (F691). It is bulkier than in VEGFR2, which has a valine (V916) instead. As a consequence, there is not enough space in the FLT3 ATP binding site to accommodate the upper phenyl ring of the naphthyl core of BAW2881. Thus, the docking model suggested a steric clash between this phenyl ring and F691 explaining the lack of FLT3 inhibitory activity of BAW2881.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. BAW2881 docked in the ATP binding site of a homology model of the kinase domain of FLT3 in the “DFG out” conformation (constructed based on PDB structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH">1UWH</a>). The steric clash between the “gate keeper” residue F691 and the naphthyl core of the compound is indicated by a cross. The smaller valine “gate keeper” residue of VEGFR2 is shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of the 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxamides is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>: Diarylether formation from 2-amino-4,6-dichloro-pyrimidine and 6-hydroxy-naphthyl carboxylate resulted in <b>1</b>. Amide formation with 3-trifluoromethylaniline with DEPC as the coupling reagent (→ <b>2</b>), followed by hydrogenative dechlorination, led to BAW2881. Alternatively, dechlorination of <b>1</b> gave the acid <b>3</b>, which then could be converted by T3P (<i>N</i>-propylphosphonic acid anhydride, cyclic trimer) to the amides <b>4</b> and <b>5</b>. Acylation of <b>4</b> with methyl chloroformate gave <b>6</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid Amides BAW2881, <b>4</b>, <b>5</b>, and <b>6</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Etherification of 4,6-dichloro-pyrimidine resulted in <b>7</b> (see <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Substitution of the chlorine by azide and reduction led to 6-(6-amino-pyrimidin-4-yloxy)-naphthalene carboxylate (<b>8</b>), which then was transformed into the amides <b>9</b>–<b>11</b>. Amide formation on <b>7</b> yielded the 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene carboxamide <b>12</b>. Carbonylation in ethanol employing Pd-catalysis then provided the ethylester <b>13</b>, which was reduced by NaBH<sub>4</sub> in <i>t</i>-butanol to the hydroxymethyl derivative BFH772. Replacement of the chlorine in <b>12</b> by cyanide gave the nitrile <b>14</b>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the 6-(Pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid Amides <b>9</b>–<b>11</b>, <b>13</b>, BFH772, and <b>14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Biology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> SAR around the 6-(Pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid Phenylamide Structure Type Series</h3><div class="NLM_p"><a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> summarizes the SAR around the 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid phenylamide structure type series in respect of its inhibitory potency against VEGFR2. Potency was assessed using a biochemical assay for VEGFR inhibition and a cellular test system addressing CHO autophosphorylation described in detail by Wood et al.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> An additional substituent at position 6 of the pyrimidine (2-amino-6-chloro-pyrimidine derivative <b>2</b>) was not tolerated consistent with the binding model (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), indicating a steric clash of the chlorine atom with the kinase hinge region. Moving the amino substituent to the 6-position of the pyrimidine led to <b>9</b>, which exhibited similar activity compared to BAW2881. This was expected due to the ability of aminopyrimidine groups to form bidentate hydrogen bonds with the hinge segment centered around C919. A 6-cyano derivative (<b>14</b>) was a slightly weaker inhibitor. Even less active was the 6-ethoxy-carbonyl derivative <b>13</b>, which, according to the model, was also clashing in the hinge region. In contrast, a 6-hydroxymethyl substituent on the pyrimidine (BFH772) led to a potent derivative. In the aniline part, a blocking fluorine at the 4-position of the phenyl ring was well tolerated (<b>4</b>, <b>10</b>). Replacing the 3-trifluoromethyl group by ethyl led to the highly active derivative <b>11</b>. Expanding the 4-position of the anilide with a piperazinyl-methyl group (<b>5</b>), as is the case for AST487, retained kinase activity but decreased the cellular potency for VEGFR2. Compound <b>5</b> was less selective (data not shown), targeting other kinases more potently than BAW2881. On the basis of the binding model, the piperazinyl group was expected to establish bifurcated H-bonds with the backbone carbonyl groups of VEGFR2 residues Ile1025 and His1026. These interactions have been observed in several crystal structures of inhibitors binding to the “DFG out” conformation of kinases. The loss of selectivity observed with this modification is consistent with the conserved nature of backbone interactions. The decrease in VEGFR2 cellular potency despite the formation of new favorable interactions may thus be ascribed to a detrimental effect of the piperazinyl group on compound cell permeability. Acylation of the 2-amino-pyrimidine group was tolerated with regard to VEGFR2 inhibition (<b>6</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of 6-(Pyrimidin-4-yloxy)-naphthalene-1-carboxamides in Respect to VEGFR2 Inhibition (Mean IC<sub>50</sub> Values in μM ± SEM are shown)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Single experiment.</p></div></div><div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Biochemical IC<sub>50</sub> Data on VEGFR Family Kinase Activity</h3><div class="NLM_p">In our biochemical assay, the naphthalene-1-carboxamide series generated potent IC<sub>50</sub>s for VEGFR2 which were slightly more potent than the earlier generation compounds PTK787 and AAL993. The multikinase inhibitor Sunitinib from Pfizer and Bayer and Onyx’s VEGFR, PDGFR, and RAF compound Sorafenib were of equal potency in the hVEGFR2 kinase assay. BAW2881, <b>4</b>, <b>9</b>, and <b>10</b> all lost potency (17-, 46-, 9- and 21-fold, respectively) against murine enzyme (FLK-1) compared to hVEGFR2. In addition, they also lost potency toward human VEGFR1 (FLT-1) and human VEGFR3 (FLT-4) versus hVEGFR2. BFH772 was highly effective at targeting VEGFR2 kinase with an IC<sub>50</sub> value of 3 nM, however, lost 500-fold potency on FLK-1, FLT-1, and FLT-4 (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of VEGFR Family Kinases<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±">BAW2881</th><th class="colsep0 rowsep0" align="center" char="±">BFH772</th><th class="colsep0 rowsep0" align="center" char="±"><b>4</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>9</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>10</b></th><th class="colsep0 rowsep0" align="center" char="±">PTK787</th><th class="colsep0 rowsep0" align="center" char="±">AAL993</th><th class="colsep0 rowsep0" align="center">Sorafenib</th><th class="colsep0 rowsep0" align="center" char="±">Sunitinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hVEGFR2 (KDR)</td><td class="colsep0 rowsep0" align="char" char="±">0.009 ± 0.0037</td><td class="colsep0 rowsep0" align="char" char="±">0.0027 ± 0.0009</td><td class="colsep0 rowsep0" align="char" char="±">0.007 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.004 ± 0.0002</td><td class="colsep0 rowsep0" align="char" char="±">0.006 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.055 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.023 ± 0.006</td><td class="colsep0 rowsep0" align="center">0.0078 ± 0.0009</td><td class="colsep0 rowsep0" align="char" char="±">0.0102 ± 0.0019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mVEGFR2 (FLK-1)</td><td class="colsep0 rowsep0" align="char" char="±">0.165 ± 0.064</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.53</td><td class="colsep0 rowsep0" align="char" char="±">0.320 ± 0.097</td><td class="colsep0 rowsep0" align="char" char="±">0.037 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.125 ± 0.026</td><td class="colsep0 rowsep0" align="char" char="±">0.27 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.055 ± 0.013</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="char" char="±">0.073 ± 0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hVEGFR1 (FLT-1)</td><td class="colsep0 rowsep0" align="char" char="±">0.82 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.36</td><td class="colsep0 rowsep0" align="char" char="±">0.223 ± 0.077</td><td class="colsep0 rowsep0" align="char" char="±">0.081 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.333 ± 0.109</td><td class="colsep0 rowsep0" align="char" char="±">0.077 ± 0.012</td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.081</td><td class="colsep0 rowsep0" align="center">0.402 ± 0.146</td><td class="colsep0 rowsep0" align="char" char="±">0.015 ± 0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hVEGFR3 (FLT-4)</td><td class="colsep0 rowsep0" align="char" char="±">0.42 ± 0.015</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.29</td><td class="colsep0 rowsep0" align="char" char="±">0.177 ± 0.052</td><td class="colsep0 rowsep0" align="char" char="±">0.050 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.235 ± 0.043</td><td class="colsep0 rowsep0" align="char" char="±">0.064 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.018 ± 0.001</td><td class="colsep0 rowsep0" align="center">0.245 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.024 ± 0.0038</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Mean IC<sub>50</sub> values in μM ± SEM are shown. Kinase activity was tested by measuring the phosphorylation of a synthetic substrate (poly[Glu, Tyr]), by purified GST-fusion kinase domains of receptor tyrosine kinases, in the presence of radiolabelled ATP; ATP-concentrations used were optimized within the Km range for the individual kinases. nd is not determined.</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Selectivity: Biochemical IC<sub>50</sub> Data on other Kinases</h3><div class="NLM_p last">Overall the naphthalene-1-carboxamide series displayed similar selectivity to the forerunner compounds PTK787 and AAL993. BAW2881 inhibited a limited number of kinases including c-RAF, B-RAF, RET, ABL, and TIE-2 at sub-μM IC<sub>50</sub>s. BFH772 was highly selective; apart from inhibiting VEGFR2 at 3 nM IC<sub>50</sub>, it also targeted B-RAF, RET, and TIE-2, albeit with at least 40-fold lower potency. These two compounds were inactive (IC<sub>50</sub> > 10 μM; > 2 μM for cKIT) against all other tyrosine specific- and serine/threonine-specific protein kinases tested. Compounds <b>4</b>, <b>9</b>, and <b>10</b> were also relatively specific but in addition to the aforementioned kinases also showed activity against a number of other protein kinases including cKIT and weakly against c-FMS. Sorafenib and Sunitinib displayed a broader spectrum of activity, with additional IC<sub>50</sub> values generated for FLT3, c-SRC, cMET, EphB4, CDK1, and FGFR3 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 1</a>).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cellular VEGFR2 Assays</h3><div class="NLM_p">In cellular VEGF-induced VEGFR2 autophosphorylation assays, PTK787 was previously reported to have an IC<sub>50</sub> of 17 ± 2 nM and 34 ± 2 nM in HUVEC and CHO cells, respectively<a onclick="showRef(event, 'ref9 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref15">(9, 15)</a> whereas AAL993 was more potent at 1.2 ± 0.19 nM in the latter assay.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Sunitinib and Sorafenib gave IC<sub>50</sub> values of 8.75 ± 0.75 and 8 ± 0.5 nM respectively when profiled in our VEGFR2 autophosphorylation assay in CHO cells. The VEGFR2 inhibitors of the 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamide structure class as exemplified by BAW2881, BFH772, <b>4</b>, <b>9</b>, and <b>10</b> revealed 5–15-fold enhanced potency when compared to PTK787. They were in the same range as AAL993, Sorafenib, and Sunitinib, exhibiting single digit nanomolar potency in the CHO cellular assay (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibition of CHO and HUVEC VEGFR2 Phosphorylation Assays<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±">BAW2881</th><th class="colsep0 rowsep0" align="center" char="±">BFH772</th><th class="colsep0 rowsep0" align="center"><b>4</b></th><th class="colsep0 rowsep0" align="center"><b>9</b></th><th class="colsep0 rowsep0" align="center"><b>10</b></th><th class="colsep0 rowsep0" align="center" char="±">PTK787</th><th class="colsep0 rowsep0" align="center">AAL993</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2 (CHO)</td><td class="colsep0 rowsep0" align="char" char="±">0.0042 ± 0.0002</td><td class="colsep0 rowsep0" align="char" char="±">0.0046 ± 0.0006</td><td class="colsep0 rowsep0" align="center">0.004 ± 0.001</td><td class="colsep0 rowsep0" align="center">0.002 ± 0.001</td><td class="colsep0 rowsep0" align="center">0.003 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.034 ± 0.002</td><td class="colsep0 rowsep0" align="center">0.0012 ± 0.0002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2 (HUVEC)</td><td class="colsep0 rowsep0" align="char" char="±">0.0029 ± 0.0003</td><td class="colsep0 rowsep0" align="char" char="±">0.003 ± 0</td><td class="colsep0 rowsep0" align="center">0.004</td><td class="colsep0 rowsep0" align="center">0.003</td><td class="colsep0 rowsep0" align="center">0.0023</td><td class="colsep0 rowsep0" align="char" char="±">0.017 ± 0.002</td><td class="colsep0 rowsep0" align="center">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Mean IC<sub>50</sub> values (μM) for inhibition of KDR tyrosine kinase in CHO-VEGFR2 and HUVEC cells. nd is not determined.</p></div></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Cellular Selectivity Assays</h3><div id="sec3_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> RTK Phosphorylation Assays</h4><div class="NLM_p">BFH772 and BAW2881 were tested in an ELISA-based assay measuring phosphorylation of the receptor tyrosine kinase after cells were stimulated with the respective ligand.</div><div class="NLM_p last">BFH772 and BAW2881 both inhibited the ligand induced autophosphorylation of RET, PDGFR, and KIT kinases, with IC<sub>50</sub> values ranging between 30 and 160 nM. The compounds were selective (IC<sub>50</sub> values >0.5 μM) against the kinases of EGFR, ERBB2, INS-R, and IGF-1R and against the cytoplasmic BCR-ABL kinase (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 2</a>).</div></div><div id="sec3_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Ba/F3 Cellular Assays</h4><div class="NLM_p">The potential for compounds to inhibit various kinases in a cellular context was also determined in the Ba/F3 assay system consisting of wild-type IL-3-dependent hematopoietic Ba/F3 cell models rendered IL-3 independent by transduction with various constitutively active tyrosine kinases.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> All compounds of the naphthalene-1-carboxamide series were 20–100-fold more potent than PTK787 and approximately the same order of magnitude as AAL993 and Sorafenib in the cellular Ba/F3 VEGFR2 assay (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In a series of additional Ba/F3 cell lines, all naphthalene-1-carboxamides targeted RET and PDGFRβ kinases in addition to VEGFR2 but displayed weak (>1 μM) activity against other kinases such as FGFR3 and c-KIT (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Sorafenib and Sunitinib were less selective, generating IC<sub>50</sub> values for many of the kinases.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Cellular Selectivity in Ba/F3 Assay<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Ba/F3 line IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">BAW2881</th><th class="colsep0 rowsep0" align="center">BFH772</th><th class="colsep0 rowsep0" align="center"><b>4</b></th><th class="colsep0 rowsep0" align="center"><b>9</b></th><th class="colsep0 rowsep0" align="center"><b>10</b></th><th class="colsep0 rowsep0" align="center">PTK787</th><th class="colsep0 rowsep0" align="center">AAL993</th><th class="colsep0 rowsep0" align="center">Sorafenib</th><th class="colsep0 rowsep0" align="center">Sunitinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-KDR-myc1.3</td><td class="colsep0 rowsep0" align="center">0.004 ± 0.001</td><td class="colsep0 rowsep0" align="center">0.002*<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">0.009 ± 0.002</td><td class="colsep0 rowsep0" align="center">0.002 ± 0.001</td><td class="colsep0 rowsep0" align="center">0.005 ± 0.002</td><td class="colsep0 rowsep0" align="center">0.215 ± 0.043</td><td class="colsep0 rowsep0" align="center">0.013 ± 0.004</td><td class="colsep0 rowsep0" align="center">0.014 ± 0.0023</td><td class="colsep0 rowsep0" align="center">0.238 ± 0.018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bcr-ABL</td><td class="colsep0 rowsep0" align="center">4.748 ± 0.844</td><td class="colsep0 rowsep0" align="center">7.5**<a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">9.5**<a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >5.5</td><td class="colsep0 rowsep0" align="center">5.82 ± 0.237</td><td class="colsep0 rowsep0" align="center">7.177 ± 2.534</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NPM-ALK</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >5.5</td><td class="colsep0 rowsep0" align="center">1.015 ± 0.12</td><td class="colsep0 rowsep0" align="center">1.154 ± 0.1302</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERBB2 (V659E)</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">5.6*<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">4.208 ± 0.173</td><td class="colsep0 rowsep0" align="center">3.846 ± 0.572</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-FGFR3</td><td class="colsep0 rowsep0" align="center">8.271 ± 0.988</td><td class="colsep0 rowsep0" align="center">6.540 ± 0.290</td><td class="colsep0 rowsep0" align="center">8.257 ± 0.091</td><td class="colsep0 rowsep0" align="center">2.279 ± 0.041</td><td class="colsep0 rowsep0" align="center">2.658 ± 0.054</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >5.5</td><td class="colsep0 rowsep0" align="center">2.458 ± 0.156</td><td class="colsep0 rowsep0" align="center">1.561 ± 0.295</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3-ITD</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">8.2*<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">5.646 ± 1.974</td><td class="colsep0 rowsep0" align="center">4.778 ± 0.152</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >5.5</td><td class="colsep0 rowsep0" align="center">0.012 ± 0.0021</td><td class="colsep0 rowsep0" align="center">0.035 ± 0.0028</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-IGF-1R</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">7.2**<a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">8.9*<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">8.4*<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">3.681 ± 0.881</td><td class="colsep0 rowsep0" align="center">1.289 ± 0.412</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KIT(D816 V)</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">8.506 ± 0.236</td><td class="colsep0 rowsep0" align="center">8.0**<a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">7.8**<a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >5.5</td><td class="colsep0 rowsep0" align="center">2.804 ± 0.33</td><td class="colsep0 rowsep0" align="center">1.469 ± 0.247</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Trp-MET</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >5.5</td><td class="colsep0 rowsep0" align="center">7.40 ± 0.786</td><td class="colsep0 rowsep0" align="center">5.124 ± 0.101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTC3-RET</td><td class="colsep0 rowsep0" align="center">0.152 ± 0.036</td><td class="colsep0 rowsep0" align="center">0.104 ± 0.026</td><td class="colsep0 rowsep0" align="center">0.226 ± 0.005</td><td class="colsep0 rowsep0" align="center">0.009 ± 0.002</td><td class="colsep0 rowsep0" align="center">0.040 ± 0.012</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">2.9*<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">0.078 ± 0.012</td><td class="colsep0 rowsep0" align="center">0.297 ± 0.0078</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-PDGFRbeta</td><td class="colsep0 rowsep0" align="center">0.009 ± 0.002</td><td class="colsep0 rowsep0" align="center">0.027 ± 0.003</td><td class="colsep0 rowsep0" align="center">0.016 ± 0.001</td><td class="colsep0 rowsep0" align="center">0.004 ± 0.001</td><td class="colsep0 rowsep0" align="center">0.010 ± 0.004</td><td class="colsep0 rowsep0" align="center">0.076 ± 0.026</td><td class="colsep0 rowsep0" align="center">0.019 ± 0.0055</td><td class="colsep0 rowsep0" align="center">0.013 ± 0.0025</td><td class="colsep0 rowsep0" align="center">0.0023 ± 0.0007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT (untransduced)</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">The concentration-dependent effect of test compound on proliferation and viability of Ba/F3 cell models was determined by the resazurin sodium reduction assay. IC<sub>50</sub> values (μM) from at least two independent experiments, unless indicated otherwise, are presented as mean ± SEM.</p></div><div class="footnote" id="t4fn1"><sup>b</sup><p class="last">*Only one determination.</p></div><div class="footnote" id="t4fn2"><sup>c</sup><p class="last">**At least one replicate value >10 μM. IC<sub>50</sub> is defined as the drug concentration inhibiting Ba/F3 cell viability to 50% of that measured for vehicle-treated controls. All cells except parental Ba/F3-wt were grown in the absence of IL-3.</p></div></div></div><div class="NLM_p last">Taking these data together, overall this new series of compounds displayed selectivity against a panel of kinases comparable to PTK787 and AAL993 but more selective than Sorafenib and Sunitinib. The naphthalene-1-carboxamides were several fold more potent than PTK787 against VEGFR2. Interestingly, the naphthalene-1-carboxamides largely showed equal potency in the enzyme tyrosine kinase profiling and in cellular assays. This suggested that the compounds efficiently penetrated the cytoplasmic membrane of cells in the latter assay, a phenomenon that we have previously observed.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div><div id="sec3_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Activity in VEGF Induced Proliferation (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>)</h4><div class="NLM_p">The naphthalene-1-carboxamides were subsequently tested in a functional assay before in vivo studies were initiated. In HUVEC endothelial cell proliferation assays, PTK787 was previously demonstrated to exhibit an IC<sub>50</sub> of 7.1 ± 5.1 nM against VEGF-induced proliferation.<a onclick="showRef(event, 'ref9 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref15">(9, 15)</a> AAL993 and Sunitinib exhibited an IC<sub>50</sub> of 1 ± 0.16 nM and 7 ± 6 nM, respectively, whereas the naphthalene-1-carboxamides were substantially more potent. IC<sub>50</sub> values of BAW2881 (0.12 ± 0.06 nM, <i>n</i> = 4), compound <b>10</b> (0.003 ± 0.002 nM, <i>n</i> = 2), BFH772 (<0.01 nM, <i>n</i> = 2 see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), and compound <b>4</b> (0.077 nM see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) demonstrated that they abrogated VEGF induced proliferation at remarkably low nM concentrations. Compound <b>9</b> at IC<sub>50</sub> values of 1.7 ± 1.6 nM, <i>n</i> = 2, was more similar to the anthranilic acid amide AAL993. The compounds were selective against VEGF induced proliferation. Only <b>10</b> revealed an IC<sub>50</sub> of 206 ± 44 nM (<i>n</i> = 2) against FGF induced proliferation of HUVEC cells, which nevertheless was several orders of magnitude higher than for VEGF-induced proliferation. The other compounds were >3 μM against bFGF. We speculate that the reason for the extremely low IC<sub>50</sub> values obtained in the VEGF induced HUVEC proliferation assay are due to the fact that these compounds are able to penetrate the cytoplasmic membrane. Because of the relatively long duration (48 h) of the experiment, we hypothesized that the inhibitors accumulated in the endothelial cells and that this translated into the subnanomolar efficacy. We were able to rule out potential cytotoxic effects because compounds started to affect viability of HUVEC cells as assessed by the YoPro assay only at 10 μM and above (data not shown).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. HUVEC proliferation assay in the presence of VEGF (10 ng/mL) (two left-hand graphs) or bFGF (0.5 ng/mL) (right-hand graph). Basal proliferation shown with the white bar, and growth factor induced proliferation with the black bar. Compounds were added at the doses shown below the bars: e.g., <i>V</i> + 0.01 is VEGF plus 0.01 nM compound; <i>b</i> + 0.1 is bFGF plus 0.1 nM compound. BFH772 in the left-hand graph shows full inhibitory activity at the lowest dose of 0.01 nM against VEGF induced proliferation. Compound <b>4</b> is shown for comparison in the middle graph. Compound <b>4</b> showed no activity against bFGF induced proliferation (right-hand graph).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Pharmacokinetics</h3><div class="NLM_p">To determine whether the most potent cellular and biochemical VEGFR2 compounds of the 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid phenylamides series were orally bioavailable, plasma concentrations were measured after administration to mice in a preliminary screen (not shown) and subsequently in rats as described.<a onclick="showRef(event, 'ref9 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref15">(9, 15)</a> Even though manifesting low aqueous solubility only, most compounds showed exposure after oral administration (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). In the preliminary mouse PK screen, the potent cellular and biochemical VEGFR2 inhibitor, compound <b>11</b>, showed a shorter half-life than compounds <b>4</b>, <b>10</b>, <b>9</b>, BFH772, and BAW2881. We hypothesized that <b>11</b> could be metabolically labile because it contains an ethyl side chain in its structure. As we had many other equipotent alternatives, we chose to deprioritize this inhibitor. Rat PK demonstrated that half-lives were variable, with <b>10</b> having the longest duration of 18.3 h when applied intravenously. Graphs of three of the compounds, BAW2881, BFH772, and <b>4</b>, are shown (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). The pharmacokinetic profile of the compounds suggested that this series would be suitable for testing in in vivo models.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Table showing dose normalized (dn) PK parameters over 24 h in a set of rat PK experiments (female OFA rats for BAW2881 and BFH772; female Sprague–Dawley rats for compounds <b>4</b>, <b>10</b>, and <b>9</b>). At 5, 15, and 30 min and 1, 2, 4, 6, 8, and 24 h time points, drug concentrations in plasma were determined by HPLC/UV. Data represent SEM (<i>n</i> = 2–4 animals per group). CL is clearance, <i>V</i><sub>ss</sub> is volume of distribution at steady state. The value <i>C</i><sub>max.</sub> represents the highest observed concentration (dose normalized) at the indicated time point (<i>t</i><sub>max.</sub>). <i>T</i><sub>1/2</sub> is the half-life of the compounds exposure in plasma. AUC is the area under the curve–total exposure over 0 h → infinity, dose normalized. BA is percent bioavailability; nm is not measured. (B) Example PK, time dependent exposure profiles for BAW2881 (<i>n</i> = 4), BFH772 (<i>n</i> = 2 for iv, and <i>n</i> = 3 for po), and compound <b>4</b> (<i>n</i> = 2 for iv and <i>n</i> = 3 for po) shown. Gray triangles are iv administration, and black diamonds are po dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Activity in Vivo</h3><div id="sec3_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> VEGF Skin Implant Miles Assay in Mouse</h4><div class="NLM_p last">Two compounds of the naphthalene-1-carboxamide series were evaluated (<b>4</b> and BFH772) in a VEGF-induced vessel leakage miles assay<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> to confirm that the compounds would be suitable for dosing in longer term in vivo models. Doses were chosen based on rodent PK calculations and potency of the compounds in the various in vitro assays. For example, at 24 h, dose normalized exposure of compound <b>4</b> was 15 nM, for BAW2881 was 31 nM, and for BFH772 was 83 nM, all of which were still more than the IC<sub>50</sub> value for VEGFR2 in vitro. We therefore opted to test inhibitors at 3 mg/kg initially because we expected that this would be sufficient to fully inhibit the VEGFR over the time period. Evans blue was injected intravenously into the mouse tail vein, and 30 min later, 2 μL of dog VEGF164 (10 ng/μL) was injected intradermally into the dorsal pinna of the ear of the mouse. Vascular permeability was visualized by Evans blue extravasation measured with a computer assisted system. Compound <b>4</b> was applied 48, 24, and 8 h before sacrifice and BFH772 at 48 and 24 h before sacrifice. Compared to time 0, both VEGFR2 inhibitors, but especially <b>4</b> due to its long half-life substantially inhibited extravasation, even at 48 h prior to application of VEGF and Evans blue (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 3</a>).</div></div><div id="sec3_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> VEGF-Induced Angiogenesis Chamber Model</h4><div class="NLM_p">The miles assay gave us confidence to assess the compound activity in more complex long-term in vivo models. The inhibition of a VEGF-mediated angiogenesis response after oral administration of the naphthalene-1-carboxamide inhibitors was measured in a growth factor chamber implant model in mice.<a onclick="showRef(event, 'ref9 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref15">(9, 15)</a> Over a 4 day period, a new blood vessel rich tissue is formed around the VEGF agar containing implanted chamber. This tissue can be removed, weighed, and TIE-2 protein as a measure of endothelial cell amount and therefore, vascularity, assessed in the lysate.</div><div class="NLM_p">As BFH772 exhibited a good PK profile in rats with good <i>C</i><sub>max</sub> and half-life characteristics as well as its potency and relative selectivity toward VEGFR2 in vitro, we considered this compound to be one of the best in the series. We also studied <b>4</b> in more detail as this compound exhibited a different profile to BFH772 in the pharmacokinetic analysis (mice), having an extended half-life of 10 h compared to 4 h for BFH772 but with a similar selectivity and potency in the in vitro profiling. Dose–response curves of BFH772 at 0.3, 1, and 3 mg/kg demonstrated that even at the lowest concentrations, this naphthalene-1-carboxamide inhibited VEGF induced tissue weight and TIE-2 levels but only reached statistical significance at 1 mg/kg and above (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A,B). Compound <b>4</b> on the other hand, already significantly reduced the tissue weight and TIE-2 levels back to basal at a dose of 0.3 mg/kg (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C,D). Other compounds of this series, <b>9</b>, <b>10</b>, and BAW2881, were also substantially more potent than the two forerunners PTK787 (IC<sub>50</sub> of 30 mg/kg) and AAL993 (IC<sub>50</sub> 7 mg/kg)<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> on tissue chamber weight (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 4</a> and data not shown). The mice tolerated the compounds well and no signs of toxicity were observed. Vandetanib, (an EGFR, VEGFR, and RET tyrosine kinase inhibitor developed by Astra Zeneca) and SU6668 (a VEGFR, PDGFR, cKIT, and bFGF inhibitor from Sugen) at 50 mg/kg inhibited tissue weight with similar efficacy to AAL993 and PTK787 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 4</a>).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Dose–response curve of BFH772 on tissue weight (A) and TIE-2 levels (B) and compound <b>4</b> on tissue weight (C) and TIE-2 levels (D). PEG200 vehicle treated animals were either implanted with agar chambers as a negative control (black bar) or with VEGF containing chambers as a positive control (white bar). BFH772 (0.3, 1, and 3 mg/kg) or compound <b>4</b> (0.3 and 3 mg/kg) treated mice were implanted with VEGF containing chambers (gray bars). Porous chambers containing VEGF (2 μg/mL) in 0.5 mL of 0.8% w/v agar (containing heparin, 20 U/mL) were implanted subcutaneously in the flank of female FVB mice. Compounds were administered po once daily in a vehicle of 100% PEG200 (dose volume 5 mL/kg). Treatment was started 4–6 h before implantation of the chambers and continued for 4 days. The chambers were removed 24 h after the last dose. Each experiment was performed on groups of six mice per dose. Values are mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Tumor Models</h3><div id="sec3_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> B16 Melanoma</h4><div class="NLM_p">The antitumor activity of these naphthalene-1-carboxamides was evaluated in an orthotopic B16 melanoma model in C57/B16 mice as described by LaMontagne et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> A primary tumor forms in the ear where the cells are implanted and spontaneously formed cranial lymph node metastases occur in 100% of the cases, making this a very reproducible tumor model. Briefly, the highly metastatic subline B16/BL6 derived from B16 melanoma cells was injected intradermally under the skin of the ear of an anaesthetized mouse and primary tumor growth measured over the following 21 days. After this time, the mice were sacrificed and cranial lymph node metastases were excised and weighed.</div><div class="NLM_p">BAW2881, <b>4</b>, <b>9</b>, <b>10</b>, and BFH772 all at 3 mg/kg orally dosed once per day potently inhibited melanoma growth (by 54–90% for primary tumor and 71–96% for metastasis growth) as depicted by treatment to control ratios (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). At 3 mg/kg, the naphthalene-1-carboxamides showed the equivalent or better inhibition of primary and metastatic tumor growth that 100 mg/kg PTK787 could achieve. AAL993, Sunitinib, and Sorafenib had to be dosed at between 50 and 100 mg/kg to attain similar efficacy, while SU6668 and Vandetanib were substantially less potent (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a> and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 5</a>). The naphthalene-1-carboxamides were well tolerated, with no obvious effects on the well-being or behavior of the mice. Body weight and spleen weight was unaffected by the administration of the naphthalene-1-carboxamides compared to a healthy naive mouse (data not shown). At the end of the experiment, blood was taken from the animals to look for any cellular abnormalities. Blood chemistry showed that mice with high tumor burden (vehicle treated animals) showed lower hematocrit levels and red blood cell counts than compound treated animals, probably due to the fact that the tumor was full of leaky blood vessels providing an avenue for loss of blood components. Hematocrit levels and red blood cell counts returned to normal nontumor bearing naïve mouse quantities in the naphthalene-1-carboxamide treated animal blood, presumably due to the compounds efficacy and reduction in abnormal vasculature (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 6</a> for BAW2881 and BFH772, others not shown). Other blood cell parameters measured (white blood cells, platelets) were normal (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 6</a> and data not shown).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Table showing compound, dose, number of experiments performed and T/C (treatment/control) for B16 primary tumor growth and metastatic weights. Treatment was started at day 7 when the primary B16 tumor was already established after assignment of female C57Bl6 to groups of 5–6 animals with similar mean and range of tumor size. Primary tumor was measured with computer assisted imaging software. After two weeks of daily qd treatment (day 21 after cell injection), the animals were sacrificed and the cervical lymph nodes weighed. Vehicle was 100% PEG 200. <i>n</i> = 6 animals per group. (B,C) TIE-2 levels in the lysates from metastases from the B16/BL6 melanoma model. Results from analysis of BAW2881 (B) and compound <b>4</b> (C) shown. <i>n</i> = 6–12 animals per group. Values are mean ± SEM *<i>p</i> < 0.05, **<i>p</i> < 0.01 statistical significance of inhibition. (D–F) DCE-MRI analysis of lymphnode metastases. The parameters determined by DCE-MRI of Ktrans (D), iAUEC (E), and Vp (F) show the changes in individual mice and the associated mean ± SEM (<i>n</i> = 7–8 animals), with significance determined by a 1-way ANOVA, where *<i>p</i> < 0.05, **<i>p</i> < 0.01 compared to vehicle-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Metastases were taken on day 21 and a protein lysate prepared from which TIE-2 levels as a measure of endothelial cell content was assessed by ELISA (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B,C). In line with the reduced tumor volumes, the naphthalene-1-carboxamides significantly reduced TIE-2 levels for BAW2881 and <b>4</b>. We ruled out any direct effects of the naphthalene-1-carboxamides on proliferation rate of the B16 melanoma cells by incubating compounds for 48 h with tumor cells and measuring BrdU incorporation (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">Figure 7</a>). These data suggest that the naphthalene-1-carboxamides, rather than affecting tumor cells, targeted the tumor vasculature, thus starving the tumor of nutrients and stunting further growth.</div><div class="NLM_p">Consistent with antiangiogenic activity, <b>4</b> and, as previously described, PTK787,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> significantly reduced the vascular permeability of B16 melanoma cervical metastases, as determined by DCE-MRI<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (Figure<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>D–F). After 3 days of daily treatment, there was a highly significant decrease in Ktrans compared to baseline, of 51% and 61% for PTK787 and <b>4</b>, respectively. Furthermore, the tumor plasma volume (<i>V</i><sub>p</sub>) and the parameter normally utilized in the clinic to assess tumor blood vessel permeability (iAUEC) were also significantly reduced by <b>4</b> by approximately 65%, while PTK787 showed a nonsignificant trend for inhibition with decreases of 33–39%.</div><div class="NLM_p">We further performed dose response studies with BFH772 and <b>4</b> in the B16 melanoma model to estimate the minimal efficacious dose. In addition, because compound <b>4</b> had a half-life of just over 10 h, we were interested in investigating whether dosing on alternate days versus daily treatment impacted tumor growth (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effect of BFH772 (A) and compound <b>4</b> (B) on primary tumor growth rate and cervical lymphnode metastasis weight in the B16 melanoma model. Treatment was started at day 7 when the primary B16 tumor was already established after assignment of female C57Bl6 to groups of 6–10 animals with similar mean and range of tumor size. Primary tumor was measured with computer assisted imaging software. Vehicle was 100% PEG 200. <i>n</i> = 10 animals per group. BFH772 and compound <b>4</b> were six animals per group. BFH772 was dosed daily from treatment start. Compound <b>4</b> was dosed daily or once every 2 days from day 7. Significance determined by a 1-way ANOVA post-Dunnet’s test, where *<i>p</i> < 0.05, compared to vehicle-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Both compounds inhibited primary and metastatic tumor growth at 3 mg/kg and BFH772 at 1 mg/kg reached statistical significance with regard to the metastasis weight. Interestingly, <b>4</b>, when applied every 2 days at 3 mg/kg, attained a statistically significant inhibition of both primary and metastatic tumor weight, the latter readout comparable to 3 mg/kg daily (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).</div></div><div id="sec3_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> BN472 Mammary Carcinoma</h4><div class="NLM_p">A second orthotopic tumor model using BN472 mammary carcinoma cells implanted into the breast pads of rats was performed with BAW2881 and <b>4</b>. Both compounds substantially inhibited tumor growth with BAW2881, showing a weaker efficacy than <b>4</b> with a T/C of 35.5% versus 5.6%, respectively. To achieve the same level of inhibition, PTK787 had to be dosed at 100 mg/kg compared to 3 mg/kg for <b>4</b> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A), while AAL993 (100 mg/kg) was reported to inhibit tumor growth with a T/C value of 0.37<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and Vandetanib (30 mg/kg), a T/C of 0.35. There were no significant effects on rat body weight for any of the treatments (results not shown).</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) BN472 tumor growth curves over 14 days with compounds treated qd. Vehicle was PEG300. Female Brown–Norway rats were randomized when tumor volume was approximately 200 mm<sup>3</sup> before treatment started. Experiment performed twice, <i>n</i> = 7–8 animals per group. (B) Histology of tumors after treatment with KDR inhibitors PTK787 and compound <b>4</b>. Perfusable blood vessels were highlighted by shortly injecting the animal with Hoechst dye 1 min before sacrifice (left panel of photomicrographs). Ten micrometer sections were stained with Ki67 to highlight tumor proliferation (middle column) or caspase 3 to observe tumor apoptosis (right column). Bar is 100 μm. All three compounds caused a significant inhibtion of tumor-growth compared to vehicle by day 14 of treatment (<i>p</i> < 0.05, 2-way RM-ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Animals were injected intravenously with Hoechst dye shortly before sacrifice to highlight perfusable blood vessels. Upon sacrifice, the tumors were excised and cryosections cut to visualize the Hoechst highlighted vasculature, tumor proliferation with Ki67 staining, and apoptosis with caspase 3 (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B). Vehicle treated tumors had a high blood vessel density, which was substantially reduced in the PTK787 treated animals and further depleted in the <b>4</b> and BAW2881 treatment groups (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B left column, vehicle, PTK787 and <b>4</b> shown). By targeting the vasculature in the tumor with the VEGFR2 kinase inhibitors, the environment is predicted to become hypoxic, leading to less proliferation and more apoptosis of the tumor cells. Indeed, less tumor proliferation was observed in the PTK787 treated animals, a feature which was augmented with the naphthalene-1-carboxamide series (middle column). Likewise, apoptosis of tumor cells was especially promoted upon treatment with <b>4</b> (right column).</div><div class="NLM_p last">A further study with compound <b>4</b> applied at 3 and 1 mg/kg daily and 1 mg/kg every 2 days to rats bearing BN472 tumors revealed T/C ratios of 0.005, 0.028, and 0.176, respectively (data not shown). This compound was therefore highly effective even when applied every other day.</div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Discussion and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This paper describes the design and synthesis of a new and potent, highly selective series of VEGFR2 inhibitors. Structure-based morphing of the rather unselective FLT3 inhibitor AST487 led to the 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides, a class of potent VEGFR2 inhibitors being devoid of residual FLT3 activity. The design was guided by the X-ray structure of AAL993 complexed to VEGFR2. Herein, the pyridine structure element of AAL993 was replaced by an aminopyrimidine as we have observed for the hinge binding motif for AST487. Subsequently, the anthranilic acid core of AAL993 was substituted by a naphthyl moiety. These modifications maintained all the favorable interactions between inhibitor and the ATP binding pocket of VEGFR2 and led to the BAW2881 series. In addition, to understand the selectivity profile of the 6-(amino-pyrimidin-4-yloxy)-naphthalene-1-carboxamides, BAW2881 was docked into the respective homology model of the kinase domain of FLT3 where it sterically clashed with the “gate keeper” residue. The binding hypothesis based on the X-ray structure of AAL993 bound to VEGFR2 explains the established SAR around the hinge binding moiety of the 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides: 2-amino- (eg BAW2881), 6-amino- (eg compound <b>9</b>), or 6-hydroxy-methyl-pyrimidines (eg BFH772) are highly potent inhibitors for VEGFR2. In contrast, bulkier hinge binders (compound <b>13</b>) or 2-amino-6-chloro-pyrimidines (compound <b>2</b>) are weaker inhibitors.</div><div class="NLM_p">In cellular assays, these compounds have low nanomolar potency against VEGFR2 and exhibit very little activity toward other kinases with the exception of RET and PDGFR. Taking into account both cellular and biochemical assays, other potential kinases targeted were RAF, a common mutation in many cancers, and weaker TIE-2 and c-KIT. VEGFR2, TIE-2, and PDGFR are well established antiangiogenesis targets by disrupting the vasculature and surrounding pericytes.<a onclick="showRef(event, 'ref4 ref22'); return false;" href="javascript:void(0);" class="ref ref4 ref22">(4, 22)</a> RET mutations are often found in thyroid cancers,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> while c-KIT mutations are associated with GIST,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> indicating that these tumor types would be potential indications for the naphthalene-1-carboxamide series.</div><div class="NLM_p">The high selectivity of our inhibitors gives them a potential advantage over the multikinase inhibitors in that side effects should be reduced. Vandetanib, Sorafenib, and Sunitinib target a broader spectrum of kinases and although efficacious for cancers of the thyroid, kidney, GIST, and liver, are associated with severe side effects such as QT prolongation, cutaneous rash, and hand-and-foot skin reaction, necessitating drug interruption for periods of time to allow the patient to recover. Although some of these side effects are not life threatening, they do impair quality of life and raise the potential for tumors to regrow during the cessation of treatment.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> On the other side, there is a growing body of evidence from the clinic that VEGFR2 therapy can rapidly lead to resistance as the tumor microenvironment starts to depend upon other pathways.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> How tumor cells communicate with the stroma and vasculature is not fully understood. However, it is appreciated that interfering with the cross talk between these with multikinase inhibitors influences the tumor microenvironment and that this may be a route to overcome drug resistance despite associated side effect profiles of these inhibitors.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The fact that there are numerous multikinase inhibitors successfully treating cancer patients would suggest that there is a benefit to targeting a broad spectrum of signaling pathways.</div><div class="NLM_p">The naphthalene-1-carboxamide compounds have the advantage that they are potent. They show reasonable pharmacokinetic exposure and are able to inhibit VEGF-induced vascular leakage, VEGF-induced chamber models, and rodent orthotopic tumor models at doses as low as 3 mg/kg per day. BFH772 and compound <b>4</b> due to their pharmacokinetic profile stood out as the best two of the series, the latter compound due to its half-life and exposure, able to show tumor weight inhibition when dosed every 2 days. As predicted by their mode of action, the compounds target tissue vasculature as observed with TIE-2 ELISA levels in the tissue chamber model and vasculature by Hoechst perfusion in a tumor model. This ultimately leads to a lower tissue weight growing around the implanted chamber and an increase in tumor cell death accompanied by lower amounts of proliferation in the tumor models, respectively.</div><div class="NLM_p">Neoangiogenesis also plays an important role in other, noncancerous diseases. Among them are inflammatory skin disorders such as psoriasis. In this context, a strong inhibitory effect of BAW2881 in in vitro and in vivo psoriasis preclinical models has been demonstrated, highlighting the fact that VEGF receptor kinase inhibitors might be useful for the treatment of patients with inflammatory skin disorders.<a onclick="showRef(event, 'cit11c'); return false;" href="javascript:void(0);" class="ref cit11c">(11c)</a> Furthermore, the inhibitory effect of BFH772 in preclinical models of skin inflammation has also been described.<a onclick="showRef(event, 'cit11d'); return false;" href="javascript:void(0);" class="ref cit11d">(11d)</a></div><div class="NLM_p last">Our findings show that this new series of naphthalene-1-carboxamides display potent, orally active, and well-tolerated inhibition of VEGF-mediated responses. With the caveats described above for selective kinase inhibitors versus multikinase drugs, our compounds have the potential to be suitable, not only for cancers dependent on VEGF for their vascularization but also for other diseases where VEGF-mediated angiogenesis plays a crucial pathogenic role.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05722" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05722" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Materials</h3><div class="NLM_p last">Human umbilical vein cells (HUVEC) were from PromoCell as were Endothelial Cell Growth Medium Kit and Endothelial Cell Basal Medium (BioConcept AG, Allschwil/Switzerland). They were used from passage of <b>4</b> to <b>7</b>. Compounds were all synthesized in the Department of Oncology Research (Novartis Pharmaceuticals). For in vitro assays, a stock solution of 10 mM compound was prepared in DMSO. This was diluted further in buffer or medium. The KDR-transfected CHO cells were obtained from the Institute of Molecular Medicine (Tumor Biology Center). For Ba/F3 cells, see ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>. VEGF<sub>164</sub> used for the chamber implant model was from the Tumor Center, Freiburg Germany. TIE-2 ELISA was with a capture antibody, anti-TIE-2 AB33 (UBI, Hauppauge, NY). Detection antibody was with goat antimouse TIE-2 (R&D Systems, Minneapolis, MN) followed by alkaline phosphatase conjugated to monoclonal antigoat antibody (Sigma, St Louis, MO). TIE-2 complexes were detected by incubating with <i>p</i>-nitrophenyl phosphate (Sigma tablets). B16/BL6 melanoma cells were a kind gift from Dr. Isaiah J Fidler, Texas Medical Center, Houston, TX. For immunohistochemistry, Hoechst dye was obtained from Sigma, rabbit antimouse active caspase 3 was from Oncogene, Uniondale, NY, and rabbit antimouse Ki67 was from Neomarkers, Fremont, CA. Secondary antibodies were goat antirabbit ALEXA 568 or 488 (Molecular Probes).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Biology</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> In Vitro Kinase Assay</h4><div class="NLM_p last">In vitro kinase assays have been described by Wood et al.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Briefly, the assay is based on a filter binding assay, using the recombinant GST-fused kinase domains expressed in baculovirus and purified over glutathione-sepharose, γ-[<sup>33</sup>P]ATP as the phosphate donor, and poly(Glu:Tyr 4:1) peptide as the acceptor. Each GST-fused kinase was incubated under optimized buffer conditions [20 mM Tris-HCl buffer (pH 7.5), 1–3 mM MnCl<sub>2</sub>, 3–10 mM MgCl<sub>2</sub>, 3–8 μg/mL poly(Glu:Tyr 4:1), 0.25 mg/mL polyethylene glycol 20000, 8 μM ATP, 10 μM sodium vanadate, 1 mM DTT] and 0.2 μCi γ-<sup>33</sup>P ATP in a total volume of 30 μL in the presence or absence of a test substance for 10 min at ambient temperature. The reaction was stopped by adding 10 mL of 250 mM EDTA. Using a 384-well filter system, half the volume was transferred onto an Immobilon-polyvinylidene difluoride membrane (Millipore, Bedford, MA). The membrane was then washed extensively and dried, and scintillation counting was performed. IC<sub>50</sub>s for compounds were calculated by linear regression analysis of the percentage inhibition.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Cellular VEGFR2 Autophosphorylation Assays</h4><div class="NLM_p last">CHO and HUVEC VEGFR2 assays were performed as described by Wood et al.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Briefly, cell-based receptor autophosphorylation assays using HUVECs that naturally express VEGFR2 or VEGFR2-transfected CHO cells were used. The cells were seeded in six-well plates and grown to 80% confluency. Compound was added in serial dilutions, and the cells incubated for 2 h at 37 °C in medium without FCS. VEGF (20 ng/mL) was then added. After 5 min incubation (37 °C), cells were washed and lysed. Nuclei were removed by full-speed centrifugation for 10 min at 4 °C using an Eppendorf centrifuge. Protein concentrations of the lysates were determined. A monoclonal antibody to VEGFR2 (monoclonal antibody 1495.12.14; Novartis) was coated to microtiter plates as a capture antibody. Cell lysates were added in triplicate together with an alkaline phosphatase-labeled antiphosphotyrosine antibody (PY-20(AP), Transduction Laboratories, Lexington, KY). After overnight incubation at 4 °C, the bound PY-20(AP) was detected with a luminescent alkaline phosphatase substrate (TROPIX, Bedford MA), and chemiluminescence was then determined.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Ba/F3 Proliferation Assays</h4><div class="NLM_p last">Different Ba/F3 cell lines rendered IL-3 independent by transduction with various constitutively active tyrosine kinases were grown in RPMI 1640 medium containing 10% fetal calf serum. For maintenance of parental Ba/F3 cells, the medium was additionally supplemented with 10 ng/mL interleukin-3 (IL-3; Biosource). For proliferation assays, Ba/F3 cells were seeded on 96-well plates in triplicates at 10000 cells per well and incubated with various concentrations of compounds for 72 h followed by quantification of viable cells using a resazurin sodium salt dye reduction readout (commercially known as Alamar Blue assay). IC<sub>50</sub> values were determined with the XLFit Excel Add-In (ID Business Solutions) using a four-parameter dose response model.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Endothelial Cell Proliferation Assays</h4><div class="NLM_p last">As a test of the ability of compounds to inhibit a functional response to VEGF, an endothelial cell proliferation assay based on BrdUrd incorporation was used (Biotrak Cell Proliferation System V.2, Amersham, England) as described previously.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Briefly, subconfluent HUVECs were incubated in triplicate in 96-well plates with basal medium containing 1.5% FCS and a constant concentration of VEGF (10 ng/mL), bFGF (0.5 ng/mL), or FCS (5%) in the presence or absence of compounds. After 24 h of incubation, BrdUrd labeling solution was added and cells incubated an additional 24 h before fixation, blocking, and addition of peroxidase-labeled anti-BrdUrd antibody. Bound antibody was then detected spectrophotometrically at 450 nm.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> In Vivo Studies</h4><div class="NLM_p last">All mice and rats were used with strict adherence and in accordance with Swiss Federal and Cantonal Authorities. Animals were kept under standard conditions (optimal health conditions, 22 °C in special, acclimatized animal rooms with 12 h dark–light cycles, light from 0600 to 1800) with free access to tap water and pelleted rodent chow.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Rat Pharmacokinetics</h4><div class="NLM_p last">Catheters were implanted into the femoral artery and vein of naïve female rats strain OFA for BFH772, and BAW2881, or in the jugular vein and femoral artery in female Sprague–Dawley rats for compounds <b>4</b>, <b>9</b>, and <b>10</b>. Animals were allowed to recover for 96 h and were housed in single cages with free access to food and water throughout the experiment. Female OFA rats received 2.5 mg/kg of BAW2881 dissolved in ethanol/dimethylisosorbide/polyethylene glycol400/D5W (10/15/35/40 v/v) or 1 mg/kg of BFH772 dissolved in <i>N</i>-methyl pyrrolidone/polyethylene glycol200 (30:70, v/v) via injection into the femoral vein. D5W is glucose 5%/water (v/v). Oral administration: BAW2881 and BFH772 were formulated as a micronized suspension (dissolved/suspended in 0.5% carboxymethyl cellulose in distilled water) and administered by gavage to female OFA rats to deliver a dose of 25 mg/kg for BAW2881 or 3 mg/kg BFH772 (<i>n</i> = 4 rats per group). For compounds <b>4</b>, <b>9</b>, and <b>10</b>, female Sprague–Dawley rats at 8 weeks of age received an intravenous dose of 3 mg/kg <b>4</b>, <b>9</b>, and <b>10</b>, formulated in ethanol/NMP/polyethylene glycol400/D5W (10/10/50/30) (<i>n</i> = 2 rats per group), or a suspension in 0.5% carboxymethyl cellulose in distilled water dosed at 50 mg/kg (<i>n</i> = 3 rats per group). At the allotted times, blood samples were collected into heparinized tubes, and the amount of compound in plasma determined by HPLC/MS-MS.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Tissue Chamber Model and TIE-2 ELISA</h4><div class="NLM_p last">Female FVB mice weighing between 18 and 20 g were housed in groups of six. Porous chambers containing VEGF (2 μg/mL) in 0.5 mL of 0.8% w/v agar (containing heparin, 20 U/mL) were implanted subcutaneously in the flank of the mice (<i>n</i> = 6 per group). VEGF induces the growth of vascularized tissue around the chamber. This response is dose-dependent and can be quantified by measuring the weight and TIE-2 levels of the tissue. Mice were treated either orally once daily with compounds or vehicle (PEG200 100%, 5 mL/kg) starting 4–6 h before implantation of the chambers and continuing for 4 days. The animals were sacrificed for measurement of the vascularized tissues 24 h after the last dose. Tissue weight was taken and then a lysate prepared for TIE-2 ELISA analysis as described by LaMontagne et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Miles Assay<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></h4><div class="NLM_p last">Female FVB mice weighing between 18 and 20 g were housed in groups of 3–4. Compound was administered to the mice at various time points before injection of Evans blue (48, 24, 8, and 2 h before), and 200 μL of Evans blue 0.5% was injected iv in the tail vein of FVB mice. Thirty minutes later, 2 μL of dog VEGF164 (10 ng/μL) was injected intradermally into the dorsal pinna of one ear of the mouse. Thirty minutes later, pictures of the ear were taken. Albumin-bounded Evans blue dye will extravasate at sites of increased microvascular permeability, generating a visible blue spot which provides a measure of vascular permeability. Measurements of the dye extravasation area (mm<sup>2</sup>) were carried out using pixel-based threshold in a computer-assisted image analysis software (KS-400 3.0 imaging system, Zeiss, Germany) (<i>n</i> = 3–4 animals per group).</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> B16/BL6 Murine Melanoma Tumor Model</h4><div class="NLM_p last">This model has been described by LaMontagne et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The B16/BL6 melanoma cells are a subline from B16 cells with a highly aggressive metastatic capability and were a kind gift from Dr Isaiah J. Fidler, Texas Medical center, Houston, TX, USA. Briefly, 50000 tumor cells were injected intradermally in the dorsal pinna of both ears of female C57BL/6JNpa mice (weighing between 18 and 20 g). Primary tumor size was measured on day 7, 14, and 21 in mm<sup>2</sup> with a computer assisted image analysis software (KS-400 3.0 imaging system, Zeiss) and a specifically designed macro. Animals were randomized into cages with groups of 5–6 so that they had roughly equal primary tumor size on day 7 and treated with the compounds or vehicle PEG300 or PEG200 daily po for the following 14 days. On day 21, mice were sacrificed and cranial lymph nodes excised and weighed. Blood was taken and measured directly by a blood analyzer which determines platelet, red, and white blood cell counts as well as hematocrit levels.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> DCE-MRI</h4><div class="NLM_p last">Dynamic-contrast-enhanced MRI (DCE-MRI) was performed exactly as previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Cohorts of at least eight C57BL/6JNpa B16 tumor bearing mice per group were anaesthetized, contrast-agent injected, and the parameters of Ktrans, iAUEC (both for tumor vessel permeability), and <i>V</i><sub>p</sub> (tumor plasma volume) of the cervical lymph-node metastases determined. Mice were then treated daily with vehicle, PTK787, or <b>4</b> and the procedure repeated. The change in the individual parameter for each mouse was recorded and results shown for the individual values for each parameter and the associated mean ± SEM with a one-way-ANOVA used to determine significance (Holm–Sidak multiple comparisons).</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> BN472 Model</h4><div class="NLM_p last">Female Brown–Norway rats weighing 160–180 g were transplanted with 3 mm<sup>3</sup> tumor fragments of BN472 tumors in the mammary fat pads as described by Ferretti et al.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Tumors were used for efficacy studies at 2–3 weeks after transplantation when the tumor had reached 200 mm<sup>2</sup>. Rats were randomized into different groups of 7–8 animals and treated orally with vehicle (PEG300) or compound.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Immunohistochemistry and Visualization of Blood Vessels</h4><div class="NLM_p last">Hoechst dye was injected into the Brown-Norway rats iv 2 min before sacrifice and excision of tumors. Metastases were embedded in OCT cryosection embedding compound and 10 μm frozen sections cut. Hoechst stained perfusable vasculature could be directly viewed if slides were mounted directly. Alternatively sections of metastases were then blocked for 30 min with 10% normal goat serum (NGS) in PBS containing 0.1% Triton X-100 and incubated overnight at 4 °C or for 2 h at room temperature with various dilutions of the primary antibodies in 3% NGS and 0.1% Triton-X100 in PBS. Primary antibodies were rabbit anti rat Ki67 (Neo Markers 1:200 dilution) and rabbit antirat caspase 3 (Oncogene 1:10 dilution). To the washed sections (3 × 5 min) were added TRITC or FITC conjugated secondary antibodies in PBS containing 3% NGS and 0.1% Triton X-100. Sections were incubated for 1 h at room temperature before washing 3 × 5 min in PBS and mounting in mowiol. Images were collected with the Hamamatsu digital camera using a Zeiss (axioplan) microscope connected to the open-lab imaging system program.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Chemistry</h3><div class="NLM_p">All reactions were performed under an inert atmosphere of N<sub>2</sub>. Starting materials were used as received from commercial sources. The purity (≥95%) of final compounds was verified by HPLC and <sup>1</sup>H NMR analysis. None of the compounds showed any clear-cut hydroscopic behavior. Column flash chromatography was performed on silica gel 60 (230–400 mesh ASTM, E. Merck). Melting points were determined in an open capillary and are not corrected. <sup>1</sup>H NMR spectra were collected with Bruker DRX-500 (500 MHz), Bruker AM-360 (360 MHz), or Varian Gemini-300 (300 MHz) instruments; chemical shifts of signals are expressed in parts per million (ppm) and are referenced to the deuterated solvents used. MS spectra were collected with an FAB-ZAB, HF (VG Analytical). HPLC spectra were recorded on a Waters Ultra Performance LC instrument.</div><div class="NLM_p">Abbreviations: aq (aqueous), brine (saturated NaCl solution), DABCO (1,4-diazabicyclo[2.2.2]octane), DEPC (diethyl cyanophosphonate), DMAP (4-dimethylamino-pyridine), org (organic), rt (room temperature), rv (rotary evaporation), T3P (<i>N</i>-propylphosphonic acid anhydride, cyclic trimer [Cas: 68957-94-8], 50% in DMF).</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (<b>1</b>)</h4><div class="NLM_p last">To a mixture of 1 N aq NaOH (160 mL) and acetone (320 mL) were added 2-amino-4,6-dichloro-pyrimidine (13.1 g; 80 mmol) and 6-hydroxy-1-naphthoic acid (15 g; 80 mmol). The mixture was stirred for 40 h at 62 °C. The cooled reaction mixture was partially evaporated by rv and the residue poured into 3 kg ice–water. Acidification with 2 N aq HCl (42 mL; pH 4) and stirring gave solid <b>1</b>, which was isolated by filtration and washing with water (23 g; 91%). MS: [M + 1]<sup>+</sup> = 316. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 8.93 (1H, d, <i>J</i> = 9 Hz), 8.16 (2H, m), 7.87 (1H, d, <i>J</i> = 2 Hz), 7.64 (1H, t, <i>J</i> = 8 Hz), 7.53 (1H, dd, <i>J</i> = 9 Hz/2 Hz), 7.17 (2H, sb), 6.38 (1H, s).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (3-Trifluoromethyl-phenyl)-amide (<b>2</b>)</h4><div class="NLM_p last">Compound <b>1</b> (3.50 g; 11.1 mmol) was dissolved in DMF (60 mL) and cooled in an ice bath. 4-Methylmorpholine (1.72 mL; 15.8 mmol) and DEPC (3.04 mL; 20 mmol) were added. After 2 min, 3-trifluoromethyl-aniline (1.52 mL; 12.2 mmol) was added and the mixture stirred for 21 h at rt. The reaction mixture was concentrated in vacuo and the residue redissolved in EtOAc and water. The aq layer was separated off and re-extracted with EtOAc (2×). Washing the org layers with water and brine, drying (Na<sub>2</sub>SO<sub>4</sub>), evaporation, and column chromatography (SiO<sub>2</sub>; hexane/EtOAc 9:1 → 1:1) gave <b>2</b> (3.13 g; 61%). MS: [M + 1]<sup>+</sup> = 459. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 10.96 (1H, s), 8.34 (1H, s), 8.29 (1H, d, <i>J</i> = 9 Hz), 8.13 (1H, d, <i>J</i> = 8 Hz), 8.04 (1H, d, <i>J</i> = 8 Hz), 7.88 (1H, s), 7.84 (1H, d, <i>J</i> = 7 Hz), 7.69 (2H, m), 7.51 (2H, m), 7.17 (2H, sb), 6.38 (1H, s).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (3-Trifluoromethyl-phenyl)-amide (BAW2881)</h4><div class="NLM_p last">A mixture of <b>2</b> (3.13 g; 6.82 mmol), Pd/C 10% (1.9 g), NEt<sub>3</sub> (1.04 mL; 7.5 mmol), and THF (330 mL) was hydrogenated at normal pressure. The catalyst was filtered off and the filtrate concentrated. The residue was redissolved in EtOAc and water. The aq layer was separated off and re-extracted with EtOAc (2×). Washing the org layers with water and brine, drying (Na<sub>2</sub>SO<sub>4</sub>), concentration, and column chromatography (SiO<sub>2</sub>; toluene/acetone 4:1 → 3:2) gave BAW2881 (2.17 g; 75%); mp 218 °C. MS: [M + 1]<sup>+</sup> = 425. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 10.96 (1H, s), 8.35 (1H, s), 8.28 (1H, d, <i>J</i> = 9 Hz), 8.19 (1H, sb), 8.12 (1H, d, <i>J</i> = 8 Hz), 8.04 (1H, d, <i>J</i> = 8 Hz), 7.84 (2H, m), 7.67 (2H, m), 7.48 (2H, m), 6.66 (2H, sb), 6.25 (1H, d, <i>J</i> = 5 Hz).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (<b>3</b>)</h4><div class="NLM_p last">A mixture of <b>1</b> (24.3 g; 77 mmol), Pd/C 10% (15 g), NEt<sub>3</sub> (100 mL), and THF (3.5 L) was hydrogenated at normal pressure. The catalyst was filtered off and washed thoroughly with THF. Partial evaporation of the filtrate led to crystallization. Filtration and washing with THF gave <b>3</b> (10.0 g; 46%). MS: [M + 1]<sup>+</sup> = 282. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 8.93 (1H, d, <i>J</i> = 9 Hz), 8.15 (3H, m), 7.83 (1H, s), 7.63 (1H, t, <i>J</i> = 8 Hz), 7.50 (1H, d, <i>J</i> = 9 Hz), 6.65 (2H, s), 6.24 (1H, d, <i>J</i> = 5 Hz).</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (4-Fluoro-3-trifluoromethyl-phenyl)-amide (<b>4</b>)</h4><div class="NLM_p last">Compound <b>3</b> (2.1 g; 7.8 mmol) was suspended in DMF (50 mL). Et<sub>3</sub>N (11 mL; 79 mmol), DMAP (0.42 g; 3.4 mmol), 4-fluoro-3-trifluoromethyl-aniline (1.6 mL; 9.7 mmol), and T3P (9.1 mL; 15.6 mmol) were added. The reaction mixture was stirred for 1 h at rt, concentrated in vacuo, and the residue redissolved in EtOAc and water. The aq layer was separated off and re-extracted with EtOAc (2×). Washing the org layers with water and brine, drying (Na<sub>2</sub>SO<sub>4</sub>), evaporation, and column chromatography (SiO<sub>2</sub>; CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 4:1 → 1:2) gave <b>4</b> (2.0 g; 59%); mp 204–205 °C. MS: [M + 1]<sup>+</sup> = 443. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 10.97 (1H, s), 8.36 (1H, m), 8.29 (1H, d, <i>J</i> = 9 Hz), 8.17 (1H, d, <i>J</i> = 5 Hz), 8.11 (2H, m), 7.86 (1H, d, <i>J</i> = 2 Hz), 7.83 (1H, d, <i>J</i> = 6 Hz), 7.68 (1H, t, <i>J</i> = 8 Hz), 7.59 (1H, m), 7.47 (1H, dd, <i>J</i> = 9 Hz/2 Hz), 6.66 (2H, sb), 6.25 (1H, d, <i>J</i> = 5 Hz).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid [4-(4-Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide (<b>5</b>)</h4><div class="NLM_p last">Compound <b>5</b> was prepared analogously to <b>4</b> (112 mg; 36%). MS: [M + 1]<sup>+</sup> = 437. <sup>1</sup>H NMR (CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ [ppm]: 8.37 (1H, d, <i>J</i> = 9 Hz), 8.23 (1H, s), 8.14 (1H, d, <i>J</i> = 6 Hz), 8.07 (1H, d, <i>J</i> = 8 Hz), 8.00 (1H, d, <i>J</i> = 9 Hz), 7.82 (2H, m), 7.77 (1H, s), 7.65 (1H, t, <i>J</i> = 8 Hz), 7.45 (1H, d, <i>J</i> = 9 Hz), 6.30 (1H, d, <i>J</i> = 6 Hz), 3.72 (2H, s), 2.59 (8H, m), 2.36 (3H, s).</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> {4-[5-(4-Fluoro-3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidin-2-yl}-carbamic Acid Methyl Ester (<b>6</b>)</h4><div class="NLM_p last">Compound <b>4</b> (300 mg; 0.68 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (4.5 mL) and pyridine (7.5 mL). Then methyl chloroformate (126 μL; 1.63 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added portionwise. After 4 h, the reaction mixture was diluted with EtOAc and water. The aq layer was separated off and re-extracted with EtOAc (2×). Washing the org layers with water and brine, drying (Na<sub>2</sub>SO<sub>4</sub>), and evaporation led to crystallization of the product. After addition of <i>i</i>-Pr<sub>2</sub>O <b>6</b> was filtered off (243 mg; 71%); mp 199–200 °C. MS: [M + 1]<sup>+</sup> = 501. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 10.98 (1H, s), 10.42 (1H, s), 8.53 (1H, d, <i>J</i> = 5 Hz), 8.37 (1H, m), 8.31 (1H, d, <i>J</i> = 9 Hz), 8.13 (1H, d, <i>J</i> = 9 Hz), 8.10 (1H, m), 8.05 (1H, d, <i>J</i> = 2 Hz), 7.85 (1H, d, <i>J</i> = 7 Hz), 7.70 (1H, t, <i>J</i> = 8 Hz), 7.58 (2H, m), 6.78 (1H, d, <i>J</i> = 5 Hz), 3.60 (3H, s).</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (<b>7</b>)</h4><div class="NLM_p last">To a mixture of 1 N aq NaOH (80 mL) and acetone (100 mL) were added 6-hydroxy-1-naphthoic acid (7.5 g; 40 mmol). Then a solution of 4,6-dichloro-pyrimidine (5.96 g; 40 mmol) in acetone (60 mL) was added dropwise. The mixture was stirred for 3 h at rt and then partially concentrated by rv. The residue was poured into 1.6 kg ice–water. Acidification with 2 N aq HCl (20 mL; pH 4) and stirring at 0 °C gave solid <b>7</b>, which was filtered off and washed with water (10.5 g; 87%). MS: [M + 1]<sup>+</sup> = 301. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 8.99 (1H, d, <i>J</i> = 9 Hz), 8.69 (1H, s), 8.19 (2H, m), 7.93 (1H, d, <i>J</i> = 2 Hz), 7.67 (1H, t, <i>J</i> = 8 Hz), 7.58 (1H, dd, <i>J</i> = 9 Hz/2 Hz), 7.54 (1H, s).</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (<b>8</b>)</h4><div class="NLM_p last">Sodium azide (8.65 g; 133 mmol) was added to a solution of <b>7</b> (20.0 g; 66.5 mmol) in DMF (220 mL). The mixture was stirred for 100 min at 65 °C, giving 6-(6-azido-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid. Pd/C 10% (4 g) was added to the cooled reaction mixture, which was then hydrogenated at normal pressure. The catalyst was filtered off and the filtrate partially evaporated. Pouring the residue into water (2 L) and aq citric acid (10%; 60 mL) led to crystallization. Compound <b>8</b> was filtered off and washed with water (10.7 g; 57%). MS: [M + 1]<sup>+</sup> = 282. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 13.2 (1H, sb), 8.94 (1H, d, <i>J</i> = 9 Hz), 8.15 (3H, m), 7.82 (1H, d, <i>J</i> = 2 Hz), 7.64 (1H, t, <i>J</i> = 8 Hz), 7.49 (1H, dd, <i>J</i> = 9 Hz/2 Hz), 6.90 (2H, sb), 5.82 (1H, s).</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (3-Trifluoromethyl-phenyl)-amide (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was prepared analogously to <b>4</b> (700 mg; 64%); mp 243–245 °C. MS: [M + 1]<sup>+</sup> = 425. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 10.96 (1H, s), 8.35 (1H, s), 8.29 (1H, d, <i>J</i> = 9 Hz), 8.12 (2H, m), 8.04 (1H, d, <i>J</i> = 8 Hz), 7.83 (2H, m), 7.67 (2H, m), 7.51 (1H, d, <i>J</i> = 8 Hz), 7.45 (1H, d, <i>J</i> = 9 Hz), 6.91 (2H, s), 5.84 (1H, s).</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (4-Fluoro-3-trifluoromethyl-phenyl)-amide (<b>10</b>)</h4><div class="NLM_p last">Compound <b>10</b> was prepared analogously to <b>4</b> (2.47 g; 70%); mp 223 °C. MS: [M + 1]<sup>+</sup> = 443. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 10.97 (1H, s), 8.37 (1H, m), 8.29 (1H, d, <i>J</i> = 9 Hz), 8.11 (3H, m), 7.83 (2H, m), 7.68 (1H, t, <i>J</i> = 8 Hz), 7.58 (1H, t, <i>J</i> = 10 Hz), 7.45 (1H, dd, <i>J</i> = 9 Hz/2 Hz), 6.91 (2H, s), 5.84 (1H, s).</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (3-Ethyl-phenyl)-amide (<b>11</b>)</h4><div class="NLM_p last">Compound <b>11</b> was prepared analogously to <b>4</b> (135 mg; 56%); mp 251–252 °C. MS: [M + 1]<sup>+</sup> = 385. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ [ppm]: 10.56 (1H, s), 8.26 (1H, d, <i>J</i> = 9 Hz), 8.11 (1H, s), 8.08 (1H, d, <i>J</i> = 8 Hz), 7.81 (1H, d, <i>J</i> = 2 Hz), 7.75 (1H, d, <i>J</i> = 7 Hz), 7.72 (1H, s), 7.65 (2H, m), 7.44 (1H, dd, <i>J</i> = 9 Hz/2 Hz), 7.30 (1H, t, <i>J</i> = 8 Hz), 7.00 (1H, d, <i>J</i> = 8 Hz), 6.91 (2H, s), 5.82 (1H, s), 2.64 (2H, q, <i>J</i> = 8 Hz), 1.22 (3H, t, <i>J</i> = 8 Hz).</div></div><div id="sec5_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (3-Trifluoromethyl-phenyl)-amide (<b>12</b>)</h4><div class="NLM_p last">Compound <b>12</b> was prepared analogously to <b>4</b> (13.6 g; 92%). MS: [M + 1]<sup>+</sup> = 444. <sup>1</sup>H NMR (CDCl<sub>3</sub>-<i>d</i>) δ [ppm]: 8.61 (1H, s), 8.52 (1H, d, <i>J</i> = 9 Hz), 8.04 (1H, s), 8.01 (1H, d, <i>J</i> = 9 Hz), 7.93 (2H, m), 7.80 (1H, d, <i>J</i> = 7 Hz), 7.72 (1H, d, <i>J</i> = 2), 7.58 (2H, m), 7.49 (1H, d, <i>J</i> = 8), 7.42(1H, dd, <i>J</i> = 9 Hz/3 Hz), 7.05 (1H, s).</div></div><div id="sec5_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-carboxylic Acid Ethyl Ester (<b>13</b>)</h4><div class="NLM_p last">A mixture of <b>12</b> (11.2 g; 25.2 mmol), Et<sub>3</sub>N (7.0 mL; 50.5 mmol), and PdCI<sub>2</sub>[P(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>]<sub>2</sub> (1.785 g; 2.52 mmol) in EtOH (150 mL) was prepared under a CO atmosphere of 120 bar in an autoclave and then heated for 30 h at 110 °C. After cooling to rt, the mixture was diluted with EtOH and filtered. The residue was washed thoroughly with EtOH and the filtrate concentrated. Column chromatography (SiO<sub>2</sub>; CH<sub>2</sub>CI<sub>2</sub>/EtOAc 19:1 → 9:1), partial concentration and filtration led to <b>13</b> (9.5 g; 78%). MS: [M + 1]<sup>+</sup> = 482. <sup>1</sup>H NMR (CDCl<sub>3</sub>-<i>d</i>) δ [ppm]: 8.91 (1H, s), 8.52 (1H, d, <i>J</i> = 9 Hz), 8.05 (1H, s), 8.01 (1H, d, <i>J</i> = 9 Hz), 7.9 (2H, m), 7.80 (1H, d, <i>J</i> = 8 Hz), 7.74 (1H, d, <i>J</i> = 2), 7.71 (1H, s), 7.6 (2H, m), 7.49 (1H, d, <i>J</i> = 8), 7.43 (1H, dd, <i>J</i> = 9 Hz/2 Hz), 4.54 (2H, q, <i>J</i> = 7 Hz), 1.50 (3H, t, <i>J</i> = 7 Hz).</div></div><div id="sec5_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 6-(6-Hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (3-Trifluoromethyl-phenyl)-amide (BFH772)</h4><div class="NLM_p last">NaBH<sub>4</sub> (24 mg; 0.6 mmol) was added to a suspension of <b>13</b> (241 mg; 0.50 mmol) in <i>t</i>-butanol (7 mL). The mixture was stirred for 30 min at 65 °C and then diluted with EtOAc and a saturated aq solution of NaHCO<sub>3</sub>. The aq layer was separated off and re-extracted with EtOAc (2×). The org layers were washed with a saturated aq solution of NaHCO<sub>3</sub> and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Column chromatography (SiO<sub>2</sub>; CH<sub>2</sub>CI<sub>2</sub>/EtOAc 65:35 → 1:1) led to BFH772 (133 mg; 61%); mp 183–184 °C. MS: [M + 1]<sup>+</sup> = 440. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>); δ [ppm]: 10.98 (1H, s), 8.68 (1H, s), 8.35 (1H, s), 8.32 (1H, d, <i>J</i> = 9 Hz), 8.13 (1H, d, <i>J</i> = 8 Hz), 8.04 (1H, d, <i>J</i> = 9 Hz), 7.93 (1H, d, <i>J</i> = 2 Hz), 7.85 (1H, d, <i>J</i> = 7 Hz), 7.70 (1H, t, <i>J</i> = 8 Hz), 7.65 (1H, t, <i>J</i> = 8 Hz), 7.52 (1H, m), 7.50 (1H, d, <i>J</i> = 2 Hz), 7.13 (1H, s), 5.70 (1H, t, <i>J</i> = 6 Hz), 4.57 (2H, d, <i>J</i> = 6 Hz).</div></div><div id="sec5_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 6-(6-Cyano-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid (3-Trifluoromethyl-phenyl)-amide (<b>14</b>)</h4><div class="NLM_p last">DABCO (0.42 g; 3.74 mmol) and KCN (1.0 g; 15.34 mmol) were added to a solution of <b>12</b> (3.32 g; 7.48 mmol) in DMSO (100 mL) and water (20 mL). The mixture was stirred for 30 min at 55 °C and then poured into water (1.2 L). This aq mixture was extracted with EtOAc (3×). The org layers were washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Column chromatography (SiO<sub>2</sub>; CH<sub>2</sub>CI<sub>2</sub>/EtOAc 98:2 → 93:7), partial concentration, dilution with hexane, and filtration led to <b>14</b> (1.27 g; 39%); mp 167 °C. MS: [M + 1]<sup>+</sup> = 435. <sup>1</sup>H NMR (CDCl<sub>3</sub>-<i>d</i>) δ [ppm]: 8.87 (1H, s), 8.56 (1H, d, <i>J</i> = 9 Hz), 8.04 (1H, s), 8.03 (1H, d, <i>J</i> = 9 Hz), 7.94 (1H, d, <i>J</i> = 8 Hz), 7.87 (1H, s), 7.84 (1H, d, <i>J</i> = 8 Hz), 7.74 (1H, d, <i>J</i> = 2), 7.63 (1H, t, <i>J</i> = 8), 7.58 (1H, t, <i>J</i> = 8 Hz), 7.50 (1H, d, <i>J</i> = 7 Hz), 7.42 (2H, m).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d131e2976-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01582">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40687" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40687" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01582" class="ext-link">10.1021/acs.jmedchem.5b01582</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Kinase selectivity in biochemical assays for VEGFR2 inhibitors; kinase selectivity in cells with BFH772 and BAW2881; compound <b>4</b> and BFH772 inhibit vascular leakage in the Miles assay; VEGFR2 inhibitors abrogate tissue chamber weight and TIE-2 levels in the VEGF chamber implant model; T/C of B16 melanoma primary and metastatic tumors in mice treated with forerunner and competitor VEGFR tyrosine kinase inhibitors; blood chemistry of BFH772 and BAW2881 treated animals in the B16 melanoma model; naphthalene-1-carboxamides show no activity on the proliferation of B16 melanoma cells (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf">jm5b01582_si_001.pdf (426.48 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01582" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guido Bold</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1671637f72793874797a72567879607764627f653875797b"><span class="__cf_email__" data-cfemail="9ef9ebf7faf1b0fcf1f2fadef0f1e8ffeceaf7edb0fdf1f3">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amanda Littlewood-Evans</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#88e9e5e9e6ece9a6e4e1fcfce4edffe7e7eca5edfee9e6fbc8e6e7fee9fafce1fba6ebe7e5"><span class="__cf_email__" data-cfemail="7e1f131f101a1f5012170a0a121b0911111a531b081f100d3e1011081f0c0a170d501d1113">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Schnell</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascal Furet</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul McSheehy</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josef Brüggen</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jürgen Mestan</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul W. Manley</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Drückes</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marion Burglin</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ursula Dürler</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacqueline Loretan</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Reuter</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Markus Wartmann</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Theuer</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beatrice Bauer-Probst</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Georg Martiny-Baron</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Allegrini</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arnaud Goepfert</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeanette Wood</span> - <span class="hlFld-Affiliation affiliation">Oncology Research, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in health and disease</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span><span class="refDoi"> DOI: 10.1038/nm0603-653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2Fnm0603-653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=12778163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=653-660&author=P.+Carmeliet&title=Angiogenesis+in+health+and+disease&doi=10.1038%2Fnm0603-653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in health and disease</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">653-660</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Blood vessels constitute the first organ in the embryo and form the largest network in our body but, sadly, are also often deadly.  When dysregulated, the formation of new blood vessels contributes to numerous malignant, ischemic, inflammatory, infectious and immune disorders.  Mol. insights into these processes are being generated at a rapidly increasing pace, offering new therapeutic opportunities that are currently being evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVe6HXO3QPLbVg90H21EOLACvtfcHk0li6kXYA3xl-9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOntbY%253D&md5=501ed35c48dbcc7c9d18b804c996284a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnm0603-653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0603-653%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520health%2520and%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D653%26epage%3D660%26doi%3D10.1038%2Fnm0603-653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Plate, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weich, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas <i>in vivo</i></span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1038/359845a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2F359845a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=1992&pages=845-848&author=K.+H.+Plateauthor=G.+Breierauthor=H.+A.+Weichauthor=W.+Risau&title=Vascular+endothelial+growth+factor+is+a+potential+tumour+angiogenesis+factor+in+human+gliomas+in+vivo&doi=10.1038%2F359845a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2F359845a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F359845a0%26sid%3Dliteratum%253Aachs%26aulast%3DPlate%26aufirst%3DK.%2BH.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DWeich%26aufirst%3DH.%2BA.%26aulast%3DRisau%26aufirst%3DW.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520is%2520a%2520potential%2520tumour%2520angiogenesis%2520factor%2520in%2520human%2520gliomas%2520in%2520vivo%26jtitle%3DNature%26date%3D1992%26volume%3D359%26spage%3D845%26epage%3D848%26doi%3D10.1038%2F359845a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Senger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, H. F.</span><span> </span><span class="NLM_article-title">Vascular permeability factor (VPF, VEGF) in tumor biology</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1007/BF00665960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1007%2FBF00665960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8281615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2cXnsVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1993&pages=303-324&author=D.+R.+Sengerauthor=L.+Van+de+Waterauthor=L.+F.+Brownauthor=J.+A.+Nagyauthor=K.+T.+Yeoauthor=T.+K.+Yeoauthor=B.+Berseauthor=R.+W.+Jackmanauthor=A.+M.+Dvorakauthor=H.+F.+Dvorak&title=Vascular+permeability+factor+%28VPF%2C+VEGF%29+in+tumor+biology&doi=10.1007%2FBF00665960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular permeability factor (VPF,VEGF) in tumor biology</span></div><div class="casAuthors">Senger, Donald R.; Van De Water, Livingston; Brown, Lawrence F.; Nagy, Janice A.; Yeo, Kiang Teck; Yeo, Tet Kin; Berse, Brygida; Jackman, Robert W.; Dvorak, Ann M.; Dvorak, Harold F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">303-24</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    </div><div class="casAbstract">A review with 89 refs.  Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine expressed and secreted at high levels by many tumor cells of animal and human origin.  As secreted by tumor cells, VPF/VEGF is a 34-42 kDa heparin-binding, dimeric, disulfide-bonded glycoprotein that acts directly on endothelial cells (EC) by way of specific receptors to activate phospholipase C and induce [Ca2+]i transients.  Two high affinity VPF/VEGF receptors, both tyrosine kinases, have thus far been described.  VPF/VEGF is likely to have a no. of important roles in tumor biol. related, but not limited to, the process of tumor angiogenesis.  As a potent permeability factor, VPF/VEGF promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix.  This matrix promotes the ingrowth of macrophages, fibroblasts, and endothelial cells.  Moreover, VPF/VEGF is a selective endothelial cell (EC) growth factor in vitro, and it presumably stimulates EC proliferation in vivo.  Furthermore, VPF/VEGF has been found in animal and human tumor effusions by immunoassay and by functional assays and very likely accounts for the induction of malignant ascites.  In addn. to its role in tumors, VPF/VEGF has recently been found to have a role in wound healing and its expression by activated macrophages suggest that it probably also participates in certain types of chronic inflammation.  VPF/VEGF is expressed in normal development and in certain normal adult organs, notably kidney, heart, adrenal gland and lung.  Its functions in normal adult tissues are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoypXw29msdV7Vg90H21EOLACvtfcHk0lgtleI576V_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXnsVejug%253D%253D&md5=bf7d474ad681de62f1cc73029a90e376</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1007%2FBF00665960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00665960%26sid%3Dliteratum%253Aachs%26aulast%3DSenger%26aufirst%3DD.%2BR.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DL.%2BF.%26aulast%3DNagy%26aufirst%3DJ.%2BA.%26aulast%3DYeo%26aufirst%3DK.%2BT.%26aulast%3DYeo%26aufirst%3DT.%2BK.%26aulast%3DBerse%26aufirst%3DB.%26aulast%3DJackman%26aufirst%3DR.%2BW.%26aulast%3DDvorak%26aufirst%3DA.%2BM.%26aulast%3DDvorak%26aufirst%3DH.%2BF.%26atitle%3DVascular%2520permeability%2520factor%2520%2528VPF%252C%2520VEGF%2529%2520in%2520tumor%2520biology%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D1993%26volume%3D12%26spage%3D303%26epage%3D324%26doi%3D10.1007%2FBF00665960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollefeyt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieckens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertsenstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenhoeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Declercq, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, A.</span><span> </span><span class="NLM_article-title">Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1038/380435a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2F380435a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8602241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK28XitVKqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=1996&pages=435-439&author=P.+Carmelietauthor=V.+Ferreiraauthor=G.+Breierauthor=S.+Pollefeytauthor=L.+Kieckensauthor=M.+Gertsensteinauthor=M.+Fahrigauthor=A.+Vandenhoeckauthor=K.+Harpalauthor=C.+Eberhardtauthor=C.+Declercqauthor=J.+Pawlingauthor=L.+Moonsauthor=D.+Collenauthor=W.+Risauauthor=A.+Nagy&title=Abnormal+blood+vessel+development+and+lethality+in+embryos+lacking+a+single+VEGF+allele&doi=10.1038%2F380435a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele</span></div><div class="casAuthors">Carmeliet, Peter; Ferreira, Valerie; Breier, Georg; Pollefeyt, Saskia; Kieckens, Lena; Gertsenstein, Marina; Fahrig, Michaela; Vandenhoeck, Ann; Harpal, Kendraprasad; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">6573</span>),
    <span class="NLM_cas:pages">435-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The endothelial cell-specific vascular endothelial growth factor (VEGF) and its cellular receptors Flt-1 and Flk-1 have been implicated in the formation of the embryonic vasculature.  This is suggested by their colocalized expression during embryogenesis and the impaired vessel formation in Flk-1 and Flt-1 deficient embryos.  However, because Flt-1 also binds placental growth factor, a VEGF homolog, the precise role of VEGF was unknown.  Here we report that formation of blood vessels was abnormal, but not abolished, in heterozygous VEGF-deficient (VEGF+/-) embryos, generated by aggregation of embryonic stem (ES) cells with tetraploid embryos (T-ES), and even more impaired in homozygous VEGF-deficient (VEGF-/-) T-ES embryos, resulting in death at mid-gestation.  Similar phenotypes were obsd. in F1-VEGF+/- embryos, generated by germline transmission.  We believe that this heterozygous lethal phenotype, which differs from the homozygous lethality in VEGF-receptor-deficient embryos, is unprecedented for a targeted autosomal gene inactivation, and is indicative of a tight dose-dependent regulation of embryonic vessel development by VEGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobatChefZSx7Vg90H21EOLACvtfcHk0lgtleI576V_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVKqtLg%253D&md5=93d159aabf470be75c118dad37a729cb</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1038%2F380435a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F380435a0%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DFerreira%26aufirst%3DV.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DPollefeyt%26aufirst%3DS.%26aulast%3DKieckens%26aufirst%3DL.%26aulast%3DGertsenstein%26aufirst%3DM.%26aulast%3DFahrig%26aufirst%3DM.%26aulast%3DVandenhoeck%26aufirst%3DA.%26aulast%3DHarpal%26aufirst%3DK.%26aulast%3DEberhardt%26aufirst%3DC.%26aulast%3DDeclercq%26aufirst%3DC.%26aulast%3DPawling%26aufirst%3DJ.%26aulast%3DMoons%26aufirst%3DL.%26aulast%3DCollen%26aufirst%3DD.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DNagy%26aufirst%3DA.%26atitle%3DAbnormal%2520blood%2520vessel%2520development%2520and%2520lethality%2520in%2520embryos%2520lacking%2520a%2520single%2520VEGF%2520allele%26jtitle%3DNature%26date%3D1996%26volume%3D380%26spage%3D435%26epage%3D439%26doi%3D10.1038%2F380435a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Klagsbrun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amore, P. A.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor and its receptors</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1016/S1359-6101(96)00027-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2FS1359-6101%2896%2900027-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8971481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2sXht1Om" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=259-270&author=M.+Klagsbrunauthor=P.+A.+D%E2%80%99Amore&title=Vascular+endothelial+growth+factor+and+its+receptors&doi=10.1016%2FS1359-6101%2896%2900027-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor and its receptors</span></div><div class="casAuthors">Klagsbrun, Michael; D'Amore, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 136 refs.  Vascular endothelial growth factor (VEGF) is a prime regulator of endothelial cell proliferation, angiogenesis, vasculogenesis and vascular permeability.  Its activity is mediated by the high affinity tyrosine kinase receptors, KDR/Flk-1 and Flt-1.  In this article, recently discovered structural, mol. and biol. properties of VEGF are described.  Among the topics discussed are VEGF and VEGF receptor structure and bioactivity, the regulation of VEGF expression, the role of VEGF and its receptors in vascular development, and the involvement of VEGF and its receptors in normal and pathol. (ocular and tumor) angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_WT8UagsqhLVg90H21EOLACvtfcHk0liQBkR4sJvHMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1Om&md5=bc8c134e76c45b16cef691ea6dc0b5b9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2896%2900027-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252896%252900027-5%26sid%3Dliteratum%253Aachs%26aulast%3DKlagsbrun%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520and%2520its%2520receptors%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D1996%26volume%3D7%26spage%3D259%26epage%3D270%26doi%3D10.1016%2FS1359-6101%2896%2900027-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Angiogenesis in cancer, vascular, rheumatoid and other disease</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1038/nm0195-27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2Fnm0195-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=7584949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=27-31&author=J.+Folkman&title=Angiogenesis+in+cancer%2C+vascular%2C+rheumatoid+and+other+disease&doi=10.1038%2Fnm0195-27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer, vascular, rheumatoid and other disease</span></div><div class="casAuthors">Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">A review with ∼72 refs.  Recent discoveries of endogenous neg. regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all assocd. with neovascularized tumors, suggest a new paradigm of tumorigenesis.  It is now helpful to think of the switch to the angiogenic phenotype as a net balance of pos. and neg. regulators of blood vessel growth.  The extent to which the neg. regulators are decreased during this switch may dictate whether a primary tumor grows rapidly or slowly and whether metastases grow at all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpF2nWHt2eJbVg90H21EOLACvtfcHk0liQBkR4sJvHMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D&md5=849f4f3828ac5d78886d666787f72d4f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnm0195-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0195-27%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%2520in%2520cancer%252C%2520vascular%252C%2520rheumatoid%2520and%2520other%2520disease%26jtitle%3DNat.%2520Med.%26date%3D1995%26volume%3D1%26spage%3D27%26epage%3D31%26doi%3D10.1038%2Fnm0195-27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1016/S0065-230X(08)60946-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2FS0065-230X%2808%2960946-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1985&pages=175-203&author=J.+Folkman&title=Tumor+angiogenesis&doi=10.1016%2FS0065-230X%2808%2960946-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2808%2960946-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252808%252960946-X%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D1985%26volume%3D43%26spage%3D175%26epage%3D203%26doi%3D10.1016%2FS0065-230X%2808%2960946-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">The role of angiogenesis in tumor growth</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1378311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A280%3ADyaK38zivFOgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1992&pages=65-71&author=J.+Folkman&title=The+role+of+angiogenesis+in+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of angiogenesis in tumor growth</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in cancer biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-71</span>
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    </div><div class="casAbstract">Experimental and clinical evidence is here assembled in support of the concept that the development of a solid tumor progresses from a prevascular phase to a vascular phase.  The prevascular tumor does not induce angiogenesis, is limited in size, and rarely metastasizes.  The vascularized tumor induces host microvessels to undergo angiogenesis, has the potential to rapidly expand its cell population, and has a propensity to metastasize.  Thus, angiogenesis is necessary but not sufficient for tumor growth and metastasis.  Neovascularization of a tumor requires that a critical number of its cells have switched to the angiogenic phenotype.  The mechanisms by which tumor cells become angiogenic, subjects of current study, are reviewed here.  At least two general categories are recognized: (i) angiogenic activity arises from the tumor cell itself in the form of the release of angiogenic molecules such as basic fibroblast growth factor; (ii) angiogenic activity arises from host cells recruited by the tumor (e.g. macrophages), or is mobilized from the extracellular matrix, or requires concomitant loss of physiological inhibition of endothelial cell proliferation.  Accumulating evidence indicates that for most tumors, the switch to the angiogenic phenotype depends upon the outcome of a balance between angiogenic stimulators and angiogenic inhibitors, both of which may be produced by tumor cells and perhaps by certain host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcUvmrMxJHHt0Q2ypr7jHkfW6udTcc2eZ2M5PnHaODp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zivFOgtA%253D%253D&md5=6db5fa60c10884b6625d5d10a1216766</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520angiogenesis%2520in%2520tumor%2520growth%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D1992%26volume%3D3%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Plate, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of developmental and tumor angiogenesis</span> <span class="citation_source-journal">Brain Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1111/j.1750-3639.1994.tb00835.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1111%2Fj.1750-3639.1994.tb00835.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=7524960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1Omtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=207-218&author=K.+H.+Plateauthor=G.+Breierauthor=W.+Risau&title=Molecular+mechanisms+of+developmental+and+tumor+angiogenesis&doi=10.1111%2Fj.1750-3639.1994.tb00835.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of developmental and tumor angiogenesis</span></div><div class="casAuthors">Plate, Karl H.; Breier, Georg; Risau, Werner</div><div class="citationInfo"><span class="NLM_cas:title">Brain Pathology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-18</span>CODEN:
                <span class="NLM_cas:coden">BRPAE7</span>;
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    </div><div class="casAbstract">A review, with 118 refs.  Angiogenesis, the sprouting of capillaries from pre-existing vessels, is of fundamental importance during embryonic development and is the principal process by which the brain and certain other organs become vascularized.  Angiogenesis occurs during embryonic development but is almost absent in adult tissues.  Transient and tightly controlled (physiol.) angiogenesis in adult tissues occurs during the female reproductive cycle and during wound healing.  In contrast, pathol. angiogenesis is characterized by the persistent proliferation of endothelial cells, and is a prominent feature of diseases such as proliferative retinopathy, rheumathoid arthritis, and psoriasis.  In addn., many tumors are able to attract blood vessels from neighboring tissues.  Tumor-induced angiogenesis requires a constitutive activation of endothelial cells.  These endothelial cells dissolve their surrounding extracellular matrix, migrate toward the tumor, proliferate, and form a new vascular network, thus supplying the tumor with nutrients and oxygen and removing waste products.  The onset of angiogenesis in human gliomas is characterized by the expression of genes encoding angiogenic growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) in tumor cells, and coordinate induction of genes in endothelial cells which encode the resp. growth factor receptors.  Developmental and tumor angiogenesis appear to be regulated by a paracrine mechanism involving VEGF and VEGF receptor-1 and -2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiXuRse7S2bVg90H21EOLACvtfcHk0lj-IwWbhPUIWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1Omtr4%253D&md5=746a7b3854ad3918ea93a66c1c869250</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.1994.tb00835.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.1994.tb00835.x%26sid%3Dliteratum%253Aachs%26aulast%3DPlate%26aufirst%3DK.%2BH.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DRisau%26aufirst%3DW.%26atitle%3DMolecular%2520mechanisms%2520of%2520developmental%2520and%2520tumor%2520angiogenesis%26jtitle%3DBrain%2520Pathol.%26date%3D1994%26volume%3D4%26spage%3D207%26epage%3D218%26doi%3D10.1111%2Fj.1750-3639.1994.tb00835.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmé, D.</span><span> </span><span class="NLM_article-title">VEGF-mediated tumour angiogenesis: a new target for cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">680</span><span class="refDoi"> DOI: 10.1016/0958-1669(95)80111-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2F0958-1669%2895%2980111-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8527839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2MXpvVSrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1995&pages=675-680&author=G.+Martiny-Baronauthor=D.+Marm%C3%A9&title=VEGF-mediated+tumour+angiogenesis%3A+a+new+target+for+cancer+therapy&doi=10.1016%2F0958-1669%2895%2980111-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF-mediated tumor angiogenesis: a new target for cancer therapy</span></div><div class="casAuthors">Martiny-Baron, Georg; Marme, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">675-80</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review with 40 refs.  Considerable evidence is gathering for the involvement of vascular endothelial growth factor (VEGF) in the vascularization and growth of primary tumors as well as in the formation of metastases.  The expression of VEGF depends on activated oncogenes and inactivated tumor suppressor genes as well as several other factors (e.g. growth factors, tumor promoters and hypoxia).  Substantial expression of the receptors for VEGF is restricted mainly to the tumor blood vessels.  The causal involvement of this angiogenic factor in the progression of disease has been successfully evaluated by monoclonal antibodies against VEGF, dominant-neg. receptor mutants and the use of antisense oligonucleotides against the VEGF mRNA.  Thus, the VEGF signaling system seems to be an appropriate target to inhibit tumor angiogenesis and metastases formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxbiY9-znjXbVg90H21EOLACvtfcHk0lj-IwWbhPUIWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpvVSrtLo%253D&md5=a10130ea57e544b5de5dbe0a46fd8ce0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0958-1669%2895%2980111-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0958-1669%252895%252980111-1%26sid%3Dliteratum%253Aachs%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMarm%25C3%25A9%26aufirst%3DD.%26atitle%3DVEGF-mediated%2520tumour%2520angiogenesis%253A%2520a%2520new%2520target%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D1995%26volume%3D6%26spage%3D675%26epage%3D680%26doi%3D10.1016%2F0958-1669%2895%2980111-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liotta, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetler-Stevenson, W. G.</span><span> </span><span class="NLM_article-title">Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1016/0092-8674(91)90642-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2F0092-8674%2891%2990642-C" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1991&pages=327-336&author=L.+A.+Liottaauthor=P.+S.+Steegauthor=W.+G.+Stetler-Stevenson&title=Cancer+metastasis+and+angiogenesis%3A+an+imbalance+of+positive+and+negative+regulation&doi=10.1016%2F0092-8674%2891%2990642-C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990642-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990642-C%26sid%3Dliteratum%253Aachs%26aulast%3DLiotta%26aufirst%3DL.%2BA.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DStetler-Stevenson%26aufirst%3DW.%2BG.%26atitle%3DCancer%2520metastasis%2520and%2520angiogenesis%253A%2520an%2520imbalance%2520of%2520positive%2520and%2520negative%2520regulation%26jtitle%3DCell%26date%3D1991%26volume%3D64%26spage%3D327%26epage%3D336%26doi%3D10.1016%2F0092-8674%2891%2990642-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Parangi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christofori, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosfeld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Antiangiogenic therapy of transgenic mice impairs de novo tumor growth</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">2002</span><span class="NLM_x">–</span> <span class="NLM_lpage">2007</span><span class="refDoi"> DOI: 10.1073/pnas.93.5.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1073%2Fpnas.93.5.2002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=2002-2007&author=S.+Parangiauthor=M.+O%27Reillyauthor=G.+Christoforiauthor=L.+Holmgrenauthor=J.+Grosfeldauthor=J.+Folkmanauthor=D.+Hanahan&title=Antiangiogenic+therapy+of+transgenic+mice+impairs+de+novo+tumor+growth&doi=10.1073%2Fpnas.93.5.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.5.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.5.2002%26sid%3Dliteratum%253Aachs%26aulast%3DParangi%26aufirst%3DS.%26aulast%3DO%2527Reilly%26aufirst%3DM.%26aulast%3DChristofori%26aufirst%3DG.%26aulast%3DHolmgren%26aufirst%3DL.%26aulast%3DGrosfeld%26aufirst%3DJ.%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DAntiangiogenic%2520therapy%2520of%2520transgenic%2520mice%2520impairs%2520de%2520novo%2520tumor%2520growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D2002%26epage%3D2007%26doi%3D10.1073%2Fpnas.93.5.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Anti-angiogenesis: new concept for therapy of solid tumors</span> <span class="citation_source-journal">Ann. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span><span class="refDoi"> DOI: 10.1097/00000658-197203000-00014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1097%2F00000658-197203000-00014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=5077799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A280%3ADyaE3s%252FitV2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1972&pages=409-416&author=J.+Folkman&title=Anti-angiogenesis%3A+new+concept+for+therapy+of+solid+tumors&doi=10.1097%2F00000658-197203000-00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenesis: new concept for therapy of solid tumors</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgery</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-16</span>
        ISSN:<span class="NLM_cas:issn">0003-4932</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBThr2iCUqj90Q2ypr7jHkfW6udTcc2ea3J9ym3XK0Yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3s%252FitV2gtA%253D%253D&md5=48381e6d0d06f30c9bd7e7d7d8a53d95</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2F00000658-197203000-00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-197203000-00014%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAnti-angiogenesis%253A%2520new%2520concept%2520for%2520therapy%2520of%2520solid%2520tumors%26jtitle%3DAnn.%2520Surg.%26date%3D1972%26volume%3D175%26spage%3D409%26epage%3D416%26doi%3D10.1097%2F00000658-197203000-00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sitohy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, H. F.</span><span> </span><span class="NLM_article-title">Anti-VEGF/VEGFR therapy for cancer: reassessing the target</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1909</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-11-3406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=22508695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Whu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1909-1914&author=B.+Sitohyauthor=J.+A.+Nagyauthor=H.+F.+Dvorak&title=Anti-VEGF%2FVEGFR+therapy+for+cancer%3A+reassessing+the+target&doi=10.1158%2F0008-5472.CAN-11-3406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target</span></div><div class="casAuthors">Sitohy, Basel; Nagy, Janice A.; Dvorak, Harold F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1909-1914</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Judah Folkman recognized that new blood vessel formation is important for tumor growth and proposed antiangiogenesis as a novel approach to cancer therapy.  Discovery of vascular permeability factor VEGF-A as the primary tumor angiogenesis factor prompted the development of a no. of drugs that targeted it or its receptors.  These agents have often been successful in halting tumor angiogenesis and in regressing rapidly growing mouse tumors.  However, results in human cancer have been less impressive.  A no. of reasons have been offered for the lack of greater success, and, here, we call attention to the heterogeneity of the tumor vasculature as an important issue.  Human and mouse tumors are supplied by at least 6 well-defined blood vessel types that arise by both angiogenesis and arterio-venogenesis.  All 6 types can be generated in mouse tissues by an adenoviral vector expressing VEGF-A164.  Once formed, 4 of the 6 types lose their VEGF-A dependency, and so their responsiveness to anti-VEGF/VEGF receptor therapy.  If therapies directed against the vasculature are to have a greater impact on human cancer, targets other than VEGF and its receptors will need to be identified on these resistant tumor vessels.  Cancer Res; 72(8); 1909-14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTzXS08U-nybVg90H21EOLACvtfcHk0liSZsC4od2dRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Whu74%253D&md5=462d169293913057773c4390c356fb18</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3406%26sid%3Dliteratum%253Aachs%26aulast%3DSitohy%26aufirst%3DB.%26aulast%3DNagy%26aufirst%3DJ.%2BA.%26aulast%3DDvorak%26aufirst%3DH.%2BF.%26atitle%3DAnti-VEGF%252FVEGFR%2520therapy%2520for%2520cancer%253A%2520reassessing%2520the%2520target%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1909%26epage%3D1914%26doi%3D10.1158%2F0008-5472.CAN-11-3406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenone, S.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10797</span><span class="NLM_x">–</span> <span class="NLM_lpage">10822</span><span class="refDoi"> DOI: 10.1021/jm301085w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301085w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10797-10822&author=F.+Musumeciauthor=M.+Radiauthor=C.+Brulloauthor=S.+Schenone&title=Vascular+endothelial+growth+factor+%28VEGF%29+receptors%3A+drugs+and+new+inhibitors&doi=10.1021%2Fjm301085w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Fjm301085w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301085w%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520receptors%253A%2520drugs%2520and%2520new%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10797%26epage%3D10822%26doi%3D10.1021%2Fjm301085w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2921</span><span class="NLM_x">–</span> <span class="NLM_lpage">2935</span><span class="refDoi"> DOI: 10.2174/138161212800672732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.2174%2F138161212800672732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=22571661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2921-2935&author=C.+Zhangauthor=C.+Tanauthor=H.+Dingauthor=T.+Xinauthor=Y.+Jiang&title=Selective+VEGFR+inhibitors+for+anticancer+therapeutics+in+clinical+use+and+clinical+trials&doi=10.2174%2F138161212800672732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials</span></div><div class="casAuthors">Zhang, Cunlong; Tan, Chunyan; Ding, Huaiwei; Xin, Tian; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2921-2935</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis.  Selective inhibition of VEGFR kinase has been explored as a highly successful clin. strategy in cancer treatment.  A no. of VEGFR inhibitors have been approved in clin. use and many more are in various stages of drug development.  This paper reviews selective small-mol. VEGFR inhibitors in clin. uses and in clin. trials, with particular focus on in vitro, in vivo and clin. trial results of these inhibitors.  The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP924FfbZz7rVg90H21EOLACvtfcHk0liSZsC4od2dRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltrg%253D&md5=7c5416e6cf9a0db8065f2c0bfa0711bd</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.2174%2F138161212800672732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672732%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSelective%2520VEGFR%2520inhibitors%2520for%2520anticancer%2520therapeutics%2520in%2520clinical%2520use%2520and%2520clinical%2520trials%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2921%26epage%3D2935%26doi%3D10.2174%2F138161212800672732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wietfeld, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sills, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acemoglu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmenegger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lässer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetterli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2310</span><span class="NLM_x">–</span> <span class="NLM_lpage">2323</span><span class="refDoi"> DOI: 10.1021/jm9909443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9909443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2310-2323&author=G.+Boldauthor=K.+H.+Altmannauthor=J.+Freiauthor=M.+Langauthor=P.+W.+Manleyauthor=P.+Traxlerauthor=B.+Wietfeldauthor=J.+Br%C3%BCggenauthor=E.+Buchdungerauthor=R.+Cozensauthor=S.+Ferrariauthor=P.+Furetauthor=F.+Hofmannauthor=G.+Martiny-Baronauthor=J.+Mestanauthor=J.+R%C3%B6selauthor=M.+Sillsauthor=D.+Stoverauthor=F.+Acemogluauthor=E.+Bossauthor=R.+Emmeneggerauthor=R.+L%C3%A4sserauthor=E.+Massoauthor=R.+Rothauthor=C.+Schlachterauthor=W.+Vetterliauthor=D.+Wyssauthor=J.+M.+Wood&title=New+anilinophthalazines+as+potent+and+orally+well+absorbed+inhibitors+of+the+VEGF+receptor+tyrosine+kinases+useful+as+antagonists+of+tumor-driven+angiogenesis&doi=10.1021%2Fjm9909443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fjm9909443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9909443%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DFrei%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DWietfeld%26aufirst%3DB.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DSills%26aufirst%3DM.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DAcemoglu%26aufirst%3DF.%26aulast%3DBoss%26aufirst%3DE.%26aulast%3DEmmenegger%26aufirst%3DR.%26aulast%3DL%25C3%25A4sser%26aufirst%3DR.%26aulast%3DMasso%26aufirst%3DE.%26aulast%3DRoth%26aufirst%3DR.%26aulast%3DSchlachter%26aufirst%3DC.%26aulast%3DVetterli%26aufirst%3DW.%26aulast%3DWyss%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DNew%2520anilinophthalazines%2520as%2520potent%2520and%2520orally%2520well%2520absorbed%2520inhibitors%2520of%2520the%2520VEGF%2520receptor%2520tyrosine%2520kinases%2520useful%2520as%2520antagonists%2520of%2520tumor-driven%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2310%26epage%3D2323%26doi%3D10.1021%2Fjm9909443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span>ibid.<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3200</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ibid.+2000%2C+43%2C+3200."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2000%26volume%3D43%26spage%3D3200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krüger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menrad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidelmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span> </span><span class="NLM_article-title">Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5687</span><span class="NLM_x">–</span> <span class="NLM_lpage">5693</span><span class="refDoi"> DOI: 10.1021/jm020899q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020899q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5687-5693&author=P.+W.+Manleyauthor=P.+Furetauthor=G.+Boldauthor=J.+Br%C3%BCggenauthor=J.+Mestanauthor=T.+Meyerauthor=C.+Schnellauthor=J.+Woodauthor=M.+Habereyauthor=A.+Huthauthor=M.+Kr%C3%BCgerauthor=A.+Menradauthor=E.+Ottowauthor=D.+Seidelmannauthor=G.+Siemeisterauthor=K.+H.+Thierauch&title=Anthranilic+acid+amides%3A+a+novel+class+of+antiangiogenic+VEGF+receptor+kinase+inhibitors&doi=10.1021%2Fjm020899q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm020899q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020899q%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DHaberey%26aufirst%3DM.%26aulast%3DHuth%26aufirst%3DA.%26aulast%3DKr%25C3%25BCger%26aufirst%3DM.%26aulast%3DMenrad%26aufirst%3DA.%26aulast%3DOttow%26aufirst%3DE.%26aulast%3DSeidelmann%26aufirst%3DD.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26atitle%3DAnthranilic%2520acid%2520amides%253A%2520a%2520novel%2520class%2520of%2520antiangiogenic%2520VEGF%2520receptor%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5687%26epage%3D5693%26doi%3D10.1021%2Fjm020899q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="note"><p class="first last">Two independent patent applications were published describing BAW2881 as an example:</p></div><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Potashman, M.; Kim, T.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J. C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A.</span><span> </span><span class="NLM_article-title">Compounds and methods of use</span>. WO 2005/070891,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Potashman&author=T.+Kim&author=S.+Bellon&author=S.+Booker&author=Y.+Cheng&author=J.+L.+Kim&author=A.+Tasker&author=N.+Xi&author=S.+Xu&author=J.+C.+Harmange&author=G.+Borg&author=M.+Weiss&author=B.+L.+Hodous&author=R.+Graceffa&author=W.+H.+Buckner&author=C.+E.+Masse&author=D.+Choquette&author=M.+W.+Martin&author=J.+Germain&author=L.+V.+Dipietro&author=S.+C.+Chaffee&author=J.+J.+Nunes&author=J.+L.+Buchanan&author=G.+J.+Habgood&author=D.+C.+McGowan&author=D.+A.+Whittington&title=Compounds+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%26atitle%3DCompounds%2520and%2520methods%2520of%2520use%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bold, G.; Capraro, H. G.; Caravatti, G.; Flörsheimer, A.; Furet, P.; Manley, P. W.; Vaupel, A.; Pissot-Soldermann, C.; Gessier, F.; Schnell, C.; Littlewood-Evans, A. J.; Kapa, P. K.; Bajwa, J. S.; Jiang, X.</span><span> </span><span class="NLM_article-title">Bicyclic amides as kinase inhibitors</span>. WO 2006/059234,<span class="NLM_x"> </span><span class="NLM_year">2006</span>. <div class="note"><p class="first last">Biological activities of two of the compounds were described in:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=G.+Bold&author=H.+G.+Capraro&author=G.+Caravatti&author=A.+Fl%C3%B6rsheimer&author=P.+Furet&author=P.+W.+Manley&author=A.+Vaupel&author=C.+Pissot-Soldermann&author=F.+Gessier&author=C.+Schnell&author=A.+J.+Littlewood-Evans&author=P.+K.+Kapa&author=J.+S.+Bajwa&author=X.+Jiang&title=Bicyclic+amides+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26atitle%3DBicyclic%2520amides%2520as%2520kinase%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Halin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrngruber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meingassner, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stütz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detmar, M.</span><span> </span><span class="NLM_article-title">Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span><span class="refDoi"> DOI: 10.2353/ajpath.2008.071074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.2353%2Fajpath.2008.071074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=18535184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2008&pages=265-277&author=C.+Halinauthor=H.+Fahrngruberauthor=J.+G.+Meingassnerauthor=G.+Boldauthor=A.+Littlewood-Evansauthor=A.+St%C3%BCtzauthor=M.+Detmar&title=Inhibition+of+chronic+and+acute+skin+inflammation+by+treatment+with+a+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitor&doi=10.2353%2Fajpath.2008.071074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Halin, Cornelia; Fahrngruber, Hermann; Meingassner, Josef G.; Bold, Guido; Littlewood-Evans, Amanda; Stuetz, Anton; Detmar, Michael</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-277</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Although vascular remodeling is a hallmark of many chronic inflammatory disorders, antivascular strategies to treat these conditions have received little attention to date.  We investigated the effects of a newly identified vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor, NVP-BAW2881, on endothelial cell function in vitro and its anti-inflammatory activity in different animal models.  NVP-BAW2881 inhibited proliferation, migration, and tube formation by human umbilical vein endothelial cells and lymphatic endothelial cells in vitro.  In a transgenic mouse model of psoriasis, NVP-BAW2881 reduced the no. of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture.  NVP-BAW2881 also displayed strong anti-inflammatory effects in models of acute inflammation; pre-treatment with topical NVP-BAW2881 significantly inhibited VEGF-A-induced vascular permeability in the skin of pigs and mice.  Furthermore, topical application of NVP-BAW2881 reduced the inflammatory response elicited in pig skin by UV-B irradn. or by contact hypersensitivity reactions.  These results demonstrate for the first time that VEGF receptor tyrosine-kinase inhibitors might be used to treat patients with inflammatory skin disorders such as psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPVs2TkCq3O7Vg90H21EOLACvtfcHk0liS1SpEh3fBbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKjsrc%253D&md5=4a07dcf97fa4547a6d49f333371703e4</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2008.071074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2008.071074%26sid%3Dliteratum%253Aachs%26aulast%3DHalin%26aufirst%3DC.%26aulast%3DFahrngruber%26aufirst%3DH.%26aulast%3DMeingassner%26aufirst%3DJ.%2BG.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSt%25C3%25BCtz%26aufirst%3DA.%26aulast%3DDetmar%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520chronic%2520and%2520acute%2520skin%2520inflammation%2520by%2520treatment%2520with%2520a%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2008%26volume%3D173%26spage%3D265%26epage%3D277%26doi%3D10.2353%2Fajpath.2008.071074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Meingassner, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrngruber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stütz, A.</span><span> </span><span class="NLM_article-title">NVP-BFH772, a potent inhibitor of VEGF receptor tyrosine kinases, is effective in models of skin inflammation</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2011&pages=480&author=J.+G.+Meingassnerauthor=H.+Fahrngruberauthor=E.+Kowalskyauthor=A.+Billichauthor=G.+Boldauthor=A.+Littlewood-Evansauthor=A.+St%C3%BCtz&title=NVP-BFH772%2C+a+potent+inhibitor+of+VEGF+receptor+tyrosine+kinases%2C+is+effective+in+models+of+skin+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeingassner%26aufirst%3DJ.%2BG.%26aulast%3DFahrngruber%26aufirst%3DH.%26aulast%3DKowalsky%26aufirst%3DE.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSt%25C3%25BCtz%26aufirst%3DA.%26atitle%3DNVP-BFH772%252C%2520a%2520potent%2520inhibitor%2520of%2520VEGF%2520receptor%2520tyrosine%2520kinases%252C%2520is%2520effective%2520in%2520models%2520of%2520skin%2520inflammation%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2011%26volume%3D131%26spage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Shieh, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sclafani, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girgis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radetich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, K.</span><span> </span><span class="NLM_article-title">Syntheses of a triad of Flt3 kinase inhibitors: from bench to pilot plant</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1146</span><span class="NLM_x">–</span> <span class="NLM_lpage">1155</span><span class="refDoi"> DOI: 10.1021/op800136f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op800136f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=1146-1155&author=W.+C.+Shiehauthor=J.+McKennaauthor=J.+A.+Sclafaniauthor=S.+Xueauthor=M.+Girgisauthor=J.+Viveloauthor=B.+Radetichauthor=K.+Prasad&title=Syntheses+of+a+triad+of+Flt3+kinase+inhibitors%3A+from+bench+to+pilot+plant&doi=10.1021%2Fop800136f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fop800136f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop800136f%26sid%3Dliteratum%253Aachs%26aulast%3DShieh%26aufirst%3DW.%2BC.%26aulast%3DMcKenna%26aufirst%3DJ.%26aulast%3DSclafani%26aufirst%3DJ.%2BA.%26aulast%3DXue%26aufirst%3DS.%26aulast%3DGirgis%26aufirst%3DM.%26aulast%3DVivelo%26aufirst%3DJ.%26aulast%3DRadetich%26aufirst%3DB.%26aulast%3DPrasad%26aufirst%3DK.%26atitle%3DSyntheses%2520of%2520a%2520triad%2520of%2520Flt3%2520kinase%2520inhibitors%253A%2520from%2520bench%2520to%2520pilot%2520plant%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2008%26volume%3D12%26spage%3D1146%26epage%3D1155%26doi%3D10.1021%2Fop800136f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazo-Kallanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">5161</span><span class="NLM_x">–</span> <span class="NLM_lpage">5170</span><span class="refDoi"> DOI: 10.1182/blood-2008-02-138065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1182%2Fblood-2008-02-138065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=5161-5170&author=E.+Weisbergauthor=J.+R%C3%B6selauthor=G.+Boldauthor=P.+Furetauthor=J.+Jiangauthor=J.+Coolsauthor=R.+D.+Wrightauthor=E.+Nelsonauthor=R.+Barrettauthor=A.+Rayauthor=D.+Morenoauthor=E.+Hall-Meyersauthor=R.+Stoneauthor=I.+Galinskyauthor=E.+Foxauthor=G.+Gillilandauthor=J.+F.+Daleyauthor=S.+Lazo-Kallanianauthor=A.+L.+Kungauthor=J.+D.+Griffin&title=Antileukemic+effects+of+the+novel%2C+mutant+FLT3+inhibitor+NVP-AST487%3A+effects+on+PKC412-sensitive+and+-resistant+FLT3-expressing+cells&doi=10.1182%2Fblood-2008-02-138065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-02-138065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-02-138065%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DDaley%26aufirst%3DJ.%2BF.%26aulast%3DLazo-Kallanian%26aufirst%3DS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DAntileukemic%2520effects%2520of%2520the%2520novel%252C%2520mutant%2520FLT3%2520inhibitor%2520NVP-AST487%253A%2520effects%2520on%2520PKC412-sensitive%2520and%2520-resistant%2520FLT3-expressing%2520cells%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D5161%26epage%3D5170%26doi%3D10.1182%2Fblood-2008-02-138065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Akeno-Stuart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauf, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaguarnera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitagliano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosios, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagin, J. A.</span><span> </span><span class="NLM_article-title">The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6956</span><span class="NLM_x">–</span> <span class="NLM_lpage">6964</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-06-4605" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6956-6964&author=N.+Akeno-Stuartauthor=M.+Croyleauthor=J.+A.+Knaufauthor=R.+Malaguarneraauthor=D.+Vitaglianoauthor=M.+Santoroauthor=C.+Stephanauthor=K.+Grosiosauthor=M.+Wartmannauthor=R.+Cozensauthor=G.+Caravattiauthor=D.+Fabbroauthor=H.+A.+Laneauthor=J.+A.+Fagin&title=The+RET+kinase+inhibitor+NVP-AST487+blocks+growth+and+calcitonin+gene+expression+through+distinct+mechanisms+in+medullary+thyroid+cancer+cells&doi=10.1158%2F0008-5472.CAN-06-4605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4605%26sid%3Dliteratum%253Aachs%26aulast%3DAkeno-Stuart%26aufirst%3DN.%26aulast%3DCroyle%26aufirst%3DM.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DMalaguarnera%26aufirst%3DR.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DGrosios%26aufirst%3DK.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520RET%2520kinase%2520inhibitor%2520NVP-AST487%2520blocks%2520growth%2520and%2520calcitonin%2520gene%2520expression%2520through%2520distinct%2520mechanisms%2520in%2520medullary%2520thyroid%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6956%26epage%3D6964%26doi%3D10.1158%2F0008-5472.CAN-06-4605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persohn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towbin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods-Cook, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menrad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drevs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmé, D.</span><span> </span><span class="NLM_article-title">PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2178</span><span class="NLM_x">–</span> <span class="NLM_lpage">2189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=2178-2189&author=J.+M.+Woodauthor=G.+Boldauthor=E.+Buchdungerauthor=R.+Cozensauthor=S.+Ferrariauthor=J.+Freiauthor=F.+Hofmannauthor=J.+Mestanauthor=H.+Mettauthor=T.+O%E2%80%99Reillyauthor=E.+Persohnauthor=J.+R%C3%B6selauthor=C.+Schnellauthor=D.+Stoverauthor=A.+Theuerauthor=H.+Towbinauthor=F.+Wengerauthor=K.+Woods-Cookauthor=A.+Menradauthor=G.+Siemeisterauthor=M.+Schirnerauthor=K.+H.+Thierauchauthor=M.+R.+Schneiderauthor=J.+Drevsauthor=G.+Martiny-Baronauthor=F.+Totzkeauthor=D.+Marm%C3%A9&title=PTK787%2FZK+222584%2C+a+novel+and+potent+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases%2C+impairs+vascular+endothelial+growth+factor-induced+responses+and+tumor+growth+after+oral+administration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DFrei%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DPersohn%26aufirst%3DE.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DTheuer%26aufirst%3DA.%26aulast%3DTowbin%26aufirst%3DH.%26aulast%3DWenger%26aufirst%3DF.%26aulast%3DWoods-Cook%26aufirst%3DK.%26aulast%3DMenrad%26aufirst%3DA.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DSchirner%26aufirst%3DM.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DSchneider%26aufirst%3DM.%2BR.%26aulast%3DDrevs%26aufirst%3DJ.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DMarm%25C3%25A9%26aufirst%3DD.%26atitle%3DPTK787%252FZK%2520222584%252C%2520a%2520novel%2520and%2520potent%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%252C%2520impairs%2520vascular%2520endothelial%2520growth%2520factor-induced%2520responses%2520and%2520tumor%2520growth%2520after%2520oral%2520administration%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D2178%26epage%3D2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyhack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1697</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2003.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2Fj.bbapap.2003.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=15023347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=17-27&author=P.+W.+Manleyauthor=G.+Boldauthor=J.+Br%C3%BCggenauthor=G.+Fendrichauthor=P.+Furetauthor=J.+Mestanauthor=C.+Schnellauthor=B.+Stolzauthor=T.+Meyerauthor=B.+Meyhackauthor=W.+Starkauthor=A.+Straussauthor=J.+Wood&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+VEGF-R+kinase+inhibitors+for+the+treatment+of+angiogenesis&doi=10.1016%2Fj.bbapap.2003.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis</span></div><div class="casAuthors">Manley, Paul William; Bold, Guido; Brueggen, Josef; Fendrich, Gabrielle; Furet, Pascal; Mestan, Jurgen; Schnell, Christian; Stolz, Barbara; Meyer, Thomas; Meyhack, Bernd; Stark, Wilhelm; Strauss, Andre; Wood, Jeanette</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">17-27</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Initial studies with angiogenesis inhibitors showed little clin. benefit.  However, recently reported clin. studies in colorectal cancer have shown that bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody, in combination with cytotoxic therapy has pos. effects on patient survival.  Furthermore, the VEGF receptor kinase (VEGF-R) tyrosine kinase inhibitor, vatalanib, has also shown encouraging results in colorectal cancer, with mol. resonance imaging providing evidence that the anti-tumor efficacy was indeed the result of anti-angiogenic activity.  Both of these agents are progressing in phase III trials.  This proof of concept has stimulated the desire for second-generation VEGF-R inhibitors having an improved profile.  Structural biol. insight regarding the binding mode of protein kinase inhibitors is valuable for the design of mols. possessing superior selectivity, efficacy and tolerability.  Towards this goal, the authors have developed a new series of VEGF-R2 kinase inhibitors, based upon an anthranilic acid amide scaffold.  An x-ray crystal structure of a representative compd., AAL993 (ZK260253), in complex with the catalytic domain of diphosphorylated VEGF-R2 has revealed that this mol. binds to an inactive conformation of the protein.  This binding mode, similar to that obsd. for the anti-leukemia drug, imatinib in complex with c-Abl kinase, may be responsible for the high selectivity of AAL993 and provides valuable insight for the design of further compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu3NYKjX0IDLVg90H21EOLACvtfcHk0lhKGoUv-ccODQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsrc%253D&md5=4ce7a134c71ea83d0a711cab9ffc0c85</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DB.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMeyhack%26aufirst%3DB.%26aulast%3DStark%26aufirst%3DW.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520VEGF-R%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520angiogenesis%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D17%26epage%3D27%26doi%3D10.1016%2Fj.bbapap.2003.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><div class="note"><p class="first last">At the time this work was accomplished, there was no crystal structure of the FLT3 kinase in the “DFG out” conformation available. We resorted to a homology model described in:</p></div><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flörsheimer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Antileukemic effects of novel first-and second-generation FLT3 inhibitors: structure-affinity comparison</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1021</span><span class="NLM_x">–</span> <span class="NLM_lpage">1032</span><span class="refDoi"> DOI: 10.1177/1947601910396505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1177%2F1947601910396505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=21779428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisF2nsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=1021-1032&author=E.+Weisbergauthor=J.+R%C3%B6selauthor=P.+Furetauthor=G.+Boldauthor=P.+Imbachauthor=A.+Fl%C3%B6rsheimerauthor=G.+Caravattiauthor=J.+Jiangauthor=P.+W.+Manleyauthor=A.+Rayauthor=J.+D.+Griffin&title=Antileukemic+effects+of+novel+first-and+second-generation+FLT3+inhibitors%3A+structure-affinity+comparison&doi=10.1177%2F1947601910396505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Antileukemic effects of novel first-and second-generation FLT3 inhibitors: structure-affinity comparison</span></div><div class="casAuthors">Weisberg, Ellen; Roesel, Johannes; Furet, Pascal; Bold, Guido; Imbach, Patricia; Florsheimer, Andreas; Caravatti, Georgio; Jiang, Jingrui; Manley, Paul; Ray, Arghya; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1021-1032</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it.  The small mol. inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clin. trials.  However, the identification of PKC412-resistant leukemic blast cells in the bone marrow of AML patients has propelled the development of novel and structurally distinct FLT3 inhibitors that have the potential to override drug resistance and more efficiently prevent disease progression or recurrence.  Here, we present the novel first-generation "type II" FLT3 inhibitors, AFG206, AFG210, and AHL196, and the second-generation "type II" derivs. and AST487 analogs, AUZ454 and ATH686.  All agents potently and selectively target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition.  Cross-resistance between "type I" inhibitors, PKC412 and AAE871, was demonstrated.  While cross-resistance was also obsd. between "type I" and first-generation "type II" FLT3 inhibitors, the high potency of the second-generation "type II" inhibitors was sufficient to potently kill "type I" inhibitor-resistant mutant FLT3-expressing cells.  The increased potency obsd. for the second-generation "type II" inhibitors was obsd. to be due to an improved interaction with the ATP pocket of FLT3, specifically assocd. with introduction of a piperazine moiety and placement of an amino group in position 2 of the pyrimidine ring.  Thus, we present 2 structurally novel classes of FLT3 inhibitors characterized by high selectivity and potency toward mutant FLT3 as a mol. target.  In addn., presentation of the antileukemic effects of "type II" inhibitors, such as AUZ454 and ATH686, highlights a new class of highly potent FLT3 inhibitors able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaZyJlPc6jT7Vg90H21EOLACvtfcHk0lhKGoUv-ccODQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisF2nsrY%253D&md5=bf25a61a240b5f9a73e11c389cb13870</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1177%2F1947601910396505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910396505%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DImbach%26aufirst%3DP.%26aulast%3DFl%25C3%25B6rsheimer%26aufirst%3DA.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DAntileukemic%2520effects%2520of%2520novel%2520first-and%2520second-generation%2520FLT3%2520inhibitors%253A%2520structure-affinity%2520comparison%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D1021%26epage%3D1032%26doi%3D10.1177%2F1947601910396505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrián, F.</span><span> </span><span class="NLM_article-title">Ba/F3 cells and their use in kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1097/CCO.0b013e328011a25f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1097%2FCCO.0b013e328011a25f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=17133113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=55-60&author=M.+Warmuthauthor=S.+Kimauthor=X.+J.+Guauthor=G.+Xiaauthor=F.+Adri%C3%A1n&title=Ba%2FF3+cells+and+their+use+in+kinase+drug+discovery&doi=10.1097%2FCCO.0b013e328011a25f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ba/F3 cells and their use in kinase drug discovery</span></div><div class="casAuthors">Warmuth, Markus; Kim, Sungjoon; Gu, Xiang-ju; Xia, Gang; Adrian, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics.  The discovery of a large no. of cancer-assocd. mutations in the kinome, and the progress in developing specific small-mol. kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.  Recent findings: Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-mol. kinase inhibitors to block kinase activity.  Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compd. profiling.  Further, several published approaches show promise in predicting resistance to small-mol. kinase inhibitors elicited by point mutations interfering with inhibitor binding.  Summary: Ba/F3 cells are an increasingly popular tool in kinase drug discovery.  The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compd. libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clin. resistance will greatly facilitate developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQmhiRwGlDLVg90H21EOLACvtfcHk0lgTS7Xg43otaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL&md5=a7f8d84dfedea69d408edb571e2eead9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328011a25f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328011a25f%26sid%3Dliteratum%253Aachs%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DAdri%25C3%25A1n%26aufirst%3DF.%26atitle%3DBa%252FF3%2520cells%2520and%2520their%2520use%2520in%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D55%26epage%3D60%26doi%3D10.1097%2FCCO.0b013e328011a25f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinks, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regenass, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlynn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent <i>in vivo</i> antitumor activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">2334</span><span class="NLM_x">–</span> <span class="NLM_lpage">2338</span><span class="refDoi"> DOI: 10.1073/pnas.91.6.2334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1073%2Fpnas.91.6.2334" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=2334-2338&author=E.+Buchdungerauthor=U.+Trinksauthor=H.+Mettauthor=U.+Regenassauthor=M.+M%C3%BCllerauthor=T.+Meyerauthor=E.+McGlynnauthor=L.+A.+Pinnaauthor=P.+Traxlerauthor=N.+B.+Lydon&title=4%2C5-Dianilinophthalimide%3A+a+protein-tyrosine+kinase+inhibitor+with+selectivity+for+the+epidermal+growth+factor+receptor+signal+transduction+pathway+and+potent+in+vivo+antitumor+activity&doi=10.1073%2Fpnas.91.6.2334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.6.2334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.6.2334%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DTrinks%26aufirst%3DU.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DRegenass%26aufirst%3DU.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMcGlynn%26aufirst%3DE.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3D4%252C5-Dianilinophthalimide%253A%2520a%2520protein-tyrosine%2520kinase%2520inhibitor%2520with%2520selectivity%2520for%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520signal%2520transduction%2520pathway%2520and%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D2334%26epage%3D2338%26doi%3D10.1073%2Fpnas.91.6.2334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">LaMontagne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-05-2001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=221-231&author=K.+LaMontagneauthor=A.+Littlewood-Evansauthor=C.+Schnellauthor=T.+O%E2%80%99Reillyauthor=L.+Wyderauthor=T.+Sanchezauthor=B.+Probstauthor=J.+Butlerauthor=A.+Woodauthor=G.+Liauauthor=E.+Billyauthor=A.+Theuerauthor=T.+Hlaauthor=J.+Wood&title=Antagonism+of+sphingosine-1-phosphate+receptors+by+FTY720+inhibits+angiogenesis+and+tumor+vascularization&doi=10.1158%2F0008-5472.CAN-05-2001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2001%26sid%3Dliteratum%253Aachs%26aulast%3DLaMontagne%26aufirst%3DK.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DWyder%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DProbst%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DLiau%26aufirst%3DG.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DTheuer%26aufirst%3DA.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAntagonism%2520of%2520sphingosine-1-phosphate%2520receptors%2520by%2520FTY720%2520inhibits%2520angiogenesis%2520and%2520tumor%2520vascularization%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D221%26epage%3D231%26doi%3D10.1158%2F0008-5472.CAN-05-2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Weidensteiner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSheehy, P.M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegrini, P. R.</span><span> </span><span class="NLM_article-title">Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T</span> <span class="citation_source-journal">Journal of Magnetic Resonance Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">656</span><span class="refDoi"> DOI: 10.1002/jmri.20676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1002%2Fjmri.20676" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=646-656&author=C.+Weidensteinerauthor=M.+Rauschauthor=P.M.+J.+McSheehyauthor=P.+R.+Allegrini&title=Quantitative+dynamic+contrast-enhanced+MRI+in+tumor-bearing+rats+and+mice+with+inversion+recovery+TrueFISP+and+two+contrast+agents+at+4.7+T&doi=10.1002%2Fjmri.20676"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjmri.20676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmri.20676%26sid%3Dliteratum%253Aachs%26aulast%3DWeidensteiner%26aufirst%3DC.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DMcSheehy%26aufirst%3DP.M.%2BJ.%26aulast%3DAllegrini%26aufirst%3DP.%2BR.%26atitle%3DQuantitative%2520dynamic%2520contrast-enhanced%2520MRI%2520in%2520tumor-bearing%2520rats%2520and%2520mice%2520with%2520inversion%2520recovery%2520TrueFISP%2520and%2520two%2520contrast%2520agents%2520at%25204.7%2520T%26jtitle%3DJournal%2520of%2520Magnetic%2520Resonance%2520Imaging%26date%3D2006%26volume%3D24%26spage%3D646%26epage%3D656%26doi%3D10.1002%2Fjmri.20676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Moss, A.</span><span> </span><span class="NLM_article-title">The angiopoietin:Tie 2 interaction: a potential target for future therapies in human vascular disease</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2013.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2Fj.cytogfr.2013.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=23838360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKnurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=579-592&author=A.+Moss&title=The+angiopoietin%3ATie+2+interaction%3A+a+potential+target+for+future+therapies+in+human+vascular+disease&doi=10.1016%2Fj.cytogfr.2013.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The angiopoietin:Tie 2 interaction: A potential target for future therapies in human vascular disease</span></div><div class="casAuthors">Moss, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-592</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiopoietin-1 and -2 are endogenous ligands for the vascular endothelial receptor tyrosine kinase Tie2.  Signalling by angiopoietin-1 promotes vascular endothelial cell survival and the sprouting and reorganisation of blood vessels, as well as inhibiting activation of the vascular endothelial barrier to reduce leakage and leukocyte migration into tissues.  Angiopoietin-2 generally has an opposing action, and is released naturally at times of vascular growth and inflammation.  There is a significant body of emerging evidence that promoting the actions of angiopoietin-1 through Tie2 is of benefit in pathologies of vascular activation, such as sepsis, stroke, diabetic retinopathy and asthma.  Similarly, methods to inhibit the actions of angiopoietin-2 are emerging and have been demonstrated to be of preclin. and clin. benefit in reducing tumor angiogenesis.  Here the author reviews the evidence for potential benefits of modulation of the interaction of angiopoietins with Tie2, and the potential applications.  Addnl., methods for delivery of the complex protein angiopoietin-1 are discussed, as well as potentially deleterious consequences of administering angiopoietin-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVmGs0WhXg27Vg90H21EOLACvtfcHk0li5yy42z4nSWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKnurfF&md5=f4f212b1f48110d9a4585e09d3b8e5f6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2013.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2013.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DA.%26atitle%3DThe%2520angiopoietin%253ATie%25202%2520interaction%253A%2520a%2520potential%2520target%2520for%2520future%2520therapies%2520in%2520human%2520vascular%2520disease%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2013%26volume%3D24%26spage%3D579%26epage%3D592%26doi%3D10.1016%2Fj.cytogfr.2013.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Fallahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galleri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, A.</span><span> </span><span class="NLM_article-title">New therapies for dedifferentiated papillary thyroid cancer</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">6153</span><span class="NLM_x">–</span> <span class="NLM_lpage">6182</span><span class="refDoi"> DOI: 10.3390/ijms16036153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.3390%2Fijms16036153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=25789503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvFCju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=6153-6182&author=P.+Fallahiauthor=V.+Mazziauthor=R.+Vitaauthor=S.+M.+Ferrariauthor=G.+Materazziauthor=D.+Galleriauthor=S.+Benvengaauthor=P.+Miccoliauthor=A.+Antonelli&title=New+therapies+for+dedifferentiated+papillary+thyroid+cancer&doi=10.3390%2Fijms16036153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for dedifferentiated papillary thyroid cancer</span></div><div class="casAuthors">Fallahi, Poupak; Mazzi, Valeria; Vita, Roberto; Ferrari, Silvia Martina; Materazzi, Gabriele; Galleri, David; Benvenga, Salvatore; Miccoli, Paolo; Antonelli, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">6153-6182</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The no. of thyroid cancers is increasing.  Std. treatment usually includes primary surgery, TSH suppressive therapy, and ablation of the thyroid remnant with radioactive iodine (RAI).  Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will develop metastatic disease, which fails to respond to RAI, exhibiting a more aggressive behavior.  The lack of specific, effective and well-tolerated drugs, the scarcity of data about the assocn. of multi-targeting drugs, and the limited role of radioiodine for dedifferentiated thyroid cancer, call for further efforts in the field of new drugs development.  Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer.  Targeted novel compds. have been demonstrated to induce clin. responses and stabilization of disease.  Sorafenib has been approved for differentiated thyroid cancer refractory to RAI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDrA45V1LxjbVg90H21EOLACvtfcHk0li5yy42z4nSWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvFCju7g%253D&md5=59c2b5eb7c23e0cf0508f98fd3b9e5c8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3390%2Fijms16036153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms16036153%26sid%3Dliteratum%253Aachs%26aulast%3DFallahi%26aufirst%3DP.%26aulast%3DMazzi%26aufirst%3DV.%26aulast%3DVita%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%2BM.%26aulast%3DMaterazzi%26aufirst%3DG.%26aulast%3DGalleri%26aufirst%3DD.%26aulast%3DBenvenga%26aufirst%3DS.%26aulast%3DMiccoli%26aufirst%3DP.%26aulast%3DAntonelli%26aufirst%3DA.%26atitle%3DNew%2520therapies%2520for%2520dedifferentiated%2520papillary%2520thyroid%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D6153%26epage%3D6182%26doi%3D10.3390%2Fijms16036153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ravegnini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammarini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astolfi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantaleo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrelia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, S.</span><span> </span><span class="NLM_article-title">Personalized medicine in gastrointestinal stromal tumor (GIST): Clinical implications of the somatic and germline DNA analysis</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">15592</span><span class="NLM_x">–</span> <span class="NLM_lpage">15608</span><span class="refDoi"> DOI: 10.3390/ijms160715592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.3390%2Fijms160715592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=26184165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2qs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=15592-15608&author=G.+Ravegniniauthor=M.+Nanniniauthor=G.+Sammariniauthor=A.+Astolfiauthor=G.+Biascoauthor=M.+A.+Pantaleoauthor=P.+Hreliaauthor=S.+Angelini&title=Personalized+medicine+in+gastrointestinal+stromal+tumor+%28GIST%29%3A+Clinical+implications+of+the+somatic+and+germline+DNA+analysis&doi=10.3390%2Fijms160715592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized medicine in gastrointestinal stromal tumor (GIST): clinical implications of the somatic and germline DNA analysis</span></div><div class="casAuthors">Ravegnini, Gloria; Nannini, Margherita; Sammarini, Giulia; Astolfi, Annalisa; Biasco, Guido; Pantaleo, Maria A.; Hrelia, Patrizia; Angelini, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">15592-15608</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract.  They are characterized by gain of function mutations in KIT or PDGFRA tyrosine kinase receptors, with their consequent constitutive activation.  The gold std. therapy is imatinib that offers a good and stable response for approx. 18-36 mo.  However, resistance is very common and it is vital to identify new biomarkers.  Up until now, there have been two main approaches with focus to characterize novel targets.  On the one hand, the focus is on the tumor genome, as the final clin. outcome depends mainly from the cancer specific mutations/alterations patterns.  However, the germline DNA is important as well, and it is inconceivable to think the patients response to the drug is not related to it.  Therefore the aim of this review is to outline the state of the art of the personalized medicine in GIST taking into account both the tumor DNA (somatic) and the patient DNA (germline).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCimapePqmLrVg90H21EOLACvtfcHk0lgTXv9AOGP2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2qs7jP&md5=18e61c308cb84c0956ed804c4a3c99f8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3390%2Fijms160715592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160715592%26sid%3Dliteratum%253Aachs%26aulast%3DRavegnini%26aufirst%3DG.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DSammarini%26aufirst%3DG.%26aulast%3DAstolfi%26aufirst%3DA.%26aulast%3DBiasco%26aufirst%3DG.%26aulast%3DPantaleo%26aufirst%3DM.%2BA.%26aulast%3DHrelia%26aufirst%3DP.%26aulast%3DAngelini%26aufirst%3DS.%26atitle%3DPersonalized%2520medicine%2520in%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%253A%2520Clinical%2520implications%2520of%2520the%2520somatic%2520and%2520germline%2520DNA%2520analysis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D15592%26epage%3D15608%26doi%3D10.3390%2Fijms160715592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fallahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spisni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span> </span><span class="NLM_article-title">Selective use of vandetanib in the treatment of thyroid cancer</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3459</span><span class="NLM_x">–</span> <span class="NLM_lpage">3470</span><span class="refDoi"> DOI: 10.2147/DDDT.S72495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.2147%2FDDDT.S72495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=26170630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FivFajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=3459-3470&author=P.+Fallahiauthor=S.+M.+Ferrariauthor=A.+Antonelliauthor=F.+Di+Bariauthor=S.+Benvengaauthor=R.+Spisniauthor=G.+Materazziauthor=P.+Miccoli&title=Selective+use+of+vandetanib+in+the+treatment+of+thyroid+cancer&doi=10.2147%2FDDDT.S72495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective use of vandetanib in the treatment of thyroid cancer</span></div><div class="casAuthors">Fallahi Poupak; Ferrari Silvia Martina; Antonelli Alessandro; Di Bari Flavia; Benvenga Salvatore; Spisni Roberto; Materazzi Gabriele; Miccoli Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3459-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyroid cancer (TC).  It is emerging as a potentially effective option in the treatment of advanced medullary thyroid cancer (MTC) and in dedifferentiated papillary thyroid cancer not responsive to radioiodine.  The most important effect of vandetanib in aggressive MTC is a prolongation of progression-free survival and a stabilization of the disease.  Significant side effects have been observed with the vandetanib therapy (as fatigue, hypertension, QTc prolongation, cutaneous rash, hand-and-foot syndrome, diarrhea, etc), and severe side effects can require the suspension of the drug.  Several studies are currently under way to evaluate the long-term efficacy and tolerability of vandetanib in MTC and in dedifferentiated papillary TC.  The efficacy of vandetanib in patients with MTC in long-term treatments could be overcome by the resistance to the drug.  However, the effectiveness of the treatment could be ameliorated by the molecular characterization of the tumor and by the possibility to test the sensitivity of primary TC cells from each subject to different tyrosine kinase inhibitor.  Association studies are evaluating the effect of the association of vandetanib with other antineoplastic agents (such as irinotecan, bortezomib, etc).  Further research is needed to determine the ideal therapy to obtain the best response in terms of survival and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSs5R1_TNnRTf3jf77P2BG3fW6udTcc2eakLAb3FVPfLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FivFajug%253D%253D&md5=ca5a6c06edd42e0d1158fe3110e4b44e</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S72495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S72495%26sid%3Dliteratum%253Aachs%26aulast%3DFallahi%26aufirst%3DP.%26aulast%3DFerrari%26aufirst%3DS.%2BM.%26aulast%3DAntonelli%26aufirst%3DA.%26aulast%3DDi%2BBari%26aufirst%3DF.%26aulast%3DBenvenga%26aufirst%3DS.%26aulast%3DSpisni%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DG.%26aulast%3DMiccoli%26aufirst%3DP.%26atitle%3DSelective%2520use%2520of%2520vandetanib%2520in%2520the%2520treatment%2520of%2520thyroid%2520cancer%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D3459%26epage%3D3470%26doi%3D10.2147%2FDDDT.S72495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lacouture, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guitart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrescu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutcher, J. P.</span><span> </span><span class="NLM_article-title">Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">1011</span><span class="refDoi"> DOI: 10.1634/theoncologist.2008-0131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1634%2Ftheoncologist.2008-0131" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=1001-1011&author=M.+E.+Lacoutureauthor=S.+Wuauthor=C.+Robertauthor=M.+B.+Atkinsauthor=H.+H.+Kongauthor=J.+Guitartauthor=C.+Garbeauthor=A.+Hauschildauthor=I.+Puzanovauthor=D.+T.+Alexandrescuauthor=R.+T.+Andersonauthor=L.+Woodauthor=J.+P.+Dutcher&title=Evolving+strategies+for+the+management+of+hand-foot+skin+reaction+associated+with+the+multitargeted+kinase+inhibitors+sorafenib+and+sunitinib&doi=10.1634%2Ftheoncologist.2008-0131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2008-0131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2008-0131%26sid%3Dliteratum%253Aachs%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DKong%26aufirst%3DH.%2BH.%26aulast%3DGuitart%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DAlexandrescu%26aufirst%3DD.%2BT.%26aulast%3DAnderson%26aufirst%3DR.%2BT.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DDutcher%26aufirst%3DJ.%2BP.%26atitle%3DEvolving%2520strategies%2520for%2520the%2520management%2520of%2520hand-foot%2520skin%2520reaction%2520associated%2520with%2520the%2520multitargeted%2520kinase%2520inhibitors%2520sorafenib%2520and%2520sunitinib%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D1001%26epage%3D1011%26doi%3D10.1634%2Ftheoncologist.2008-0131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ellis, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span> </span><span class="NLM_article-title">Pathways mediating resistance to vascular endothelial growth factor-targeted therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6371</span><span class="NLM_x">–</span> <span class="NLM_lpage">6375</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-5287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F1078-0432.CCR-07-5287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=18927275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6371-6375&author=L.+M.+Ellisauthor=D.+J.+Hicklin&title=Pathways+mediating+resistance+to+vascular+endothelial+growth+factor-targeted+therapy&doi=10.1158%2F1078-0432.CCR-07-5287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy</span></div><div class="casAuthors">Ellis, Lee M.; Hicklin, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6371-6375</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factor (VEGF)-targeted therapy has become an important treatment option for the management of a no. of human malignancies.  Unfortunately, a significant no. of patients do not respond to VEGF-targeted therapy when used as a single agent or in combination with chemotherapy.  Furthermore, the duration of benefit from VEGF-targeted therapy can be relatively short (weeks to months).  Ultimately, the vast majority of patients who initially respond to therapy will develop resistance.  To date, the mol. and cellular mechanisms assocd. with resistance to VEGF-targeted agents are poorly understood.  The mechanisms of action of anti-VEGF therapy are diverse, and it is entirely possible that resistance mechanisms are similarly diverse and depend on the tumor type.  A better understanding of these mechanisms will help in the selection of those patients that are more likely to benefit from VEGF-targeted therapy and also provide for the rational development of therapies that circumvent or overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof9jwBsqNaErVg90H21EOLACvtfcHk0lgTXv9AOGP2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrJ&md5=5b5a06a0aa43bec60a2644a67a262820</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5287%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BM.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DPathways%2520mediating%2520resistance%2520to%2520vascular%2520endothelial%2520growth%2520factor-targeted%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6371%26epage%3D6375%26doi%3D10.1158%2F1078-0432.CCR-07-5287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Ding, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1771</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.4155/fmc.14.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.4155%2Ffmc.14.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=25407368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCit7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1771-1789&author=C.+Dingauthor=C.+Zhangauthor=M.+Zhangauthor=Y.+Z.+Chenauthor=C.+Tanauthor=Y.+Tanauthor=Y.+Jiang&title=Multitarget+inhibitors+derived+from+crosstalk+mechanism+involving+VEGFR2&doi=10.4155%2Ffmc.14.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2</span></div><div class="casAuthors">Ding, Chao; Zhang, Cunlong; Zhang, Mingli; Chen, Yu Zong; Tan, Chunyan; Tan, Ying; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1771-1789</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Seven VEGFR small-mol. inhibitors have been approved by the US FDA as anticancer drugs, which confirms the therapeutic value of angiogenesis inhibitors.  However, much more evidence indicates that VEGFR inhibition alone is usually not sufficient to block the tumor progress.  The potential of some agents targeting VEGFR owes partially to the simultaneous inhibition of addnl. targets in other signaling pathways.  In this review, the crosstalk between VEGFR2 and the addnl. targets in other signaling pathways, such as EGFR, MET, FGFR, PDGFR, c-Kit, Raf, PI3K and HDAC, and the synergistic effects derived from multitarget activities against these crosstalks are discussed.  We also briefly describe the multitarget inhibitors in clin. trials or reported in the literature and patents under the different multitarget categories involving VEGFR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqseqvb3DgFk7Vg90H21EOLACvtfcHk0ljE3NDPxCpqAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCit7jM&md5=4843bab8ca10b7672e361b05acd10c5b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.112%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DMultitarget%2520inhibitors%2520derived%2520from%2520crosstalk%2520mechanism%2520involving%2520VEGFR2%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1771%26epage%3D1789%26doi%3D10.4155%2Ffmc.14.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Boulay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuleux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The Ret receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3743</span><span class="NLM_x">–</span> <span class="NLM_lpage">3751</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-07-5100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3743-3751&author=A.+Boulayauthor=M.+Breuleuxauthor=C.+Stephanauthor=C.+Fuxauthor=C.+Briskenauthor=M.+Ficheauthor=M.+Wartmannauthor=M.+Stummauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+Ret+receptor+tyrosine+kinase+pathway+functionally+interacts+with+the+ER%CE%B1+pathway+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-07-5100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5100%26sid%3Dliteratum%253Aachs%26aulast%3DBoulay%26aufirst%3DA.%26aulast%3DBreuleux%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DFux%26aufirst%3DC.%26aulast%3DBrisken%26aufirst%3DC.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520Ret%2520receptor%2520tyrosine%2520kinase%2520pathway%2520functionally%2520interacts%2520with%2520the%2520ER%25CE%25B1%2520pathway%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3743%26epage%3D3751%26doi%3D10.1158%2F0008-5472.CAN-07-5100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Ferretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegrini, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSheehy, P. M.</span><span> </span><span class="NLM_article-title">Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">7773</span><span class="NLM_x">–</span> <span class="NLM_lpage">7784</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F1078-0432.CCR-05-1165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=16278399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2isL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=7773-7784&author=S.+Ferrettiauthor=P.+R.+Allegriniauthor=T.+O%E2%80%99Reillyauthor=C.+Schnellauthor=M.+Stummauthor=M.+Wartmannauthor=J.+Woodauthor=P.+M.+McSheehy&title=Patupilone+induced+vascular+disruption+in+orthotopic+rodent+tumor+models+detected+by+magnetic+resonance+imaging+and+interstitial+fluid+pressure&doi=10.1158%2F1078-0432.CCR-05-1165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure</span></div><div class="casAuthors">Ferretti, Stephane; Allegrini, Peter R.; O'Reilly, Terence; Schnell, Christian; Stumm, Michael; Wartmann, Markus; Wood, Jeanette; McSheehy, Paul M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7773-7784</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Evaluation of vascular disruptive activity in orthotopic models as potential surrogate biomarkers of tumor response to the microtubule-stabilizing agent patupilone.  Mice bearing metastatic B16/BL6 melanoma and rats bearing mammary BN472 tumors received vehicle or efficacious patupilone doses (4 and 0.8-1.5 mg/kg i.v., resp.).  Tumor vascularity assessment by dynamic contrast-enhanced or dynamic susceptibility contrast magnetic resonance imaging and interstitial fluid pressure (IFP) occurred at baseline, 2 days (mice and rats), and 6 days (rats) after treatment and were compared with histol. measurements and correlated with tumor response.  In B16/BL6 metastases, patupilone (4 mg/kg) induced a 21 ± 5% decrease (P < 0.001) in tumor blood vol. and a 32 ± 15% decrease (P = 0.02) in IFP after 2 days and reduced tumor growth and vessel d. (>42%) after 2 wk (P ≤ 0.014).  Patupilone dose-dependently inhibited BN472 tumor growth (day 6) and reduced IFP on days 2 and 6 (-21% to -70%), and the percentage change in IFP correlated (P < 0.01) with the change in tumor vol.  In both models, histol. and vascular casts confirmed decreases in tumor blood vol.  One patupilone (0.8 mg/kg) administration decreased (P < 0.01) tumor IFP (54 ± 4%), tumor blood vol. (50 ± 6%), and vessel diam. (40 ± 11%) by day 6 but not the apparent diffusion coeff., whereas histol. showed that apoptosis was increased 2.4-fold and necrosis was unchanged.  Apoptosis correlated neg. (P < 0.001) with IFP, tumor blood vol., and tumor vol., whereas tumor blood vol. and IFP were correlated pos. (P = 0.0005).  Vascular disruptive effects of patupilone were detected in situ using dynamic contrast-enhanced or dynamic susceptibility contrast magnetic resonance imaging and IFP.  Changes in IFP preceded and correlated with tumor response, suggesting that IFP may be a surrogate biomarker for patupilone efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6VaOmfcjxrVg90H21EOLACvtfcHk0ljE3NDPxCpqAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2isL7K&md5=4c6fd11e474126cbe94c4ac5961c6085</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1165%26sid%3Dliteratum%253Aachs%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DAllegrini%26aufirst%3DP.%2BR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DMcSheehy%26aufirst%3DP.%2BM.%26atitle%3DPatupilone%2520induced%2520vascular%2520disruption%2520in%2520orthotopic%2520rodent%2520tumor%2520models%2520detected%2520by%2520magnetic%2520resonance%2520imaging%2520and%2520interstitial%2520fluid%2520pressure%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D7773%26epage%3D7784%26doi%3D10.1158%2F1078-0432.CCR-05-1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c','cit11d'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Fei Meng, Honglin Zhang, Jie Li, Jianlin Chun, Yun Shi, Han He, Bin Chen, Zhenbo Gao, <span class="NLM_string-name hlFld-ContribAuthor">Yingguang Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective and Switchable Access to Tetrasubstituted Alkenyl Sulfones and Naphthyl Sulfones: 1,4-Aryl Migration versus Cyclization. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (21)
                                     , 8537-8542. <a href="https://doi.org/10.1021/acs.orglett.9b03003" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03003%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DHighly%252BSelective%252Band%252BSwitchable%252BAccess%252Bto%252BTetrasubstituted%252BAlkenyl%252BSulfones%252Band%252BNaphthyl%252BSulfones%25253A%252B1%25252C4-Aryl%252BMigration%252Bversus%252BCyclization%26aulast%3DMeng%26aufirst%3DFei%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22082019%26date%3D23102019%26volume%3D21%26issue%3D21%26spage%3D8537%26epage%3D8542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feifei Fang, Chunmei Zhang, Chaofan Zhou, Yazhou Li, Yu Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Rh(III)-Catalyzed C–H Activation of Benzoylacetonitriles and Tandem Cyclization with Diazo Compounds to Substituted Benzo[de]chromenes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (7)
                                     , 1720-1724. <a href="https://doi.org/10.1021/acs.orglett.8b00103" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00103%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRh%252528III%252529-Catalyzed%252BC%2525E2%252580%252593H%252BActivation%252Bof%252BBenzoylacetonitriles%252Band%252BTandem%252BCyclization%252Bwith%252BDiazo%252BCompounds%252Bto%252BSubstituted%252BBenzo%25255Bde%25255Dchromenes%26aulast%3DFang%26aufirst%3DFeifei%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09012018%26date%3D22032018%26volume%3D20%26issue%3D7%26spage%3D1720%26epage%3D1724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher M.  Adams</span>, <span class="hlFld-ContribAuthor ">Karen  Anderson</span>, <span class="hlFld-ContribAuthor ">Gerald  Artman, III</span>, <span class="hlFld-ContribAuthor ">Jean-Claude  Bizec</span>, <span class="hlFld-ContribAuthor ">Rosemarie  Cepeda</span>, <span class="hlFld-ContribAuthor ">Jason  Elliott</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Fassbender</span>, <span class="hlFld-ContribAuthor ">Malay  Ghosh</span>, <span class="hlFld-ContribAuthor ">Shawn  Hanks</span>, <span class="hlFld-ContribAuthor ">Leo A.  Hardegger</span>, <span class="hlFld-ContribAuthor ">Vinayak P.  Hosagrahara</span>, <span class="hlFld-ContribAuthor ">Bruce  Jaffee</span>, <span class="hlFld-ContribAuthor ">Keith  Jendza</span>, <span class="hlFld-ContribAuthor ">Nan  Ji</span>, <span class="hlFld-ContribAuthor ">Leland  Johnson</span>, <span class="hlFld-ContribAuthor ">Wendy  Lee</span>, <span class="hlFld-ContribAuthor ">Donglei  Liu</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Debby  Long</span>, <span class="hlFld-ContribAuthor ">Fupeng  Ma</span>, <span class="hlFld-ContribAuthor ">Nello  Mainolfi</span>, <span class="hlFld-ContribAuthor ">Erik L.  Meredith</span>, <span class="hlFld-ContribAuthor ">Karl  Miranda</span>, <span class="hlFld-ContribAuthor ">Yao  Peng</span>, <span class="hlFld-ContribAuthor ">Stephen  Poor</span>, <span class="hlFld-ContribAuthor ">James  Powers</span>, <span class="hlFld-ContribAuthor ">Yubin  Qiu</span>, <span class="hlFld-ContribAuthor ">Chang  Rao</span>, <span class="hlFld-ContribAuthor ">Siyuan  Shen</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Sivak</span>, <span class="hlFld-ContribAuthor ">Catherine  Solovay</span>, <span class="hlFld-ContribAuthor ">Peter  Tarsa</span>, <span class="hlFld-ContribAuthor ">Amber  Woolfenden</span>, <span class="hlFld-ContribAuthor ">Chun  Zhang</span>, and <span class="hlFld-ContribAuthor ">Yiqin  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (4)
                                     , 1622-1635. <a href="https://doi.org/10.1021/acs.jmedchem.7b01731" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01731%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Bof%252BN-%2525281-Methyl-5-%252528trifluoromethyl%252529-1H-pyrazol-3-yl%252529-5-%252528%2525286-%252B%252528%252528methylamino%252529methyl%252529pyrimidin-4-yl%252529oxy%252529-1H-indole-1-carboxamide%252B%252528Acrizanib%252529%25252C%252Ba%252BVEGFR-2%252BInhibitor%252BSpecifically%252BDesigned%252Bfor%252BTopical%252BOcular%252BDelivery%25252C%252Bas%252Ba%252BTherapy%252Bfor%252BNeovascular%252BAge-Related%252BMacular%252BDegeneration%26aulast%3DAdams%26aufirst%3DChristopher%2BM.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D28112017%26date%3D05022018%26date%3D22022018%26volume%3D61%26issue%3D4%26spage%3D1622%26epage%3D1635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Danfeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, and <span class="hlFld-ContribAuthor ">Yu  Jiao</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (1)
                                     , 140-157. <a href="https://doi.org/10.1021/acs.jmedchem.7b01091" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01091%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPotent%252BVEGFR-2%252BInhibitors%252BExerting%252BSignificant%252BAntiproliferative%252BActivity%252Bagainst%252BCancer%252BCell%252BLines%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D25072017%26date%3D19122017%26date%3D11012018%26date%3D30112017%26volume%3D61%26issue%3D1%26spage%3D140%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juraj  Velcicky</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Miltz</span>, <span class="hlFld-ContribAuthor ">Berndt  Oberhauser</span>, <span class="hlFld-ContribAuthor ">David  Orain</span>, <span class="hlFld-ContribAuthor ">Andrea  Vaupel</span>, <span class="hlFld-ContribAuthor ">Klaus  Weigand</span>, <span class="hlFld-ContribAuthor ">Janet  Dawson King</span>, <span class="hlFld-ContribAuthor ">Amanda  Littlewood-Evans</span>, <span class="hlFld-ContribAuthor ">Mark  Nash</span>, <span class="hlFld-ContribAuthor ">Roland  Feifel</span>, and <span class="hlFld-ContribAuthor ">Pius  Loetscher</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (9)
                                     , 3672-3683. <a href="https://doi.org/10.1021/acs.jmedchem.6b01703" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01703%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BSelective%25252C%252BOrally%252BActive%252BGPR4%252BAntagonists%252Bwith%252BModulatory%252BEffects%252Bon%252BNociception%25252C%252BInflammation%25252C%252Band%252BAngiogenesis%26aulast%3DVelcicky%26aufirst%3DJuraj%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D21112016%26date%3D26042017%26date%3D11052017%26volume%3D60%26issue%3D9%26spage%3D3672%26epage%3D3683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Zhao</span>, <span class="hlFld-ContribAuthor ">Hio-Tong  Kam</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Guiyi  Gong</span>, <span class="hlFld-ContribAuthor ">Maggie Pui-Man  Hoi</span>, <span class="hlFld-ContribAuthor ">Krystyna  Skalicka-Woźniak</span>, <span class="hlFld-ContribAuthor ">Alberto Carlos Pires  Dias</span>, <span class="hlFld-ContribAuthor ">Simon Ming-Yuen  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Crocetin and Its Glycoside Crocin, Two Bioactive Constituents From Crocus sativus L. (Saffron), Differentially Inhibit Angiogenesis by Inhibiting Endothelial Cytoskeleton Organization and Cell Migration Through VEGFR2/SRC/FAK and VEGFR2/MEK/ERK Signaling Pathways. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.675359" title="DOI URL">https://doi.org/10.3389/fphar.2021.675359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.675359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.675359%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DCrocetin%252Band%252BIts%252BGlycoside%252BCrocin%25252C%252BTwo%252BBioactive%252BConstituents%252BFrom%252BCrocus%252Bsativus%252BL.%252B%252528Saffron%252529%25252C%252BDifferentially%252BInhibit%252BAngiogenesis%252Bby%252BInhibiting%252BEndothelial%252BCytoskeleton%252BOrganization%252Band%252BCell%252BMigration%252BThrough%252BVEGFR2%25252FSRC%25252FFAK%252Band%252BVEGFR2%25252FMEK%25252FERK%252BSignaling%252BPathways%26aulast%3DZhao%26aufirst%3DChen%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siddharth J.  Modi</span>, <span class="hlFld-ContribAuthor ">Vithal M.  Kulkarni</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, ‘DFG-out’ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>1 </em>, 1-16. <a href="https://doi.org/10.1080/07391102.2021.1872417" title="DOI URL">https://doi.org/10.1080/07391102.2021.1872417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1872417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1872417%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DExploration%252Bof%252Bstructural%252Brequirements%252Bfor%252Bthe%252Binhibition%252Bof%252BVEGFR-2%252Btyrosine%252Bkinase%25253A%252BBinding%252Bsite%252Banalysis%252Bof%252Btype%252BII%25252C%252B%2525E2%252580%252598DFG-out%2525E2%252580%252599%252Binhibitors%26aulast%3DModi%26aufirst%3DSiddharth%2BJ.%26date%3D2021%26date%3D2021%26volume%3D1%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fernanda P.  Pauli</span>, <span class="hlFld-ContribAuthor ">Juliana R.  Martins</span>, <span class="hlFld-ContribAuthor ">Thaysa  Paschoalin</span>, <span class="hlFld-ContribAuthor ">Marisa  Ionta</span>, <span class="hlFld-ContribAuthor ">Maria Leticia C.  Barbosa</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Novel VEGFR‐2 inhibitors with an
              N
              ‐acylhydrazone scaffold. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (11)
                                     , 2000130. <a href="https://doi.org/10.1002/ardp.202000130" title="DOI URL">https://doi.org/10.1002/ardp.202000130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000130%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DNovel%252BVEGFR%2525E2%252580%2525902%252Binhibitors%252Bwith%252Ban%252BN%252B%2525E2%252580%252590acylhydrazone%252Bscaffold%26aulast%3DPauli%26aufirst%3DFernanda%2BP.%26date%3D2020%26date%3D2020%26volume%3D353%26issue%3D11%26spage%3D2000130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aysegul  Hanikoglu</span>, <span class="hlFld-ContribAuthor ">Hakan  Ozben</span>, <span class="hlFld-ContribAuthor ">Ferhat  Hanikoglu</span>, <span class="hlFld-ContribAuthor ">Tomris  Ozben</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (13)
                                     , 2118-2132. <a href="https://doi.org/10.2174/0929867325666180719145819" title="DOI URL">https://doi.org/10.2174/0929867325666180719145819</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180719145819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180719145819%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DHybrid%252BCompounds%252B%252526%252BOxidative%252BStress%252BInduced%252BApoptosis%252Bin%252BCancer%252BTherapy%26aulast%3DHanikoglu%26aufirst%3DAysegul%26date%3D2020%26volume%3D27%26issue%3D13%26spage%3D2118%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kereyagalahally Honneshappa  Narasimhamurthy</span>, <span class="hlFld-ContribAuthor ">Chandra</span>, <span class="hlFld-ContribAuthor ">Toreshettahally Ramesh  Swaroop</span>, <span class="hlFld-ContribAuthor ">Swamy  Jagadish</span>, <span class="hlFld-ContribAuthor ">Kanchugarakoppal Subbegowda  Rangappa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Piperidine Conjugated Dihydroquinazolin-4(1H)-ones and their Antiproliferative Activity, Molecular Docking Studies and DFT Calculations. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2019,</strong> <em>17 </em>
                                    (1)
                                     , 85-93. <a href="https://doi.org/10.2174/1570180816666190613120349" title="DOI URL">https://doi.org/10.2174/1570180816666190613120349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180816666190613120349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180816666190613120349%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DSynthesis%252Bof%252BPiperidine%252BConjugated%252BDihydroquinazolin-4%2525281H%252529-ones%252Band%252Btheir%252BAntiproliferative%252BActivity%25252C%252BMolecular%252BDocking%252BStudies%252Band%252BDFT%252BCalculations%26aulast%3DNarasimhamurthy%26aufirst%3DKereyagalahally%2BHonneshappa%26date%3D2019%26volume%3D17%26issue%3D1%26spage%3D85%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huai-Xiang  Hao</span>, <span class="hlFld-ContribAuthor ">Hongyun  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Liu</span>, <span class="hlFld-ContribAuthor ">Steven  Kovats</span>, <span class="hlFld-ContribAuthor ">Roberto  Velazquez</span>, <span class="hlFld-ContribAuthor ">Hengyu  Lu</span>, <span class="hlFld-ContribAuthor ">Bhavesh  Pant</span>, <span class="hlFld-ContribAuthor ">Matthew  Shirley</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Meyer</span>, <span class="hlFld-ContribAuthor ">Minying  Pu</span>, <span class="hlFld-ContribAuthor ">Joanne  Lim</span>, <span class="hlFld-ContribAuthor ">Michael  Fleming</span>, <span class="hlFld-ContribAuthor ">LeighAnn  Alexander</span>, <span class="hlFld-ContribAuthor ">Ali  Farsidjani</span>, <span class="hlFld-ContribAuthor ">Matthew J.  LaMarche</span>, <span class="hlFld-ContribAuthor ">Susan  Moody</span>, <span class="hlFld-ContribAuthor ">Serena J.  Silver</span>, <span class="hlFld-ContribAuthor ">Giordano  Caponigro</span>, <span class="hlFld-ContribAuthor ">Darrin D.  Stuart</span>, <span class="hlFld-ContribAuthor ">Tinya J.  Abrams</span>, <span class="hlFld-ContribAuthor ">Peter S.  Hammerman</span>, <span class="hlFld-ContribAuthor ">Juliet  Williams</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Engelman</span>, <span class="hlFld-ContribAuthor ">Silvia  Goldoni</span>, <span class="hlFld-ContribAuthor ">Morvarid  Mohseni</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2019,</strong> <em>18 </em>
                                    (12)
                                     , 2368-2380. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0170" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0170%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DTumor%252BIntrinsic%252BEfficacy%252Bby%252BSHP2%252Band%252BRTK%252BInhibitors%252Bin%252BKRAS-Mutant%252BCancers%26aulast%3DHao%26aufirst%3DHuai-Xiang%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D12%26spage%3D2368%26epage%3D2380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Yuan</span>, <span class="hlFld-ContribAuthor ">Qingyi  Yang</span>, <span class="hlFld-ContribAuthor ">Tongyan  Liu</span>, <span class="hlFld-ContribAuthor ">Ke  Li</span>, <span class="hlFld-ContribAuthor ">Yuwen  Liu</span>, <span class="hlFld-ContribAuthor ">Changcheng  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhiyun  Zhang</span>, <span class="hlFld-ContribAuthor ">Linghua  Li</span>, <span class="hlFld-ContribAuthor ">Conghai  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingjin  Xie</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 147-165. <a href="https://doi.org/10.1016/j.ejmech.2019.06.054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin%2525C2%2525A0vitro%252Bevaluation%252Bof%252B6-amide-2-aryl%252Bbenzoxazole%25252Fbenzimidazole%252Bderivatives%252Bagainst%252Btumor%252Bcells%252Bby%252Binhibiting%252BVEGFR-2%252Bkinase%26aulast%3DYuan%26aufirst%3DXu%26date%3D2019%26volume%3D179%26spage%3D147%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin‐Cherng  Lien</span>, <span class="hlFld-ContribAuthor ">Chi‐Li  Chung</span>, <span class="hlFld-ContribAuthor ">Tur‐Fu  Huang</span>, <span class="hlFld-ContribAuthor ">Tsung‐Chia  Chang</span>, <span class="hlFld-ContribAuthor ">Kuan‐Chung  Chen</span>, <span class="hlFld-ContribAuthor ">Ging‐Yan  Gao</span>, <span class="hlFld-ContribAuthor ">Ming‐Jen  Hsu</span>, <span class="hlFld-ContribAuthor ">Shiu‐Wen  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">A novel 2‐aminobenzimidazole‐based compound Jzu 17 exhibits anti‐angiogenesis effects by targeting VEGFR‐2 signalling. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2019,</strong> <em>176 </em>
                                    (20)
                                     , 4034-4049. <a href="https://doi.org/10.1111/bph.14813" title="DOI URL">https://doi.org/10.1111/bph.14813</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14813%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DA%252Bnovel%252B2%2525E2%252580%252590aminobenzimidazole%2525E2%252580%252590based%252Bcompound%252BJzu%252B17%252Bexhibits%252Banti%2525E2%252580%252590angiogenesis%252Beffects%252Bby%252Btargeting%252BVEGFR%2525E2%252580%2525902%252Bsignalling%26aulast%3DLien%26aufirst%3DJin%25E2%2580%2590Cherng%26date%3D2019%26date%3D2019%26volume%3D176%26issue%3D20%26spage%3D4034%26epage%3D4049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nevine M.Y.  Elsayed</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Mai F.  Tolba</span>, <span class="hlFld-ContribAuthor ">Marawan  Ahmed</span>, <span class="hlFld-ContribAuthor ">Khaled  Barakat</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>82 </em>, 340-359. <a href="https://doi.org/10.1016/j.bioorg.2018.10.071" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.071%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bdynamics%252Bsimulation%252Bof%252Bindazole%252Bderivatives%252Bwith%252Bantiangiogenic%252Band%252Bantiproliferative%252Banticancer%252Bactivity%26aulast%3DElsayed%26aufirst%3DNevine%2BM.Y.%26date%3D2019%26volume%3D82%26spage%3D340%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.  Zhang</span>, <span class="hlFld-ContribAuthor ">D.  Xu</span>, <span class="hlFld-ContribAuthor ">J.  Wang</span>, <span class="hlFld-ContribAuthor ">C.  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Biological Activity of Novel Indole Derivatives as VEGFR-2 Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of General Chemistry</span><span> <strong>2017,</strong> <em>87 </em>
                                    (12)
                                     , 3006-3016. <a href="https://doi.org/10.1134/S1070363217120465" title="DOI URL">https://doi.org/10.1134/S1070363217120465</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070363217120465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070363217120465%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520General%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBiological%252BActivity%252Bof%252BNovel%252BIndole%252BDerivatives%252Bas%252BVEGFR-2%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DZhang%26aufirst%3DC.%26date%3D2017%26date%3D2018%26volume%3D87%26issue%3D12%26spage%3D3006%26epage%3D3016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He  Song</span>, <span class="hlFld-ContribAuthor ">Xiaochong  Liu</span>, <span class="hlFld-ContribAuthor ">Chenglong  Wang</span>, <span class="hlFld-ContribAuthor ">Jingyi  Qiao</span>, <span class="hlFld-ContribAuthor ">Wenyi  Chu</span>, <span class="hlFld-ContribAuthor ">Zhizhong  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Cu(TFA)
              2
              -Catalyzed Picolinamido-Directed C(sp
              2
              )−H Cyanation of Naphthalenes by Using Benzoyl Cyanide as a Cyano Source. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>6 </em>
                                    (11)
                                     , 1693-1698. <a href="https://doi.org/10.1002/ajoc.201700418" title="DOI URL">https://doi.org/10.1002/ajoc.201700418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201700418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201700418%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCu%252528TFA%252529%252B2%252B-Catalyzed%252BPicolinamido-Directed%252BC%252528sp%252B2%252B%252529%2525E2%252588%252592H%252BCyanation%252Bof%252BNaphthalenes%252Bby%252BUsing%252BBenzoyl%252BCyanide%252Bas%252Ba%252BCyano%252BSource%26aulast%3DSong%26aufirst%3DHe%26date%3D2017%26date%3D2017%26volume%3D6%26issue%3D11%26spage%3D1693%26epage%3D1698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kseniya N.  Sedenkova</span>, <span class="hlFld-ContribAuthor ">Elena B.  Averina</span>, <span class="hlFld-ContribAuthor ">Yuri K.  Grishin</span>, <span class="hlFld-ContribAuthor ">Julia V.  Kolodyazhnaya</span>, <span class="hlFld-ContribAuthor ">Victor B.  Rybakov</span>, <span class="hlFld-ContribAuthor ">Dmitry A.  Vasilenko</span>, <span class="hlFld-ContribAuthor ">Dmitry V.  Steglenko</span>, <span class="hlFld-ContribAuthor ">Vladimir I.  Minkin</span>, <span class="hlFld-ContribAuthor ">Tamara S.  Kuznetsova</span>, <span class="hlFld-ContribAuthor ">Nikolay S.  Zefirov</span>. </span><span class="cited-content_cbyCitation_article-title">Heterocyclization of gem -dichlorocyclopropanes: “Fine tuning” of reactivity towards nitronium triflate. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (30)
                                     , 2955-2958. <a href="https://doi.org/10.1016/j.tetlet.2017.06.047" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.06.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.06.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.06.047%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DHeterocyclization%252Bof%252Bgem%252B-dichlorocyclopropanes%25253A%252B%2525E2%252580%25259CFine%252Btuning%2525E2%252580%25259D%252Bof%252Breactivity%252Btowards%252Bnitronium%252Btriflate%26aulast%3DSedenkova%26aufirst%3DKseniya%2BN.%26date%3D2017%26volume%3D58%26issue%3D30%26spage%3D2955%26epage%3D2958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingjie  Zhao</span>, <span class="hlFld-ContribAuthor ">Guozheng  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Hybrids. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 193-218. <a href="https://doi.org/10.1016/B978-0-08-101011-2.00007-6" title="DOI URL">https://doi.org/10.1016/B978-0-08-101011-2.00007-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-101011-2.00007-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-101011-2.00007-6%26sid%3Dliteratum%253Aachs%26atitle%3DAnticancer%252BHybrids%26aulast%3DZhao%26aufirst%3DQingjie%26date%3D2017%26spage%3D193%26epage%3D218%26pub%3DElsevier%26atitle%3DDesign%252Bof%252BHybrid%252BMolecules%252Bfor%252BDrug%252BDevelopment%26date%3D2017%26volume%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhexuan  Lin</span>, <span class="hlFld-ContribAuthor ">Quanwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenhong  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2016,</strong> <em>793 </em>, 76-81. <a href="https://doi.org/10.1016/j.ejphar.2016.10.039" title="DOI URL">https://doi.org/10.1016/j.ejphar.2016.10.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2016.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2016.10.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DAngiogenesis%252Binhibitors%252Bas%252Btherapeutic%252Bagents%252Bin%252Bcancer%25253A%252BChallenges%252Band%252Bfuture%252Bdirections%26aulast%3DLin%26aufirst%3DZhexuan%26date%3D2016%26volume%3D793%26spage%3D76%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuemin  Liu</span>, <span class="hlFld-ContribAuthor ">Anpeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Junxi  Xiang</span>, <span class="hlFld-ContribAuthor ">Yi  Lv</span>, <span class="hlFld-ContribAuthor ">Xufeng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway. </span><span class="cited-content_cbyCitation_journal-name">Oncology Reports</span><span> <strong>2016,</strong> <em>36 </em>
                                    (3)
                                     , 1385-1392. <a href="https://doi.org/10.3892/or.2016.4971" title="DOI URL">https://doi.org/10.3892/or.2016.4971</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/or.2016.4971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2For.2016.4971%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Reports%26atitle%3DmiR-451%252Bacts%252Bas%252Ba%252Bsuppressor%252Bof%252Bangiogenesis%252Bin%252Bhepatocellular%252Bcarcinoma%252Bby%252Btargeting%252Bthe%252BIL-6R-STAT3%252Bpathway%26aulast%3DLiu%26aufirst%3DXuemin%26date%3D2016%26date%3D2016%26volume%3D36%26issue%3D3%26spage%3D1385%26epage%3D1392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuguang  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinhu  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Wang</span>, <span class="hlFld-ContribAuthor ">Chao  Song</span>, <span class="hlFld-ContribAuthor ">Kehao  Chen</span>, <span class="hlFld-ContribAuthor ">Jin  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Enaminones as Synthons for a Directed C−H Functionalization: Rh
              III
              ‐Catalyzed Synthesis of Naphthalenes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2016,</strong> <em>128 </em>
                                    (32)
                                     , 9530-9534. <a href="https://doi.org/10.1002/ange.201603943" title="DOI URL">https://doi.org/10.1002/ange.201603943</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201603943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201603943%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEnaminones%252Bas%252BSynthons%252Bfor%252Ba%252BDirected%252BC%2525E2%252588%252592H%252BFunctionalization%25253A%252BRh%252BIII%252B%2525E2%252580%252590Catalyzed%252BSynthesis%252Bof%252BNaphthalenes%26aulast%3DZhou%26aufirst%3DShuguang%26date%3D2016%26date%3D2016%26volume%3D128%26issue%3D32%26spage%3D9530%26epage%3D9534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuguang  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinhu  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Wang</span>, <span class="hlFld-ContribAuthor ">Chao  Song</span>, <span class="hlFld-ContribAuthor ">Kehao  Chen</span>, <span class="hlFld-ContribAuthor ">Jin  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Enaminones as Synthons for a Directed C−H Functionalization: Rh
              III
              ‐Catalyzed Synthesis of Naphthalenes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2016,</strong> <em>55 </em>
                                    (32)
                                     , 9384-9388. <a href="https://doi.org/10.1002/anie.201603943" title="DOI URL">https://doi.org/10.1002/anie.201603943</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201603943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201603943%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DEnaminones%252Bas%252BSynthons%252Bfor%252Ba%252BDirected%252BC%2525E2%252588%252592H%252BFunctionalization%25253A%252BRh%252BIII%252B%2525E2%252580%252590Catalyzed%252BSynthesis%252Bof%252BNaphthalenes%26aulast%3DZhou%26aufirst%3DShuguang%26date%3D2016%26volume%3D55%26issue%3D32%26spage%3D9384%26epage%3D9388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Forerunner compounds PTK787 and AAL993 are shown in comparison to AST487 and later generation BAW2881. Comparative inhibitory activity toward VEGFR2 versus FLT3 in cellular assays shown for the latter two compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. AAL993 (green) bound in the ATP pocket of the VEGFR2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW3">5EW3</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Only the residues proximal to the inhibitor are represented. Hydrogen bonds appear as dashed lines. BAW2881 docked in the pocket according to the design concept (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. BAW2881 docked in the ATP binding site of a homology model of the kinase domain of FLT3 in the “DFG out” conformation (constructed based on PDB structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH">1UWH</a>). The steric clash between the “gate keeper” residue F691 and the naphthyl core of the compound is indicated by a cross. The smaller valine “gate keeper” residue of VEGFR2 is shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid Amides BAW2881, <b>4</b>, <b>5</b>, and <b>6</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the 6-(Pyrimidin-4-yloxy)-naphthalene-1-carboxylic Acid Amides <b>9</b>–<b>11</b>, <b>13</b>, BFH772, and <b>14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. HUVEC proliferation assay in the presence of VEGF (10 ng/mL) (two left-hand graphs) or bFGF (0.5 ng/mL) (right-hand graph). Basal proliferation shown with the white bar, and growth factor induced proliferation with the black bar. Compounds were added at the doses shown below the bars: e.g., <i>V</i> + 0.01 is VEGF plus 0.01 nM compound; <i>b</i> + 0.1 is bFGF plus 0.1 nM compound. BFH772 in the left-hand graph shows full inhibitory activity at the lowest dose of 0.01 nM against VEGF induced proliferation. Compound <b>4</b> is shown for comparison in the middle graph. Compound <b>4</b> showed no activity against bFGF induced proliferation (right-hand graph).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Table showing dose normalized (dn) PK parameters over 24 h in a set of rat PK experiments (female OFA rats for BAW2881 and BFH772; female Sprague–Dawley rats for compounds <b>4</b>, <b>10</b>, and <b>9</b>). At 5, 15, and 30 min and 1, 2, 4, 6, 8, and 24 h time points, drug concentrations in plasma were determined by HPLC/UV. Data represent SEM (<i>n</i> = 2–4 animals per group). CL is clearance, <i>V</i><sub>ss</sub> is volume of distribution at steady state. The value <i>C</i><sub>max.</sub> represents the highest observed concentration (dose normalized) at the indicated time point (<i>t</i><sub>max.</sub>). <i>T</i><sub>1/2</sub> is the half-life of the compounds exposure in plasma. AUC is the area under the curve–total exposure over 0 h → infinity, dose normalized. BA is percent bioavailability; nm is not measured. (B) Example PK, time dependent exposure profiles for BAW2881 (<i>n</i> = 4), BFH772 (<i>n</i> = 2 for iv, and <i>n</i> = 3 for po), and compound <b>4</b> (<i>n</i> = 2 for iv and <i>n</i> = 3 for po) shown. Gray triangles are iv administration, and black diamonds are po dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Dose–response curve of BFH772 on tissue weight (A) and TIE-2 levels (B) and compound <b>4</b> on tissue weight (C) and TIE-2 levels (D). PEG200 vehicle treated animals were either implanted with agar chambers as a negative control (black bar) or with VEGF containing chambers as a positive control (white bar). BFH772 (0.3, 1, and 3 mg/kg) or compound <b>4</b> (0.3 and 3 mg/kg) treated mice were implanted with VEGF containing chambers (gray bars). Porous chambers containing VEGF (2 μg/mL) in 0.5 mL of 0.8% w/v agar (containing heparin, 20 U/mL) were implanted subcutaneously in the flank of female FVB mice. Compounds were administered po once daily in a vehicle of 100% PEG200 (dose volume 5 mL/kg). Treatment was started 4–6 h before implantation of the chambers and continued for 4 days. The chambers were removed 24 h after the last dose. Each experiment was performed on groups of six mice per dose. Values are mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Table showing compound, dose, number of experiments performed and T/C (treatment/control) for B16 primary tumor growth and metastatic weights. Treatment was started at day 7 when the primary B16 tumor was already established after assignment of female C57Bl6 to groups of 5–6 animals with similar mean and range of tumor size. Primary tumor was measured with computer assisted imaging software. After two weeks of daily qd treatment (day 21 after cell injection), the animals were sacrificed and the cervical lymph nodes weighed. Vehicle was 100% PEG 200. <i>n</i> = 6 animals per group. (B,C) TIE-2 levels in the lysates from metastases from the B16/BL6 melanoma model. Results from analysis of BAW2881 (B) and compound <b>4</b> (C) shown. <i>n</i> = 6–12 animals per group. Values are mean ± SEM *<i>p</i> < 0.05, **<i>p</i> < 0.01 statistical significance of inhibition. (D–F) DCE-MRI analysis of lymphnode metastases. The parameters determined by DCE-MRI of Ktrans (D), iAUEC (E), and Vp (F) show the changes in individual mice and the associated mean ± SEM (<i>n</i> = 7–8 animals), with significance determined by a 1-way ANOVA, where *<i>p</i> < 0.05, **<i>p</i> < 0.01 compared to vehicle-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effect of BFH772 (A) and compound <b>4</b> (B) on primary tumor growth rate and cervical lymphnode metastasis weight in the B16 melanoma model. Treatment was started at day 7 when the primary B16 tumor was already established after assignment of female C57Bl6 to groups of 6–10 animals with similar mean and range of tumor size. Primary tumor was measured with computer assisted imaging software. Vehicle was 100% PEG 200. <i>n</i> = 10 animals per group. BFH772 and compound <b>4</b> were six animals per group. BFH772 was dosed daily from treatment start. Compound <b>4</b> was dosed daily or once every 2 days from day 7. Significance determined by a 1-way ANOVA post-Dunnet’s test, where *<i>p</i> < 0.05, compared to vehicle-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/medium/jm-2015-01582p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) BN472 tumor growth curves over 14 days with compounds treated qd. Vehicle was PEG300. Female Brown–Norway rats were randomized when tumor volume was approximately 200 mm<sup>3</sup> before treatment started. Experiment performed twice, <i>n</i> = 7–8 animals per group. (B) Histology of tumors after treatment with KDR inhibitors PTK787 and compound <b>4</b>. Perfusable blood vessels were highlighted by shortly injecting the animal with Hoechst dye 1 min before sacrifice (left panel of photomicrographs). Ten micrometer sections were stained with Ki67 to highlight tumor proliferation (middle column) or caspase 3 to observe tumor apoptosis (right column). Bar is 100 μm. All three compounds caused a significant inhibtion of tumor-growth compared to vehicle by day 14 of treatment (<i>p</i> < 0.05, 2-way RM-ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01582/20160113/images/large/jm-2015-01582p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01582&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i60">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in health and disease</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span><span class="refDoi"> DOI: 10.1038/nm0603-653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2Fnm0603-653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=12778163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=653-660&author=P.+Carmeliet&title=Angiogenesis+in+health+and+disease&doi=10.1038%2Fnm0603-653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in health and disease</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">653-660</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Blood vessels constitute the first organ in the embryo and form the largest network in our body but, sadly, are also often deadly.  When dysregulated, the formation of new blood vessels contributes to numerous malignant, ischemic, inflammatory, infectious and immune disorders.  Mol. insights into these processes are being generated at a rapidly increasing pace, offering new therapeutic opportunities that are currently being evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVe6HXO3QPLbVg90H21EOLACvtfcHk0ljPno9Y2snymQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOntbY%253D&md5=501ed35c48dbcc7c9d18b804c996284a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnm0603-653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0603-653%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520health%2520and%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D653%26epage%3D660%26doi%3D10.1038%2Fnm0603-653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Plate, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weich, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas <i>in vivo</i></span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1038/359845a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2F359845a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=1992&pages=845-848&author=K.+H.+Plateauthor=G.+Breierauthor=H.+A.+Weichauthor=W.+Risau&title=Vascular+endothelial+growth+factor+is+a+potential+tumour+angiogenesis+factor+in+human+gliomas+in+vivo&doi=10.1038%2F359845a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2F359845a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F359845a0%26sid%3Dliteratum%253Aachs%26aulast%3DPlate%26aufirst%3DK.%2BH.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DWeich%26aufirst%3DH.%2BA.%26aulast%3DRisau%26aufirst%3DW.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520is%2520a%2520potential%2520tumour%2520angiogenesis%2520factor%2520in%2520human%2520gliomas%2520in%2520vivo%26jtitle%3DNature%26date%3D1992%26volume%3D359%26spage%3D845%26epage%3D848%26doi%3D10.1038%2F359845a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Senger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, H. F.</span><span> </span><span class="NLM_article-title">Vascular permeability factor (VPF, VEGF) in tumor biology</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1007/BF00665960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1007%2FBF00665960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8281615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2cXnsVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1993&pages=303-324&author=D.+R.+Sengerauthor=L.+Van+de+Waterauthor=L.+F.+Brownauthor=J.+A.+Nagyauthor=K.+T.+Yeoauthor=T.+K.+Yeoauthor=B.+Berseauthor=R.+W.+Jackmanauthor=A.+M.+Dvorakauthor=H.+F.+Dvorak&title=Vascular+permeability+factor+%28VPF%2C+VEGF%29+in+tumor+biology&doi=10.1007%2FBF00665960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular permeability factor (VPF,VEGF) in tumor biology</span></div><div class="casAuthors">Senger, Donald R.; Van De Water, Livingston; Brown, Lawrence F.; Nagy, Janice A.; Yeo, Kiang Teck; Yeo, Tet Kin; Berse, Brygida; Jackman, Robert W.; Dvorak, Ann M.; Dvorak, Harold F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">303-24</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    </div><div class="casAbstract">A review with 89 refs.  Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine expressed and secreted at high levels by many tumor cells of animal and human origin.  As secreted by tumor cells, VPF/VEGF is a 34-42 kDa heparin-binding, dimeric, disulfide-bonded glycoprotein that acts directly on endothelial cells (EC) by way of specific receptors to activate phospholipase C and induce [Ca2+]i transients.  Two high affinity VPF/VEGF receptors, both tyrosine kinases, have thus far been described.  VPF/VEGF is likely to have a no. of important roles in tumor biol. related, but not limited to, the process of tumor angiogenesis.  As a potent permeability factor, VPF/VEGF promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix.  This matrix promotes the ingrowth of macrophages, fibroblasts, and endothelial cells.  Moreover, VPF/VEGF is a selective endothelial cell (EC) growth factor in vitro, and it presumably stimulates EC proliferation in vivo.  Furthermore, VPF/VEGF has been found in animal and human tumor effusions by immunoassay and by functional assays and very likely accounts for the induction of malignant ascites.  In addn. to its role in tumors, VPF/VEGF has recently been found to have a role in wound healing and its expression by activated macrophages suggest that it probably also participates in certain types of chronic inflammation.  VPF/VEGF is expressed in normal development and in certain normal adult organs, notably kidney, heart, adrenal gland and lung.  Its functions in normal adult tissues are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoypXw29msdV7Vg90H21EOLACvtfcHk0liP_6E-qB3_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXnsVejug%253D%253D&md5=bf7d474ad681de62f1cc73029a90e376</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1007%2FBF00665960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00665960%26sid%3Dliteratum%253Aachs%26aulast%3DSenger%26aufirst%3DD.%2BR.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DL.%2BF.%26aulast%3DNagy%26aufirst%3DJ.%2BA.%26aulast%3DYeo%26aufirst%3DK.%2BT.%26aulast%3DYeo%26aufirst%3DT.%2BK.%26aulast%3DBerse%26aufirst%3DB.%26aulast%3DJackman%26aufirst%3DR.%2BW.%26aulast%3DDvorak%26aufirst%3DA.%2BM.%26aulast%3DDvorak%26aufirst%3DH.%2BF.%26atitle%3DVascular%2520permeability%2520factor%2520%2528VPF%252C%2520VEGF%2529%2520in%2520tumor%2520biology%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D1993%26volume%3D12%26spage%3D303%26epage%3D324%26doi%3D10.1007%2FBF00665960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollefeyt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieckens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertsenstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenhoeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Declercq, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, A.</span><span> </span><span class="NLM_article-title">Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1038/380435a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2F380435a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8602241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK28XitVKqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=1996&pages=435-439&author=P.+Carmelietauthor=V.+Ferreiraauthor=G.+Breierauthor=S.+Pollefeytauthor=L.+Kieckensauthor=M.+Gertsensteinauthor=M.+Fahrigauthor=A.+Vandenhoeckauthor=K.+Harpalauthor=C.+Eberhardtauthor=C.+Declercqauthor=J.+Pawlingauthor=L.+Moonsauthor=D.+Collenauthor=W.+Risauauthor=A.+Nagy&title=Abnormal+blood+vessel+development+and+lethality+in+embryos+lacking+a+single+VEGF+allele&doi=10.1038%2F380435a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele</span></div><div class="casAuthors">Carmeliet, Peter; Ferreira, Valerie; Breier, Georg; Pollefeyt, Saskia; Kieckens, Lena; Gertsenstein, Marina; Fahrig, Michaela; Vandenhoeck, Ann; Harpal, Kendraprasad; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">6573</span>),
    <span class="NLM_cas:pages">435-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The endothelial cell-specific vascular endothelial growth factor (VEGF) and its cellular receptors Flt-1 and Flk-1 have been implicated in the formation of the embryonic vasculature.  This is suggested by their colocalized expression during embryogenesis and the impaired vessel formation in Flk-1 and Flt-1 deficient embryos.  However, because Flt-1 also binds placental growth factor, a VEGF homolog, the precise role of VEGF was unknown.  Here we report that formation of blood vessels was abnormal, but not abolished, in heterozygous VEGF-deficient (VEGF+/-) embryos, generated by aggregation of embryonic stem (ES) cells with tetraploid embryos (T-ES), and even more impaired in homozygous VEGF-deficient (VEGF-/-) T-ES embryos, resulting in death at mid-gestation.  Similar phenotypes were obsd. in F1-VEGF+/- embryos, generated by germline transmission.  We believe that this heterozygous lethal phenotype, which differs from the homozygous lethality in VEGF-receptor-deficient embryos, is unprecedented for a targeted autosomal gene inactivation, and is indicative of a tight dose-dependent regulation of embryonic vessel development by VEGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobatChefZSx7Vg90H21EOLACvtfcHk0liP_6E-qB3_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVKqtLg%253D&md5=93d159aabf470be75c118dad37a729cb</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1038%2F380435a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F380435a0%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DFerreira%26aufirst%3DV.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DPollefeyt%26aufirst%3DS.%26aulast%3DKieckens%26aufirst%3DL.%26aulast%3DGertsenstein%26aufirst%3DM.%26aulast%3DFahrig%26aufirst%3DM.%26aulast%3DVandenhoeck%26aufirst%3DA.%26aulast%3DHarpal%26aufirst%3DK.%26aulast%3DEberhardt%26aufirst%3DC.%26aulast%3DDeclercq%26aufirst%3DC.%26aulast%3DPawling%26aufirst%3DJ.%26aulast%3DMoons%26aufirst%3DL.%26aulast%3DCollen%26aufirst%3DD.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DNagy%26aufirst%3DA.%26atitle%3DAbnormal%2520blood%2520vessel%2520development%2520and%2520lethality%2520in%2520embryos%2520lacking%2520a%2520single%2520VEGF%2520allele%26jtitle%3DNature%26date%3D1996%26volume%3D380%26spage%3D435%26epage%3D439%26doi%3D10.1038%2F380435a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Klagsbrun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amore, P. A.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor and its receptors</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1016/S1359-6101(96)00027-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2FS1359-6101%2896%2900027-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8971481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2sXht1Om" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=259-270&author=M.+Klagsbrunauthor=P.+A.+D%E2%80%99Amore&title=Vascular+endothelial+growth+factor+and+its+receptors&doi=10.1016%2FS1359-6101%2896%2900027-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor and its receptors</span></div><div class="casAuthors">Klagsbrun, Michael; D'Amore, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 136 refs.  Vascular endothelial growth factor (VEGF) is a prime regulator of endothelial cell proliferation, angiogenesis, vasculogenesis and vascular permeability.  Its activity is mediated by the high affinity tyrosine kinase receptors, KDR/Flk-1 and Flt-1.  In this article, recently discovered structural, mol. and biol. properties of VEGF are described.  Among the topics discussed are VEGF and VEGF receptor structure and bioactivity, the regulation of VEGF expression, the role of VEGF and its receptors in vascular development, and the involvement of VEGF and its receptors in normal and pathol. (ocular and tumor) angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_WT8UagsqhLVg90H21EOLACvtfcHk0liyy39-O2hgpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1Om&md5=bc8c134e76c45b16cef691ea6dc0b5b9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2896%2900027-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252896%252900027-5%26sid%3Dliteratum%253Aachs%26aulast%3DKlagsbrun%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520and%2520its%2520receptors%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D1996%26volume%3D7%26spage%3D259%26epage%3D270%26doi%3D10.1016%2FS1359-6101%2896%2900027-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Angiogenesis in cancer, vascular, rheumatoid and other disease</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1038/nm0195-27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1038%2Fnm0195-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=7584949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=27-31&author=J.+Folkman&title=Angiogenesis+in+cancer%2C+vascular%2C+rheumatoid+and+other+disease&doi=10.1038%2Fnm0195-27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer, vascular, rheumatoid and other disease</span></div><div class="casAuthors">Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">A review with ∼72 refs.  Recent discoveries of endogenous neg. regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all assocd. with neovascularized tumors, suggest a new paradigm of tumorigenesis.  It is now helpful to think of the switch to the angiogenic phenotype as a net balance of pos. and neg. regulators of blood vessel growth.  The extent to which the neg. regulators are decreased during this switch may dictate whether a primary tumor grows rapidly or slowly and whether metastases grow at all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpF2nWHt2eJbVg90H21EOLACvtfcHk0liyy39-O2hgpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D&md5=849f4f3828ac5d78886d666787f72d4f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnm0195-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0195-27%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%2520in%2520cancer%252C%2520vascular%252C%2520rheumatoid%2520and%2520other%2520disease%26jtitle%3DNat.%2520Med.%26date%3D1995%26volume%3D1%26spage%3D27%26epage%3D31%26doi%3D10.1038%2Fnm0195-27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1016/S0065-230X(08)60946-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2FS0065-230X%2808%2960946-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1985&pages=175-203&author=J.+Folkman&title=Tumor+angiogenesis&doi=10.1016%2FS0065-230X%2808%2960946-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2808%2960946-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252808%252960946-X%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D1985%26volume%3D43%26spage%3D175%26epage%3D203%26doi%3D10.1016%2FS0065-230X%2808%2960946-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">The role of angiogenesis in tumor growth</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1378311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A280%3ADyaK38zivFOgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1992&pages=65-71&author=J.+Folkman&title=The+role+of+angiogenesis+in+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of angiogenesis in tumor growth</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in cancer biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-71</span>
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    </div><div class="casAbstract">Experimental and clinical evidence is here assembled in support of the concept that the development of a solid tumor progresses from a prevascular phase to a vascular phase.  The prevascular tumor does not induce angiogenesis, is limited in size, and rarely metastasizes.  The vascularized tumor induces host microvessels to undergo angiogenesis, has the potential to rapidly expand its cell population, and has a propensity to metastasize.  Thus, angiogenesis is necessary but not sufficient for tumor growth and metastasis.  Neovascularization of a tumor requires that a critical number of its cells have switched to the angiogenic phenotype.  The mechanisms by which tumor cells become angiogenic, subjects of current study, are reviewed here.  At least two general categories are recognized: (i) angiogenic activity arises from the tumor cell itself in the form of the release of angiogenic molecules such as basic fibroblast growth factor; (ii) angiogenic activity arises from host cells recruited by the tumor (e.g. macrophages), or is mobilized from the extracellular matrix, or requires concomitant loss of physiological inhibition of endothelial cell proliferation.  Accumulating evidence indicates that for most tumors, the switch to the angiogenic phenotype depends upon the outcome of a balance between angiogenic stimulators and angiogenic inhibitors, both of which may be produced by tumor cells and perhaps by certain host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcUvmrMxJHHt0Q2ypr7jHkfW6udTcc2eapsrl_zLRkJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zivFOgtA%253D%253D&md5=6db5fa60c10884b6625d5d10a1216766</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520angiogenesis%2520in%2520tumor%2520growth%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D1992%26volume%3D3%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Plate, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of developmental and tumor angiogenesis</span> <span class="citation_source-journal">Brain Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1111/j.1750-3639.1994.tb00835.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1111%2Fj.1750-3639.1994.tb00835.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=7524960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1Omtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=207-218&author=K.+H.+Plateauthor=G.+Breierauthor=W.+Risau&title=Molecular+mechanisms+of+developmental+and+tumor+angiogenesis&doi=10.1111%2Fj.1750-3639.1994.tb00835.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of developmental and tumor angiogenesis</span></div><div class="casAuthors">Plate, Karl H.; Breier, Georg; Risau, Werner</div><div class="citationInfo"><span class="NLM_cas:title">Brain Pathology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-18</span>CODEN:
                <span class="NLM_cas:coden">BRPAE7</span>;
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    </div><div class="casAbstract">A review, with 118 refs.  Angiogenesis, the sprouting of capillaries from pre-existing vessels, is of fundamental importance during embryonic development and is the principal process by which the brain and certain other organs become vascularized.  Angiogenesis occurs during embryonic development but is almost absent in adult tissues.  Transient and tightly controlled (physiol.) angiogenesis in adult tissues occurs during the female reproductive cycle and during wound healing.  In contrast, pathol. angiogenesis is characterized by the persistent proliferation of endothelial cells, and is a prominent feature of diseases such as proliferative retinopathy, rheumathoid arthritis, and psoriasis.  In addn., many tumors are able to attract blood vessels from neighboring tissues.  Tumor-induced angiogenesis requires a constitutive activation of endothelial cells.  These endothelial cells dissolve their surrounding extracellular matrix, migrate toward the tumor, proliferate, and form a new vascular network, thus supplying the tumor with nutrients and oxygen and removing waste products.  The onset of angiogenesis in human gliomas is characterized by the expression of genes encoding angiogenic growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) in tumor cells, and coordinate induction of genes in endothelial cells which encode the resp. growth factor receptors.  Developmental and tumor angiogenesis appear to be regulated by a paracrine mechanism involving VEGF and VEGF receptor-1 and -2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiXuRse7S2bVg90H21EOLACvtfcHk0ljX3fK_9f-tNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1Omtr4%253D&md5=746a7b3854ad3918ea93a66c1c869250</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.1994.tb00835.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.1994.tb00835.x%26sid%3Dliteratum%253Aachs%26aulast%3DPlate%26aufirst%3DK.%2BH.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DRisau%26aufirst%3DW.%26atitle%3DMolecular%2520mechanisms%2520of%2520developmental%2520and%2520tumor%2520angiogenesis%26jtitle%3DBrain%2520Pathol.%26date%3D1994%26volume%3D4%26spage%3D207%26epage%3D218%26doi%3D10.1111%2Fj.1750-3639.1994.tb00835.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmé, D.</span><span> </span><span class="NLM_article-title">VEGF-mediated tumour angiogenesis: a new target for cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">680</span><span class="refDoi"> DOI: 10.1016/0958-1669(95)80111-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2F0958-1669%2895%2980111-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=8527839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADyaK2MXpvVSrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1995&pages=675-680&author=G.+Martiny-Baronauthor=D.+Marm%C3%A9&title=VEGF-mediated+tumour+angiogenesis%3A+a+new+target+for+cancer+therapy&doi=10.1016%2F0958-1669%2895%2980111-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF-mediated tumor angiogenesis: a new target for cancer therapy</span></div><div class="casAuthors">Martiny-Baron, Georg; Marme, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">675-80</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review with 40 refs.  Considerable evidence is gathering for the involvement of vascular endothelial growth factor (VEGF) in the vascularization and growth of primary tumors as well as in the formation of metastases.  The expression of VEGF depends on activated oncogenes and inactivated tumor suppressor genes as well as several other factors (e.g. growth factors, tumor promoters and hypoxia).  Substantial expression of the receptors for VEGF is restricted mainly to the tumor blood vessels.  The causal involvement of this angiogenic factor in the progression of disease has been successfully evaluated by monoclonal antibodies against VEGF, dominant-neg. receptor mutants and the use of antisense oligonucleotides against the VEGF mRNA.  Thus, the VEGF signaling system seems to be an appropriate target to inhibit tumor angiogenesis and metastases formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxbiY9-znjXbVg90H21EOLACvtfcHk0ljX3fK_9f-tNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpvVSrtLo%253D&md5=a10130ea57e544b5de5dbe0a46fd8ce0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0958-1669%2895%2980111-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0958-1669%252895%252980111-1%26sid%3Dliteratum%253Aachs%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMarm%25C3%25A9%26aufirst%3DD.%26atitle%3DVEGF-mediated%2520tumour%2520angiogenesis%253A%2520a%2520new%2520target%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D1995%26volume%3D6%26spage%3D675%26epage%3D680%26doi%3D10.1016%2F0958-1669%2895%2980111-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liotta, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetler-Stevenson, W. G.</span><span> </span><span class="NLM_article-title">Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1016/0092-8674(91)90642-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2F0092-8674%2891%2990642-C" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1991&pages=327-336&author=L.+A.+Liottaauthor=P.+S.+Steegauthor=W.+G.+Stetler-Stevenson&title=Cancer+metastasis+and+angiogenesis%3A+an+imbalance+of+positive+and+negative+regulation&doi=10.1016%2F0092-8674%2891%2990642-C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2891%2990642-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252891%252990642-C%26sid%3Dliteratum%253Aachs%26aulast%3DLiotta%26aufirst%3DL.%2BA.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DStetler-Stevenson%26aufirst%3DW.%2BG.%26atitle%3DCancer%2520metastasis%2520and%2520angiogenesis%253A%2520an%2520imbalance%2520of%2520positive%2520and%2520negative%2520regulation%26jtitle%3DCell%26date%3D1991%26volume%3D64%26spage%3D327%26epage%3D336%26doi%3D10.1016%2F0092-8674%2891%2990642-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Parangi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christofori, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosfeld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Antiangiogenic therapy of transgenic mice impairs de novo tumor growth</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">2002</span><span class="NLM_x">–</span> <span class="NLM_lpage">2007</span><span class="refDoi"> DOI: 10.1073/pnas.93.5.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1073%2Fpnas.93.5.2002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=2002-2007&author=S.+Parangiauthor=M.+O%27Reillyauthor=G.+Christoforiauthor=L.+Holmgrenauthor=J.+Grosfeldauthor=J.+Folkmanauthor=D.+Hanahan&title=Antiangiogenic+therapy+of+transgenic+mice+impairs+de+novo+tumor+growth&doi=10.1073%2Fpnas.93.5.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.5.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.5.2002%26sid%3Dliteratum%253Aachs%26aulast%3DParangi%26aufirst%3DS.%26aulast%3DO%2527Reilly%26aufirst%3DM.%26aulast%3DChristofori%26aufirst%3DG.%26aulast%3DHolmgren%26aufirst%3DL.%26aulast%3DGrosfeld%26aufirst%3DJ.%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DAntiangiogenic%2520therapy%2520of%2520transgenic%2520mice%2520impairs%2520de%2520novo%2520tumor%2520growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D2002%26epage%3D2007%26doi%3D10.1073%2Fpnas.93.5.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Anti-angiogenesis: new concept for therapy of solid tumors</span> <span class="citation_source-journal">Ann. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span><span class="refDoi"> DOI: 10.1097/00000658-197203000-00014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1097%2F00000658-197203000-00014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=5077799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A280%3ADyaE3s%252FitV2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1972&pages=409-416&author=J.+Folkman&title=Anti-angiogenesis%3A+new+concept+for+therapy+of+solid+tumors&doi=10.1097%2F00000658-197203000-00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenesis: new concept for therapy of solid tumors</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgery</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-16</span>
        ISSN:<span class="NLM_cas:issn">0003-4932</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBThr2iCUqj90Q2ypr7jHkfW6udTcc2eYLkmhqNveJHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3s%252FitV2gtA%253D%253D&md5=48381e6d0d06f30c9bd7e7d7d8a53d95</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2F00000658-197203000-00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-197203000-00014%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAnti-angiogenesis%253A%2520new%2520concept%2520for%2520therapy%2520of%2520solid%2520tumors%26jtitle%3DAnn.%2520Surg.%26date%3D1972%26volume%3D175%26spage%3D409%26epage%3D416%26doi%3D10.1097%2F00000658-197203000-00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sitohy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, H. F.</span><span> </span><span class="NLM_article-title">Anti-VEGF/VEGFR therapy for cancer: reassessing the target</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1909</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-11-3406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=22508695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Whu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1909-1914&author=B.+Sitohyauthor=J.+A.+Nagyauthor=H.+F.+Dvorak&title=Anti-VEGF%2FVEGFR+therapy+for+cancer%3A+reassessing+the+target&doi=10.1158%2F0008-5472.CAN-11-3406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target</span></div><div class="casAuthors">Sitohy, Basel; Nagy, Janice A.; Dvorak, Harold F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1909-1914</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Judah Folkman recognized that new blood vessel formation is important for tumor growth and proposed antiangiogenesis as a novel approach to cancer therapy.  Discovery of vascular permeability factor VEGF-A as the primary tumor angiogenesis factor prompted the development of a no. of drugs that targeted it or its receptors.  These agents have often been successful in halting tumor angiogenesis and in regressing rapidly growing mouse tumors.  However, results in human cancer have been less impressive.  A no. of reasons have been offered for the lack of greater success, and, here, we call attention to the heterogeneity of the tumor vasculature as an important issue.  Human and mouse tumors are supplied by at least 6 well-defined blood vessel types that arise by both angiogenesis and arterio-venogenesis.  All 6 types can be generated in mouse tissues by an adenoviral vector expressing VEGF-A164.  Once formed, 4 of the 6 types lose their VEGF-A dependency, and so their responsiveness to anti-VEGF/VEGF receptor therapy.  If therapies directed against the vasculature are to have a greater impact on human cancer, targets other than VEGF and its receptors will need to be identified on these resistant tumor vessels.  Cancer Res; 72(8); 1909-14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTzXS08U-nybVg90H21EOLACvtfcHk0lgHh8eXLoVoXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Whu74%253D&md5=462d169293913057773c4390c356fb18</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3406%26sid%3Dliteratum%253Aachs%26aulast%3DSitohy%26aufirst%3DB.%26aulast%3DNagy%26aufirst%3DJ.%2BA.%26aulast%3DDvorak%26aufirst%3DH.%2BF.%26atitle%3DAnti-VEGF%252FVEGFR%2520therapy%2520for%2520cancer%253A%2520reassessing%2520the%2520target%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1909%26epage%3D1914%26doi%3D10.1158%2F0008-5472.CAN-11-3406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenone, S.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10797</span><span class="NLM_x">–</span> <span class="NLM_lpage">10822</span><span class="refDoi"> DOI: 10.1021/jm301085w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301085w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10797-10822&author=F.+Musumeciauthor=M.+Radiauthor=C.+Brulloauthor=S.+Schenone&title=Vascular+endothelial+growth+factor+%28VEGF%29+receptors%3A+drugs+and+new+inhibitors&doi=10.1021%2Fjm301085w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Fjm301085w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301085w%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520receptors%253A%2520drugs%2520and%2520new%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10797%26epage%3D10822%26doi%3D10.1021%2Fjm301085w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2921</span><span class="NLM_x">–</span> <span class="NLM_lpage">2935</span><span class="refDoi"> DOI: 10.2174/138161212800672732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.2174%2F138161212800672732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=22571661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2921-2935&author=C.+Zhangauthor=C.+Tanauthor=H.+Dingauthor=T.+Xinauthor=Y.+Jiang&title=Selective+VEGFR+inhibitors+for+anticancer+therapeutics+in+clinical+use+and+clinical+trials&doi=10.2174%2F138161212800672732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials</span></div><div class="casAuthors">Zhang, Cunlong; Tan, Chunyan; Ding, Huaiwei; Xin, Tian; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2921-2935</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis.  Selective inhibition of VEGFR kinase has been explored as a highly successful clin. strategy in cancer treatment.  A no. of VEGFR inhibitors have been approved in clin. use and many more are in various stages of drug development.  This paper reviews selective small-mol. VEGFR inhibitors in clin. uses and in clin. trials, with particular focus on in vitro, in vivo and clin. trial results of these inhibitors.  The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP924FfbZz7rVg90H21EOLACvtfcHk0lhFShsf3jOJ6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltrg%253D&md5=7c5416e6cf9a0db8065f2c0bfa0711bd</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.2174%2F138161212800672732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672732%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSelective%2520VEGFR%2520inhibitors%2520for%2520anticancer%2520therapeutics%2520in%2520clinical%2520use%2520and%2520clinical%2520trials%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2921%26epage%3D2935%26doi%3D10.2174%2F138161212800672732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wietfeld, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sills, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acemoglu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmenegger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lässer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetterli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2310</span><span class="NLM_x">–</span> <span class="NLM_lpage">2323</span><span class="refDoi"> DOI: 10.1021/jm9909443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9909443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2310-2323&author=G.+Boldauthor=K.+H.+Altmannauthor=J.+Freiauthor=M.+Langauthor=P.+W.+Manleyauthor=P.+Traxlerauthor=B.+Wietfeldauthor=J.+Br%C3%BCggenauthor=E.+Buchdungerauthor=R.+Cozensauthor=S.+Ferrariauthor=P.+Furetauthor=F.+Hofmannauthor=G.+Martiny-Baronauthor=J.+Mestanauthor=J.+R%C3%B6selauthor=M.+Sillsauthor=D.+Stoverauthor=F.+Acemogluauthor=E.+Bossauthor=R.+Emmeneggerauthor=R.+L%C3%A4sserauthor=E.+Massoauthor=R.+Rothauthor=C.+Schlachterauthor=W.+Vetterliauthor=D.+Wyssauthor=J.+M.+Wood&title=New+anilinophthalazines+as+potent+and+orally+well+absorbed+inhibitors+of+the+VEGF+receptor+tyrosine+kinases+useful+as+antagonists+of+tumor-driven+angiogenesis&doi=10.1021%2Fjm9909443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fjm9909443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9909443%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DFrei%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DWietfeld%26aufirst%3DB.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DSills%26aufirst%3DM.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DAcemoglu%26aufirst%3DF.%26aulast%3DBoss%26aufirst%3DE.%26aulast%3DEmmenegger%26aufirst%3DR.%26aulast%3DL%25C3%25A4sser%26aufirst%3DR.%26aulast%3DMasso%26aufirst%3DE.%26aulast%3DRoth%26aufirst%3DR.%26aulast%3DSchlachter%26aufirst%3DC.%26aulast%3DVetterli%26aufirst%3DW.%26aulast%3DWyss%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DNew%2520anilinophthalazines%2520as%2520potent%2520and%2520orally%2520well%2520absorbed%2520inhibitors%2520of%2520the%2520VEGF%2520receptor%2520tyrosine%2520kinases%2520useful%2520as%2520antagonists%2520of%2520tumor-driven%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2310%26epage%3D2323%26doi%3D10.1021%2Fjm9909443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span>ibid.<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3200</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ibid.+2000%2C+43%2C+3200."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2000%26volume%3D43%26spage%3D3200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krüger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menrad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidelmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span> </span><span class="NLM_article-title">Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5687</span><span class="NLM_x">–</span> <span class="NLM_lpage">5693</span><span class="refDoi"> DOI: 10.1021/jm020899q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020899q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5687-5693&author=P.+W.+Manleyauthor=P.+Furetauthor=G.+Boldauthor=J.+Br%C3%BCggenauthor=J.+Mestanauthor=T.+Meyerauthor=C.+Schnellauthor=J.+Woodauthor=M.+Habereyauthor=A.+Huthauthor=M.+Kr%C3%BCgerauthor=A.+Menradauthor=E.+Ottowauthor=D.+Seidelmannauthor=G.+Siemeisterauthor=K.+H.+Thierauch&title=Anthranilic+acid+amides%3A+a+novel+class+of+antiangiogenic+VEGF+receptor+kinase+inhibitors&doi=10.1021%2Fjm020899q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm020899q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020899q%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DHaberey%26aufirst%3DM.%26aulast%3DHuth%26aufirst%3DA.%26aulast%3DKr%25C3%25BCger%26aufirst%3DM.%26aulast%3DMenrad%26aufirst%3DA.%26aulast%3DOttow%26aufirst%3DE.%26aulast%3DSeidelmann%26aufirst%3DD.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26atitle%3DAnthranilic%2520acid%2520amides%253A%2520a%2520novel%2520class%2520of%2520antiangiogenic%2520VEGF%2520receptor%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5687%26epage%3D5693%26doi%3D10.1021%2Fjm020899q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="note"><p class="first last">Two independent patent applications were published describing BAW2881 as an example:</p></div><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Potashman, M.; Kim, T.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J. C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A.</span><span> </span><span class="NLM_article-title">Compounds and methods of use</span>. WO 2005/070891,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Potashman&author=T.+Kim&author=S.+Bellon&author=S.+Booker&author=Y.+Cheng&author=J.+L.+Kim&author=A.+Tasker&author=N.+Xi&author=S.+Xu&author=J.+C.+Harmange&author=G.+Borg&author=M.+Weiss&author=B.+L.+Hodous&author=R.+Graceffa&author=W.+H.+Buckner&author=C.+E.+Masse&author=D.+Choquette&author=M.+W.+Martin&author=J.+Germain&author=L.+V.+Dipietro&author=S.+C.+Chaffee&author=J.+J.+Nunes&author=J.+L.+Buchanan&author=G.+J.+Habgood&author=D.+C.+McGowan&author=D.+A.+Whittington&title=Compounds+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%26atitle%3DCompounds%2520and%2520methods%2520of%2520use%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bold, G.; Capraro, H. G.; Caravatti, G.; Flörsheimer, A.; Furet, P.; Manley, P. W.; Vaupel, A.; Pissot-Soldermann, C.; Gessier, F.; Schnell, C.; Littlewood-Evans, A. J.; Kapa, P. K.; Bajwa, J. S.; Jiang, X.</span><span> </span><span class="NLM_article-title">Bicyclic amides as kinase inhibitors</span>. WO 2006/059234,<span class="NLM_x"> </span><span class="NLM_year">2006</span>. <div class="note"><p class="first last">Biological activities of two of the compounds were described in:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=G.+Bold&author=H.+G.+Capraro&author=G.+Caravatti&author=A.+Fl%C3%B6rsheimer&author=P.+Furet&author=P.+W.+Manley&author=A.+Vaupel&author=C.+Pissot-Soldermann&author=F.+Gessier&author=C.+Schnell&author=A.+J.+Littlewood-Evans&author=P.+K.+Kapa&author=J.+S.+Bajwa&author=X.+Jiang&title=Bicyclic+amides+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26atitle%3DBicyclic%2520amides%2520as%2520kinase%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Halin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrngruber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meingassner, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stütz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detmar, M.</span><span> </span><span class="NLM_article-title">Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span><span class="refDoi"> DOI: 10.2353/ajpath.2008.071074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.2353%2Fajpath.2008.071074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=18535184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2008&pages=265-277&author=C.+Halinauthor=H.+Fahrngruberauthor=J.+G.+Meingassnerauthor=G.+Boldauthor=A.+Littlewood-Evansauthor=A.+St%C3%BCtzauthor=M.+Detmar&title=Inhibition+of+chronic+and+acute+skin+inflammation+by+treatment+with+a+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitor&doi=10.2353%2Fajpath.2008.071074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Halin, Cornelia; Fahrngruber, Hermann; Meingassner, Josef G.; Bold, Guido; Littlewood-Evans, Amanda; Stuetz, Anton; Detmar, Michael</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-277</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Although vascular remodeling is a hallmark of many chronic inflammatory disorders, antivascular strategies to treat these conditions have received little attention to date.  We investigated the effects of a newly identified vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor, NVP-BAW2881, on endothelial cell function in vitro and its anti-inflammatory activity in different animal models.  NVP-BAW2881 inhibited proliferation, migration, and tube formation by human umbilical vein endothelial cells and lymphatic endothelial cells in vitro.  In a transgenic mouse model of psoriasis, NVP-BAW2881 reduced the no. of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture.  NVP-BAW2881 also displayed strong anti-inflammatory effects in models of acute inflammation; pre-treatment with topical NVP-BAW2881 significantly inhibited VEGF-A-induced vascular permeability in the skin of pigs and mice.  Furthermore, topical application of NVP-BAW2881 reduced the inflammatory response elicited in pig skin by UV-B irradn. or by contact hypersensitivity reactions.  These results demonstrate for the first time that VEGF receptor tyrosine-kinase inhibitors might be used to treat patients with inflammatory skin disorders such as psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPVs2TkCq3O7Vg90H21EOLACvtfcHk0liT3z1e6eEA8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKjsrc%253D&md5=4a07dcf97fa4547a6d49f333371703e4</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2008.071074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2008.071074%26sid%3Dliteratum%253Aachs%26aulast%3DHalin%26aufirst%3DC.%26aulast%3DFahrngruber%26aufirst%3DH.%26aulast%3DMeingassner%26aufirst%3DJ.%2BG.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSt%25C3%25BCtz%26aufirst%3DA.%26aulast%3DDetmar%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520chronic%2520and%2520acute%2520skin%2520inflammation%2520by%2520treatment%2520with%2520a%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2008%26volume%3D173%26spage%3D265%26epage%3D277%26doi%3D10.2353%2Fajpath.2008.071074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Meingassner, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahrngruber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stütz, A.</span><span> </span><span class="NLM_article-title">NVP-BFH772, a potent inhibitor of VEGF receptor tyrosine kinases, is effective in models of skin inflammation</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2011&pages=480&author=J.+G.+Meingassnerauthor=H.+Fahrngruberauthor=E.+Kowalskyauthor=A.+Billichauthor=G.+Boldauthor=A.+Littlewood-Evansauthor=A.+St%C3%BCtz&title=NVP-BFH772%2C+a+potent+inhibitor+of+VEGF+receptor+tyrosine+kinases%2C+is+effective+in+models+of+skin+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeingassner%26aufirst%3DJ.%2BG.%26aulast%3DFahrngruber%26aufirst%3DH.%26aulast%3DKowalsky%26aufirst%3DE.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSt%25C3%25BCtz%26aufirst%3DA.%26atitle%3DNVP-BFH772%252C%2520a%2520potent%2520inhibitor%2520of%2520VEGF%2520receptor%2520tyrosine%2520kinases%252C%2520is%2520effective%2520in%2520models%2520of%2520skin%2520inflammation%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2011%26volume%3D131%26spage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Shieh, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sclafani, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girgis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radetich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, K.</span><span> </span><span class="NLM_article-title">Syntheses of a triad of Flt3 kinase inhibitors: from bench to pilot plant</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1146</span><span class="NLM_x">–</span> <span class="NLM_lpage">1155</span><span class="refDoi"> DOI: 10.1021/op800136f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op800136f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=1146-1155&author=W.+C.+Shiehauthor=J.+McKennaauthor=J.+A.+Sclafaniauthor=S.+Xueauthor=M.+Girgisauthor=J.+Viveloauthor=B.+Radetichauthor=K.+Prasad&title=Syntheses+of+a+triad+of+Flt3+kinase+inhibitors%3A+from+bench+to+pilot+plant&doi=10.1021%2Fop800136f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fop800136f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop800136f%26sid%3Dliteratum%253Aachs%26aulast%3DShieh%26aufirst%3DW.%2BC.%26aulast%3DMcKenna%26aufirst%3DJ.%26aulast%3DSclafani%26aufirst%3DJ.%2BA.%26aulast%3DXue%26aufirst%3DS.%26aulast%3DGirgis%26aufirst%3DM.%26aulast%3DVivelo%26aufirst%3DJ.%26aulast%3DRadetich%26aufirst%3DB.%26aulast%3DPrasad%26aufirst%3DK.%26atitle%3DSyntheses%2520of%2520a%2520triad%2520of%2520Flt3%2520kinase%2520inhibitors%253A%2520from%2520bench%2520to%2520pilot%2520plant%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2008%26volume%3D12%26spage%3D1146%26epage%3D1155%26doi%3D10.1021%2Fop800136f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazo-Kallanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">5161</span><span class="NLM_x">–</span> <span class="NLM_lpage">5170</span><span class="refDoi"> DOI: 10.1182/blood-2008-02-138065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1182%2Fblood-2008-02-138065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=5161-5170&author=E.+Weisbergauthor=J.+R%C3%B6selauthor=G.+Boldauthor=P.+Furetauthor=J.+Jiangauthor=J.+Coolsauthor=R.+D.+Wrightauthor=E.+Nelsonauthor=R.+Barrettauthor=A.+Rayauthor=D.+Morenoauthor=E.+Hall-Meyersauthor=R.+Stoneauthor=I.+Galinskyauthor=E.+Foxauthor=G.+Gillilandauthor=J.+F.+Daleyauthor=S.+Lazo-Kallanianauthor=A.+L.+Kungauthor=J.+D.+Griffin&title=Antileukemic+effects+of+the+novel%2C+mutant+FLT3+inhibitor+NVP-AST487%3A+effects+on+PKC412-sensitive+and+-resistant+FLT3-expressing+cells&doi=10.1182%2Fblood-2008-02-138065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-02-138065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-02-138065%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DDaley%26aufirst%3DJ.%2BF.%26aulast%3DLazo-Kallanian%26aufirst%3DS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DAntileukemic%2520effects%2520of%2520the%2520novel%252C%2520mutant%2520FLT3%2520inhibitor%2520NVP-AST487%253A%2520effects%2520on%2520PKC412-sensitive%2520and%2520-resistant%2520FLT3-expressing%2520cells%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D5161%26epage%3D5170%26doi%3D10.1182%2Fblood-2008-02-138065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Akeno-Stuart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauf, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaguarnera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitagliano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosios, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagin, J. A.</span><span> </span><span class="NLM_article-title">The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6956</span><span class="NLM_x">–</span> <span class="NLM_lpage">6964</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-06-4605" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6956-6964&author=N.+Akeno-Stuartauthor=M.+Croyleauthor=J.+A.+Knaufauthor=R.+Malaguarneraauthor=D.+Vitaglianoauthor=M.+Santoroauthor=C.+Stephanauthor=K.+Grosiosauthor=M.+Wartmannauthor=R.+Cozensauthor=G.+Caravattiauthor=D.+Fabbroauthor=H.+A.+Laneauthor=J.+A.+Fagin&title=The+RET+kinase+inhibitor+NVP-AST487+blocks+growth+and+calcitonin+gene+expression+through+distinct+mechanisms+in+medullary+thyroid+cancer+cells&doi=10.1158%2F0008-5472.CAN-06-4605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4605%26sid%3Dliteratum%253Aachs%26aulast%3DAkeno-Stuart%26aufirst%3DN.%26aulast%3DCroyle%26aufirst%3DM.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DMalaguarnera%26aufirst%3DR.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DGrosios%26aufirst%3DK.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520RET%2520kinase%2520inhibitor%2520NVP-AST487%2520blocks%2520growth%2520and%2520calcitonin%2520gene%2520expression%2520through%2520distinct%2520mechanisms%2520in%2520medullary%2520thyroid%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6956%26epage%3D6964%26doi%3D10.1158%2F0008-5472.CAN-06-4605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persohn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towbin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods-Cook, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menrad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drevs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmé, D.</span><span> </span><span class="NLM_article-title">PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2178</span><span class="NLM_x">–</span> <span class="NLM_lpage">2189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=2178-2189&author=J.+M.+Woodauthor=G.+Boldauthor=E.+Buchdungerauthor=R.+Cozensauthor=S.+Ferrariauthor=J.+Freiauthor=F.+Hofmannauthor=J.+Mestanauthor=H.+Mettauthor=T.+O%E2%80%99Reillyauthor=E.+Persohnauthor=J.+R%C3%B6selauthor=C.+Schnellauthor=D.+Stoverauthor=A.+Theuerauthor=H.+Towbinauthor=F.+Wengerauthor=K.+Woods-Cookauthor=A.+Menradauthor=G.+Siemeisterauthor=M.+Schirnerauthor=K.+H.+Thierauchauthor=M.+R.+Schneiderauthor=J.+Drevsauthor=G.+Martiny-Baronauthor=F.+Totzkeauthor=D.+Marm%C3%A9&title=PTK787%2FZK+222584%2C+a+novel+and+potent+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases%2C+impairs+vascular+endothelial+growth+factor-induced+responses+and+tumor+growth+after+oral+administration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DFrei%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DPersohn%26aufirst%3DE.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DTheuer%26aufirst%3DA.%26aulast%3DTowbin%26aufirst%3DH.%26aulast%3DWenger%26aufirst%3DF.%26aulast%3DWoods-Cook%26aufirst%3DK.%26aulast%3DMenrad%26aufirst%3DA.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DSchirner%26aufirst%3DM.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DSchneider%26aufirst%3DM.%2BR.%26aulast%3DDrevs%26aufirst%3DJ.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DMarm%25C3%25A9%26aufirst%3DD.%26atitle%3DPTK787%252FZK%2520222584%252C%2520a%2520novel%2520and%2520potent%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%252C%2520impairs%2520vascular%2520endothelial%2520growth%2520factor-induced%2520responses%2520and%2520tumor%2520growth%2520after%2520oral%2520administration%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D2178%26epage%3D2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyhack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1697</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2003.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2Fj.bbapap.2003.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=15023347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=17-27&author=P.+W.+Manleyauthor=G.+Boldauthor=J.+Br%C3%BCggenauthor=G.+Fendrichauthor=P.+Furetauthor=J.+Mestanauthor=C.+Schnellauthor=B.+Stolzauthor=T.+Meyerauthor=B.+Meyhackauthor=W.+Starkauthor=A.+Straussauthor=J.+Wood&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+VEGF-R+kinase+inhibitors+for+the+treatment+of+angiogenesis&doi=10.1016%2Fj.bbapap.2003.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis</span></div><div class="casAuthors">Manley, Paul William; Bold, Guido; Brueggen, Josef; Fendrich, Gabrielle; Furet, Pascal; Mestan, Jurgen; Schnell, Christian; Stolz, Barbara; Meyer, Thomas; Meyhack, Bernd; Stark, Wilhelm; Strauss, Andre; Wood, Jeanette</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">17-27</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Initial studies with angiogenesis inhibitors showed little clin. benefit.  However, recently reported clin. studies in colorectal cancer have shown that bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody, in combination with cytotoxic therapy has pos. effects on patient survival.  Furthermore, the VEGF receptor kinase (VEGF-R) tyrosine kinase inhibitor, vatalanib, has also shown encouraging results in colorectal cancer, with mol. resonance imaging providing evidence that the anti-tumor efficacy was indeed the result of anti-angiogenic activity.  Both of these agents are progressing in phase III trials.  This proof of concept has stimulated the desire for second-generation VEGF-R inhibitors having an improved profile.  Structural biol. insight regarding the binding mode of protein kinase inhibitors is valuable for the design of mols. possessing superior selectivity, efficacy and tolerability.  Towards this goal, the authors have developed a new series of VEGF-R2 kinase inhibitors, based upon an anthranilic acid amide scaffold.  An x-ray crystal structure of a representative compd., AAL993 (ZK260253), in complex with the catalytic domain of diphosphorylated VEGF-R2 has revealed that this mol. binds to an inactive conformation of the protein.  This binding mode, similar to that obsd. for the anti-leukemia drug, imatinib in complex with c-Abl kinase, may be responsible for the high selectivity of AAL993 and provides valuable insight for the design of further compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu3NYKjX0IDLVg90H21EOLACvtfcHk0lgVa_Yr3YlzkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsrc%253D&md5=4ce7a134c71ea83d0a711cab9ffc0c85</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DB.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMeyhack%26aufirst%3DB.%26aulast%3DStark%26aufirst%3DW.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520VEGF-R%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520angiogenesis%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D17%26epage%3D27%26doi%3D10.1016%2Fj.bbapap.2003.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><div class="note"><p class="first last">At the time this work was accomplished, there was no crystal structure of the FLT3 kinase in the “DFG out” conformation available. We resorted to a homology model described in:</p></div><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flörsheimer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Antileukemic effects of novel first-and second-generation FLT3 inhibitors: structure-affinity comparison</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1021</span><span class="NLM_x">–</span> <span class="NLM_lpage">1032</span><span class="refDoi"> DOI: 10.1177/1947601910396505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1177%2F1947601910396505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=21779428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisF2nsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=1021-1032&author=E.+Weisbergauthor=J.+R%C3%B6selauthor=P.+Furetauthor=G.+Boldauthor=P.+Imbachauthor=A.+Fl%C3%B6rsheimerauthor=G.+Caravattiauthor=J.+Jiangauthor=P.+W.+Manleyauthor=A.+Rayauthor=J.+D.+Griffin&title=Antileukemic+effects+of+novel+first-and+second-generation+FLT3+inhibitors%3A+structure-affinity+comparison&doi=10.1177%2F1947601910396505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Antileukemic effects of novel first-and second-generation FLT3 inhibitors: structure-affinity comparison</span></div><div class="casAuthors">Weisberg, Ellen; Roesel, Johannes; Furet, Pascal; Bold, Guido; Imbach, Patricia; Florsheimer, Andreas; Caravatti, Georgio; Jiang, Jingrui; Manley, Paul; Ray, Arghya; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1021-1032</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it.  The small mol. inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clin. trials.  However, the identification of PKC412-resistant leukemic blast cells in the bone marrow of AML patients has propelled the development of novel and structurally distinct FLT3 inhibitors that have the potential to override drug resistance and more efficiently prevent disease progression or recurrence.  Here, we present the novel first-generation "type II" FLT3 inhibitors, AFG206, AFG210, and AHL196, and the second-generation "type II" derivs. and AST487 analogs, AUZ454 and ATH686.  All agents potently and selectively target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition.  Cross-resistance between "type I" inhibitors, PKC412 and AAE871, was demonstrated.  While cross-resistance was also obsd. between "type I" and first-generation "type II" FLT3 inhibitors, the high potency of the second-generation "type II" inhibitors was sufficient to potently kill "type I" inhibitor-resistant mutant FLT3-expressing cells.  The increased potency obsd. for the second-generation "type II" inhibitors was obsd. to be due to an improved interaction with the ATP pocket of FLT3, specifically assocd. with introduction of a piperazine moiety and placement of an amino group in position 2 of the pyrimidine ring.  Thus, we present 2 structurally novel classes of FLT3 inhibitors characterized by high selectivity and potency toward mutant FLT3 as a mol. target.  In addn., presentation of the antileukemic effects of "type II" inhibitors, such as AUZ454 and ATH686, highlights a new class of highly potent FLT3 inhibitors able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaZyJlPc6jT7Vg90H21EOLACvtfcHk0lgVa_Yr3YlzkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisF2nsrY%253D&md5=bf25a61a240b5f9a73e11c389cb13870</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1177%2F1947601910396505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910396505%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DR%25C3%25B6sel%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DImbach%26aufirst%3DP.%26aulast%3DFl%25C3%25B6rsheimer%26aufirst%3DA.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DAntileukemic%2520effects%2520of%2520novel%2520first-and%2520second-generation%2520FLT3%2520inhibitors%253A%2520structure-affinity%2520comparison%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D1021%26epage%3D1032%26doi%3D10.1177%2F1947601910396505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrián, F.</span><span> </span><span class="NLM_article-title">Ba/F3 cells and their use in kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1097/CCO.0b013e328011a25f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1097%2FCCO.0b013e328011a25f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=17133113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=55-60&author=M.+Warmuthauthor=S.+Kimauthor=X.+J.+Guauthor=G.+Xiaauthor=F.+Adri%C3%A1n&title=Ba%2FF3+cells+and+their+use+in+kinase+drug+discovery&doi=10.1097%2FCCO.0b013e328011a25f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ba/F3 cells and their use in kinase drug discovery</span></div><div class="casAuthors">Warmuth, Markus; Kim, Sungjoon; Gu, Xiang-ju; Xia, Gang; Adrian, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics.  The discovery of a large no. of cancer-assocd. mutations in the kinome, and the progress in developing specific small-mol. kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.  Recent findings: Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-mol. kinase inhibitors to block kinase activity.  Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compd. profiling.  Further, several published approaches show promise in predicting resistance to small-mol. kinase inhibitors elicited by point mutations interfering with inhibitor binding.  Summary: Ba/F3 cells are an increasingly popular tool in kinase drug discovery.  The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compd. libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clin. resistance will greatly facilitate developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQmhiRwGlDLVg90H21EOLACvtfcHk0ljy6Emkbq3xZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL&md5=a7f8d84dfedea69d408edb571e2eead9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328011a25f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328011a25f%26sid%3Dliteratum%253Aachs%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DAdri%25C3%25A1n%26aufirst%3DF.%26atitle%3DBa%252FF3%2520cells%2520and%2520their%2520use%2520in%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D55%26epage%3D60%26doi%3D10.1097%2FCCO.0b013e328011a25f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinks, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regenass, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlynn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent <i>in vivo</i> antitumor activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">2334</span><span class="NLM_x">–</span> <span class="NLM_lpage">2338</span><span class="refDoi"> DOI: 10.1073/pnas.91.6.2334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1073%2Fpnas.91.6.2334" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=2334-2338&author=E.+Buchdungerauthor=U.+Trinksauthor=H.+Mettauthor=U.+Regenassauthor=M.+M%C3%BCllerauthor=T.+Meyerauthor=E.+McGlynnauthor=L.+A.+Pinnaauthor=P.+Traxlerauthor=N.+B.+Lydon&title=4%2C5-Dianilinophthalimide%3A+a+protein-tyrosine+kinase+inhibitor+with+selectivity+for+the+epidermal+growth+factor+receptor+signal+transduction+pathway+and+potent+in+vivo+antitumor+activity&doi=10.1073%2Fpnas.91.6.2334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.6.2334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.6.2334%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DTrinks%26aufirst%3DU.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DRegenass%26aufirst%3DU.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMcGlynn%26aufirst%3DE.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3D4%252C5-Dianilinophthalimide%253A%2520a%2520protein-tyrosine%2520kinase%2520inhibitor%2520with%2520selectivity%2520for%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520signal%2520transduction%2520pathway%2520and%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D2334%26epage%3D2338%26doi%3D10.1073%2Fpnas.91.6.2334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">LaMontagne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-05-2001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=221-231&author=K.+LaMontagneauthor=A.+Littlewood-Evansauthor=C.+Schnellauthor=T.+O%E2%80%99Reillyauthor=L.+Wyderauthor=T.+Sanchezauthor=B.+Probstauthor=J.+Butlerauthor=A.+Woodauthor=G.+Liauauthor=E.+Billyauthor=A.+Theuerauthor=T.+Hlaauthor=J.+Wood&title=Antagonism+of+sphingosine-1-phosphate+receptors+by+FTY720+inhibits+angiogenesis+and+tumor+vascularization&doi=10.1158%2F0008-5472.CAN-05-2001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2001%26sid%3Dliteratum%253Aachs%26aulast%3DLaMontagne%26aufirst%3DK.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DWyder%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DProbst%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DLiau%26aufirst%3DG.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DTheuer%26aufirst%3DA.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAntagonism%2520of%2520sphingosine-1-phosphate%2520receptors%2520by%2520FTY720%2520inhibits%2520angiogenesis%2520and%2520tumor%2520vascularization%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D221%26epage%3D231%26doi%3D10.1158%2F0008-5472.CAN-05-2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Weidensteiner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSheehy, P.M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegrini, P. R.</span><span> </span><span class="NLM_article-title">Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T</span> <span class="citation_source-journal">Journal of Magnetic Resonance Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">656</span><span class="refDoi"> DOI: 10.1002/jmri.20676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1002%2Fjmri.20676" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=646-656&author=C.+Weidensteinerauthor=M.+Rauschauthor=P.M.+J.+McSheehyauthor=P.+R.+Allegrini&title=Quantitative+dynamic+contrast-enhanced+MRI+in+tumor-bearing+rats+and+mice+with+inversion+recovery+TrueFISP+and+two+contrast+agents+at+4.7+T&doi=10.1002%2Fjmri.20676"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjmri.20676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmri.20676%26sid%3Dliteratum%253Aachs%26aulast%3DWeidensteiner%26aufirst%3DC.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DMcSheehy%26aufirst%3DP.M.%2BJ.%26aulast%3DAllegrini%26aufirst%3DP.%2BR.%26atitle%3DQuantitative%2520dynamic%2520contrast-enhanced%2520MRI%2520in%2520tumor-bearing%2520rats%2520and%2520mice%2520with%2520inversion%2520recovery%2520TrueFISP%2520and%2520two%2520contrast%2520agents%2520at%25204.7%2520T%26jtitle%3DJournal%2520of%2520Magnetic%2520Resonance%2520Imaging%26date%3D2006%26volume%3D24%26spage%3D646%26epage%3D656%26doi%3D10.1002%2Fjmri.20676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Moss, A.</span><span> </span><span class="NLM_article-title">The angiopoietin:Tie 2 interaction: a potential target for future therapies in human vascular disease</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2013.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1016%2Fj.cytogfr.2013.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=23838360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKnurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=579-592&author=A.+Moss&title=The+angiopoietin%3ATie+2+interaction%3A+a+potential+target+for+future+therapies+in+human+vascular+disease&doi=10.1016%2Fj.cytogfr.2013.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The angiopoietin:Tie 2 interaction: A potential target for future therapies in human vascular disease</span></div><div class="casAuthors">Moss, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-592</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiopoietin-1 and -2 are endogenous ligands for the vascular endothelial receptor tyrosine kinase Tie2.  Signalling by angiopoietin-1 promotes vascular endothelial cell survival and the sprouting and reorganisation of blood vessels, as well as inhibiting activation of the vascular endothelial barrier to reduce leakage and leukocyte migration into tissues.  Angiopoietin-2 generally has an opposing action, and is released naturally at times of vascular growth and inflammation.  There is a significant body of emerging evidence that promoting the actions of angiopoietin-1 through Tie2 is of benefit in pathologies of vascular activation, such as sepsis, stroke, diabetic retinopathy and asthma.  Similarly, methods to inhibit the actions of angiopoietin-2 are emerging and have been demonstrated to be of preclin. and clin. benefit in reducing tumor angiogenesis.  Here the author reviews the evidence for potential benefits of modulation of the interaction of angiopoietins with Tie2, and the potential applications.  Addnl., methods for delivery of the complex protein angiopoietin-1 are discussed, as well as potentially deleterious consequences of administering angiopoietin-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVmGs0WhXg27Vg90H21EOLACvtfcHk0lheGw7oKziQjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKnurfF&md5=f4f212b1f48110d9a4585e09d3b8e5f6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2013.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2013.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DA.%26atitle%3DThe%2520angiopoietin%253ATie%25202%2520interaction%253A%2520a%2520potential%2520target%2520for%2520future%2520therapies%2520in%2520human%2520vascular%2520disease%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2013%26volume%3D24%26spage%3D579%26epage%3D592%26doi%3D10.1016%2Fj.cytogfr.2013.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Fallahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galleri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, A.</span><span> </span><span class="NLM_article-title">New therapies for dedifferentiated papillary thyroid cancer</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">6153</span><span class="NLM_x">–</span> <span class="NLM_lpage">6182</span><span class="refDoi"> DOI: 10.3390/ijms16036153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.3390%2Fijms16036153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=25789503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvFCju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=6153-6182&author=P.+Fallahiauthor=V.+Mazziauthor=R.+Vitaauthor=S.+M.+Ferrariauthor=G.+Materazziauthor=D.+Galleriauthor=S.+Benvengaauthor=P.+Miccoliauthor=A.+Antonelli&title=New+therapies+for+dedifferentiated+papillary+thyroid+cancer&doi=10.3390%2Fijms16036153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for dedifferentiated papillary thyroid cancer</span></div><div class="casAuthors">Fallahi, Poupak; Mazzi, Valeria; Vita, Roberto; Ferrari, Silvia Martina; Materazzi, Gabriele; Galleri, David; Benvenga, Salvatore; Miccoli, Paolo; Antonelli, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">6153-6182</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The no. of thyroid cancers is increasing.  Std. treatment usually includes primary surgery, TSH suppressive therapy, and ablation of the thyroid remnant with radioactive iodine (RAI).  Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will develop metastatic disease, which fails to respond to RAI, exhibiting a more aggressive behavior.  The lack of specific, effective and well-tolerated drugs, the scarcity of data about the assocn. of multi-targeting drugs, and the limited role of radioiodine for dedifferentiated thyroid cancer, call for further efforts in the field of new drugs development.  Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer.  Targeted novel compds. have been demonstrated to induce clin. responses and stabilization of disease.  Sorafenib has been approved for differentiated thyroid cancer refractory to RAI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDrA45V1LxjbVg90H21EOLACvtfcHk0lheGw7oKziQjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvFCju7g%253D&md5=59c2b5eb7c23e0cf0508f98fd3b9e5c8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3390%2Fijms16036153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms16036153%26sid%3Dliteratum%253Aachs%26aulast%3DFallahi%26aufirst%3DP.%26aulast%3DMazzi%26aufirst%3DV.%26aulast%3DVita%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%2BM.%26aulast%3DMaterazzi%26aufirst%3DG.%26aulast%3DGalleri%26aufirst%3DD.%26aulast%3DBenvenga%26aufirst%3DS.%26aulast%3DMiccoli%26aufirst%3DP.%26aulast%3DAntonelli%26aufirst%3DA.%26atitle%3DNew%2520therapies%2520for%2520dedifferentiated%2520papillary%2520thyroid%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D6153%26epage%3D6182%26doi%3D10.3390%2Fijms16036153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ravegnini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammarini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astolfi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantaleo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrelia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, S.</span><span> </span><span class="NLM_article-title">Personalized medicine in gastrointestinal stromal tumor (GIST): Clinical implications of the somatic and germline DNA analysis</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">15592</span><span class="NLM_x">–</span> <span class="NLM_lpage">15608</span><span class="refDoi"> DOI: 10.3390/ijms160715592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.3390%2Fijms160715592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=26184165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2qs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=15592-15608&author=G.+Ravegniniauthor=M.+Nanniniauthor=G.+Sammariniauthor=A.+Astolfiauthor=G.+Biascoauthor=M.+A.+Pantaleoauthor=P.+Hreliaauthor=S.+Angelini&title=Personalized+medicine+in+gastrointestinal+stromal+tumor+%28GIST%29%3A+Clinical+implications+of+the+somatic+and+germline+DNA+analysis&doi=10.3390%2Fijms160715592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized medicine in gastrointestinal stromal tumor (GIST): clinical implications of the somatic and germline DNA analysis</span></div><div class="casAuthors">Ravegnini, Gloria; Nannini, Margherita; Sammarini, Giulia; Astolfi, Annalisa; Biasco, Guido; Pantaleo, Maria A.; Hrelia, Patrizia; Angelini, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">15592-15608</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract.  They are characterized by gain of function mutations in KIT or PDGFRA tyrosine kinase receptors, with their consequent constitutive activation.  The gold std. therapy is imatinib that offers a good and stable response for approx. 18-36 mo.  However, resistance is very common and it is vital to identify new biomarkers.  Up until now, there have been two main approaches with focus to characterize novel targets.  On the one hand, the focus is on the tumor genome, as the final clin. outcome depends mainly from the cancer specific mutations/alterations patterns.  However, the germline DNA is important as well, and it is inconceivable to think the patients response to the drug is not related to it.  Therefore the aim of this review is to outline the state of the art of the personalized medicine in GIST taking into account both the tumor DNA (somatic) and the patient DNA (germline).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCimapePqmLrVg90H21EOLACvtfcHk0li7CuIjnq85Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2qs7jP&md5=18e61c308cb84c0956ed804c4a3c99f8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3390%2Fijms160715592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160715592%26sid%3Dliteratum%253Aachs%26aulast%3DRavegnini%26aufirst%3DG.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DSammarini%26aufirst%3DG.%26aulast%3DAstolfi%26aufirst%3DA.%26aulast%3DBiasco%26aufirst%3DG.%26aulast%3DPantaleo%26aufirst%3DM.%2BA.%26aulast%3DHrelia%26aufirst%3DP.%26aulast%3DAngelini%26aufirst%3DS.%26atitle%3DPersonalized%2520medicine%2520in%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%253A%2520Clinical%2520implications%2520of%2520the%2520somatic%2520and%2520germline%2520DNA%2520analysis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D15592%26epage%3D15608%26doi%3D10.3390%2Fijms160715592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fallahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spisni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span> </span><span class="NLM_article-title">Selective use of vandetanib in the treatment of thyroid cancer</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3459</span><span class="NLM_x">–</span> <span class="NLM_lpage">3470</span><span class="refDoi"> DOI: 10.2147/DDDT.S72495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.2147%2FDDDT.S72495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=26170630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FivFajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=3459-3470&author=P.+Fallahiauthor=S.+M.+Ferrariauthor=A.+Antonelliauthor=F.+Di+Bariauthor=S.+Benvengaauthor=R.+Spisniauthor=G.+Materazziauthor=P.+Miccoli&title=Selective+use+of+vandetanib+in+the+treatment+of+thyroid+cancer&doi=10.2147%2FDDDT.S72495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective use of vandetanib in the treatment of thyroid cancer</span></div><div class="casAuthors">Fallahi Poupak; Ferrari Silvia Martina; Antonelli Alessandro; Di Bari Flavia; Benvenga Salvatore; Spisni Roberto; Materazzi Gabriele; Miccoli Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3459-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyroid cancer (TC).  It is emerging as a potentially effective option in the treatment of advanced medullary thyroid cancer (MTC) and in dedifferentiated papillary thyroid cancer not responsive to radioiodine.  The most important effect of vandetanib in aggressive MTC is a prolongation of progression-free survival and a stabilization of the disease.  Significant side effects have been observed with the vandetanib therapy (as fatigue, hypertension, QTc prolongation, cutaneous rash, hand-and-foot syndrome, diarrhea, etc), and severe side effects can require the suspension of the drug.  Several studies are currently under way to evaluate the long-term efficacy and tolerability of vandetanib in MTC and in dedifferentiated papillary TC.  The efficacy of vandetanib in patients with MTC in long-term treatments could be overcome by the resistance to the drug.  However, the effectiveness of the treatment could be ameliorated by the molecular characterization of the tumor and by the possibility to test the sensitivity of primary TC cells from each subject to different tyrosine kinase inhibitor.  Association studies are evaluating the effect of the association of vandetanib with other antineoplastic agents (such as irinotecan, bortezomib, etc).  Further research is needed to determine the ideal therapy to obtain the best response in terms of survival and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSs5R1_TNnRTf3jf77P2BG3fW6udTcc2eYzkHOjwfhkCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FivFajug%253D%253D&md5=ca5a6c06edd42e0d1158fe3110e4b44e</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S72495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S72495%26sid%3Dliteratum%253Aachs%26aulast%3DFallahi%26aufirst%3DP.%26aulast%3DFerrari%26aufirst%3DS.%2BM.%26aulast%3DAntonelli%26aufirst%3DA.%26aulast%3DDi%2BBari%26aufirst%3DF.%26aulast%3DBenvenga%26aufirst%3DS.%26aulast%3DSpisni%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DG.%26aulast%3DMiccoli%26aufirst%3DP.%26atitle%3DSelective%2520use%2520of%2520vandetanib%2520in%2520the%2520treatment%2520of%2520thyroid%2520cancer%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D3459%26epage%3D3470%26doi%3D10.2147%2FDDDT.S72495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lacouture, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guitart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrescu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutcher, J. P.</span><span> </span><span class="NLM_article-title">Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">1011</span><span class="refDoi"> DOI: 10.1634/theoncologist.2008-0131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1634%2Ftheoncologist.2008-0131" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=1001-1011&author=M.+E.+Lacoutureauthor=S.+Wuauthor=C.+Robertauthor=M.+B.+Atkinsauthor=H.+H.+Kongauthor=J.+Guitartauthor=C.+Garbeauthor=A.+Hauschildauthor=I.+Puzanovauthor=D.+T.+Alexandrescuauthor=R.+T.+Andersonauthor=L.+Woodauthor=J.+P.+Dutcher&title=Evolving+strategies+for+the+management+of+hand-foot+skin+reaction+associated+with+the+multitargeted+kinase+inhibitors+sorafenib+and+sunitinib&doi=10.1634%2Ftheoncologist.2008-0131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2008-0131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2008-0131%26sid%3Dliteratum%253Aachs%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DKong%26aufirst%3DH.%2BH.%26aulast%3DGuitart%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DAlexandrescu%26aufirst%3DD.%2BT.%26aulast%3DAnderson%26aufirst%3DR.%2BT.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DDutcher%26aufirst%3DJ.%2BP.%26atitle%3DEvolving%2520strategies%2520for%2520the%2520management%2520of%2520hand-foot%2520skin%2520reaction%2520associated%2520with%2520the%2520multitargeted%2520kinase%2520inhibitors%2520sorafenib%2520and%2520sunitinib%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D1001%26epage%3D1011%26doi%3D10.1634%2Ftheoncologist.2008-0131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ellis, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span> </span><span class="NLM_article-title">Pathways mediating resistance to vascular endothelial growth factor-targeted therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6371</span><span class="NLM_x">–</span> <span class="NLM_lpage">6375</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-5287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F1078-0432.CCR-07-5287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=18927275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6371-6375&author=L.+M.+Ellisauthor=D.+J.+Hicklin&title=Pathways+mediating+resistance+to+vascular+endothelial+growth+factor-targeted+therapy&doi=10.1158%2F1078-0432.CCR-07-5287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy</span></div><div class="casAuthors">Ellis, Lee M.; Hicklin, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6371-6375</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factor (VEGF)-targeted therapy has become an important treatment option for the management of a no. of human malignancies.  Unfortunately, a significant no. of patients do not respond to VEGF-targeted therapy when used as a single agent or in combination with chemotherapy.  Furthermore, the duration of benefit from VEGF-targeted therapy can be relatively short (weeks to months).  Ultimately, the vast majority of patients who initially respond to therapy will develop resistance.  To date, the mol. and cellular mechanisms assocd. with resistance to VEGF-targeted agents are poorly understood.  The mechanisms of action of anti-VEGF therapy are diverse, and it is entirely possible that resistance mechanisms are similarly diverse and depend on the tumor type.  A better understanding of these mechanisms will help in the selection of those patients that are more likely to benefit from VEGF-targeted therapy and also provide for the rational development of therapies that circumvent or overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof9jwBsqNaErVg90H21EOLACvtfcHk0lgQOzftmnQUXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrJ&md5=5b5a06a0aa43bec60a2644a67a262820</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5287%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BM.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DPathways%2520mediating%2520resistance%2520to%2520vascular%2520endothelial%2520growth%2520factor-targeted%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6371%26epage%3D6375%26doi%3D10.1158%2F1078-0432.CCR-07-5287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Ding, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1771</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.4155/fmc.14.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.4155%2Ffmc.14.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=25407368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCit7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1771-1789&author=C.+Dingauthor=C.+Zhangauthor=M.+Zhangauthor=Y.+Z.+Chenauthor=C.+Tanauthor=Y.+Tanauthor=Y.+Jiang&title=Multitarget+inhibitors+derived+from+crosstalk+mechanism+involving+VEGFR2&doi=10.4155%2Ffmc.14.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2</span></div><div class="casAuthors">Ding, Chao; Zhang, Cunlong; Zhang, Mingli; Chen, Yu Zong; Tan, Chunyan; Tan, Ying; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1771-1789</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Seven VEGFR small-mol. inhibitors have been approved by the US FDA as anticancer drugs, which confirms the therapeutic value of angiogenesis inhibitors.  However, much more evidence indicates that VEGFR inhibition alone is usually not sufficient to block the tumor progress.  The potential of some agents targeting VEGFR owes partially to the simultaneous inhibition of addnl. targets in other signaling pathways.  In this review, the crosstalk between VEGFR2 and the addnl. targets in other signaling pathways, such as EGFR, MET, FGFR, PDGFR, c-Kit, Raf, PI3K and HDAC, and the synergistic effects derived from multitarget activities against these crosstalks are discussed.  We also briefly describe the multitarget inhibitors in clin. trials or reported in the literature and patents under the different multitarget categories involving VEGFR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqseqvb3DgFk7Vg90H21EOLACvtfcHk0lgQOzftmnQUXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCit7jM&md5=4843bab8ca10b7672e361b05acd10c5b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.112%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DMultitarget%2520inhibitors%2520derived%2520from%2520crosstalk%2520mechanism%2520involving%2520VEGFR2%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1771%26epage%3D1789%26doi%3D10.4155%2Ffmc.14.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Boulay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuleux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The Ret receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3743</span><span class="NLM_x">–</span> <span class="NLM_lpage">3751</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F0008-5472.CAN-07-5100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3743-3751&author=A.+Boulayauthor=M.+Breuleuxauthor=C.+Stephanauthor=C.+Fuxauthor=C.+Briskenauthor=M.+Ficheauthor=M.+Wartmannauthor=M.+Stummauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+Ret+receptor+tyrosine+kinase+pathway+functionally+interacts+with+the+ER%CE%B1+pathway+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-07-5100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5100%26sid%3Dliteratum%253Aachs%26aulast%3DBoulay%26aufirst%3DA.%26aulast%3DBreuleux%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DFux%26aufirst%3DC.%26aulast%3DBrisken%26aufirst%3DC.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520Ret%2520receptor%2520tyrosine%2520kinase%2520pathway%2520functionally%2520interacts%2520with%2520the%2520ER%25CE%25B1%2520pathway%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3743%26epage%3D3751%26doi%3D10.1158%2F0008-5472.CAN-07-5100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Ferretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegrini, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSheehy, P. M.</span><span> </span><span class="NLM_article-title">Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">7773</span><span class="NLM_x">–</span> <span class="NLM_lpage">7784</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=10.1158%2F1078-0432.CCR-05-1165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=16278399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2isL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=7773-7784&author=S.+Ferrettiauthor=P.+R.+Allegriniauthor=T.+O%E2%80%99Reillyauthor=C.+Schnellauthor=M.+Stummauthor=M.+Wartmannauthor=J.+Woodauthor=P.+M.+McSheehy&title=Patupilone+induced+vascular+disruption+in+orthotopic+rodent+tumor+models+detected+by+magnetic+resonance+imaging+and+interstitial+fluid+pressure&doi=10.1158%2F1078-0432.CCR-05-1165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure</span></div><div class="casAuthors">Ferretti, Stephane; Allegrini, Peter R.; O'Reilly, Terence; Schnell, Christian; Stumm, Michael; Wartmann, Markus; Wood, Jeanette; McSheehy, Paul M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7773-7784</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Evaluation of vascular disruptive activity in orthotopic models as potential surrogate biomarkers of tumor response to the microtubule-stabilizing agent patupilone.  Mice bearing metastatic B16/BL6 melanoma and rats bearing mammary BN472 tumors received vehicle or efficacious patupilone doses (4 and 0.8-1.5 mg/kg i.v., resp.).  Tumor vascularity assessment by dynamic contrast-enhanced or dynamic susceptibility contrast magnetic resonance imaging and interstitial fluid pressure (IFP) occurred at baseline, 2 days (mice and rats), and 6 days (rats) after treatment and were compared with histol. measurements and correlated with tumor response.  In B16/BL6 metastases, patupilone (4 mg/kg) induced a 21 ± 5% decrease (P < 0.001) in tumor blood vol. and a 32 ± 15% decrease (P = 0.02) in IFP after 2 days and reduced tumor growth and vessel d. (>42%) after 2 wk (P ≤ 0.014).  Patupilone dose-dependently inhibited BN472 tumor growth (day 6) and reduced IFP on days 2 and 6 (-21% to -70%), and the percentage change in IFP correlated (P < 0.01) with the change in tumor vol.  In both models, histol. and vascular casts confirmed decreases in tumor blood vol.  One patupilone (0.8 mg/kg) administration decreased (P < 0.01) tumor IFP (54 ± 4%), tumor blood vol. (50 ± 6%), and vessel diam. (40 ± 11%) by day 6 but not the apparent diffusion coeff., whereas histol. showed that apoptosis was increased 2.4-fold and necrosis was unchanged.  Apoptosis correlated neg. (P < 0.001) with IFP, tumor blood vol., and tumor vol., whereas tumor blood vol. and IFP were correlated pos. (P = 0.0005).  Vascular disruptive effects of patupilone were detected in situ using dynamic contrast-enhanced or dynamic susceptibility contrast magnetic resonance imaging and IFP.  Changes in IFP preceded and correlated with tumor response, suggesting that IFP may be a surrogate biomarker for patupilone efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6VaOmfcjxrVg90H21EOLACvtfcHk0lir298ha_8vog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2isL7K&md5=4c6fd11e474126cbe94c4ac5961c6085</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1165%26sid%3Dliteratum%253Aachs%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DAllegrini%26aufirst%3DP.%2BR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DMcSheehy%26aufirst%3DP.%2BM.%26atitle%3DPatupilone%2520induced%2520vascular%2520disruption%2520in%2520orthotopic%2520rodent%2520tumor%2520models%2520detected%2520by%2520magnetic%2520resonance%2520imaging%2520and%2520interstitial%2520fluid%2520pressure%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D7773%26epage%3D7784%26doi%3D10.1158%2F1078-0432.CCR-05-1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EW3','PDB','5EW3'); return false;">PDB: 5EW3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH','PDB','1UWH'); return false;">PDB: 1UWH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d131e2976-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i58"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01582">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_14342"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01582">10.1021/acs.jmedchem.5b01582</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Kinase selectivity in biochemical assays for VEGFR2 inhibitors; kinase selectivity in cells with BFH772 and BAW2881; compound <b>4</b> and BFH772 inhibit vascular leakage in the Miles assay; VEGFR2 inhibitors abrogate tissue chamber weight and TIE-2 levels in the VEGF chamber implant model; T/C of B16 melanoma primary and metastatic tumors in mice treated with forerunner and competitor VEGFR tyrosine kinase inhibitors; blood chemistry of BFH772 and BAW2881 treated animals in the B16 melanoma model; naphthalene-1-carboxamides show no activity on the proliferation of B16 melanoma cells (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01582/suppl_file/jm5b01582_si_001.pdf">jm5b01582_si_001.pdf (426.48 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01582&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-1%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01582%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01582" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677af4c729a82212","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
